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1  Introduction 
1.1  Zoonoses and emerging infectious diseases 
A zoonosis is defined by the World Health Organization (WHO) as “any disease or infection that 
is naturally transmissible from vertebrate animals to humans and vice-versa”. Zoonoses are 
caused by bacteria (e.g. Salmonella – Salmonellosis, Yersinia pestis – Plague), parasites (e.g. 
Toxoplasma gondii – Toxoplasmosis) and viruses (e.g. Lyssaviruses – Rabies, Ebola viruses – Ebola 
hemorrhagic fever). An “emerging zoonosis” is described to be “newly recognized or newly 
evolved, or that has occurred previously but shows an increase in incidence or expansion in 
geographical, host or vector range”.  
 The topic of  “emerging zoonoses” came into the limelight around 1945 with increasing articles 
in “The Journal of  Infectious Diseases” [1]. A proposed reason for this development is the 
increased cross-host exposure, because the separation of  donor and recipient host was drastically 
reduced due to changes in geographical and ecological behavior [2]. Expansion of  the human 
population results in interference with so far untouched habitats including wildlife and pathogens. 
Extensive global travelling enables global pathogen distribution in only a few days [2]. 
Agricultural expansion comes along with the exploitation of  pristine habitats, bringing livestock 
into close contact to wildlife, which in turn increases the risk of  transmission of  infections to 
humans [3]. The disturbance of  habitats by humans inevitably leads to a loss of  biodiversity, 
which can indirectly promote the increase of  emerging diseases [4]. This phenomenon has been 
described as the “dilution effect”, postulating that a decrease in host diversity leads to an increase 
of  prevalence of  infectious diseases and vice versa [5]. Viral pathogens make up about 25% of  all 
emerging infectious diseases (EIDs) [1]. 
Zoonotic viruses can be highly pathogenic for humans but in many cases the underlying factors 
that enable viruses to cross the species barrier are not known. It is believed that genetic 
relatedness of  species favors cross-species transmission of  pathogens [2, 6]. For successful 
transmission, viruses have to overcome ecological and/or molecular species barriers. Virus entry 
is often mediated by species-specific receptors. Even after the crossing of  receptor-dependent 
barriers, genome replication, gene expression and morphogenesis have to adapt to new 
intracellular environments. Moreover, the innate immunity of  the new host needs to be evaded to 
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establish successful replication [7, 8]. “Generalist” viruses with a broad host range, which can use 
different host cell mechanisms for replication, are therefore more likely to gain access to new 
hosts than “specialist” viruses, which infect only closely related hosts [2]. Transmission patterns 
play an important role in the definition of  ecological species barriers. Direct zoonotic virus 
transmission, for instance, can occur by contaminated saliva from reservoir animals, as in the case 
of  rabies. Viruses can also make use of  “helpers”, such as vectors or intermediate amplifying 
hosts. Arthropod-borne viruses, like Alpha-, Bunya-, or Flaviviruses, are transmitted to humans 
via insects or ticks, which take up the virus when feeding on infected animals. Intermediate or 
amplifying hosts serve as bridges between two species, possibly giving viruses a chance for 
stepwise adaptation and/or bringing the virus into contact with recipient hosts [2]. For example 
severe acute respiratory syndrome coronavirus (SARS-CoV) was not directly transmitted from 
bats, but underwent an adaptation in civets probably through repeated transfer of  virus from 
civets to humans and back, resulting in the pandemic strain [9, 10]. Finally, rapid genetic 
evolution of  zoonotic viruses is crucial for successful transmission to a new host. Here, especially 
RNA viruses, like SARS-CoV, with error-prone replication, insufficient or complete lack of  
proof-reading mechanisms and short virus generation times come into focus [11, 12]. 
The increasing emergence of  viral zoonoses calls for research into mechanisms driving viruses 
from their animal hosts. New virus species are found in wild animals almost minutely these days. 
These viruses need to be characterized for their zoonotic potential. In addition, known zoonotic 
viruses have to be investigated in context of  their natural reservoirs and the cellular mechanisms 
and in vivo determinants, which normally keep them confined, have to be explored. The SARS-
CoV is an exceptional archetype for zoonoses research, because the virus itself  has been studied 
intensively following the pandemic it caused and its reservoir is known.  
 
1.2  The severe acute respiratory syndrome 
coronavirus 
Coronavirinae are a subfamily of  the Coronaviridae family (order Nidovirales). They are divided into 
the three genera; Alpha-, Beta- and Gammacoronaviruses. There are currently five human 
coronaviruses (hCoV) known, which, except for SARS-CoV, cause only mild disease of  the upper 
respiratory tract; hCoV-229E [13] and hCoV-NL63 [14] belonging to the Alphacoronaviruses and 
hCoV-OC43 [15], SARS-CoV [16, 17] and hCoV-HKU1 [18] defining the Betacoronaviruses.  
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SARS-CoV caused the first pandemic of  a transmissible disease with a previously unknown cause 
[19]. It started in November 2002 and was brought under control by July 2003. Until then, SARS-
CoV spread to 33 countries on five continents, caused over 8000 infections and more than 700 
deaths [19]. For this reason it is the most pathogenic hCoV and was subject to a huge variety of  
studies on coronavirus replication, interaction with the host immune response and pathogenesis, 
making it now the best understood coronavirus and an ideal prototype virus for studies on 
zoonotic disease emergence.  
SARS-CoV virions are spherical enveloped particles with club-shaped spike proteins protruding 
from the envelope. These spikes are seen as a “crown” (lat. Corona) around the virus particles in 
electron microscopy, earning the virus family its name (Fig. 1.1B). 
 
 
  
Figure 1.1: Coronavirus particle.  
(A) Model of  a Coronavirus particle. The virion membrane contains the spike (S), envelope (E) and 
matrix (M) proteins. The RNA genome is associated with nucleocapsid protein N [20]. (B) Electron 
microscopy showing the typical coronavirus “crown” of  the S proteins (picture taken by H.R. 
Gelderblom, Robert Koch-Institute). 
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1.2.1  SARS-CoV genome organization 
SARS-CoV, like all coronaviruses, contains a single stranded, 5’-capped, positive strand RNA 
genome [21, 22]. The first open reading frame, ORF1ab, makes up two-thirds of  its 29.7 kb 
genome and codes for proteins contributing to virus replication. Almost all of  these proteins are 
not packaged into virions and therefore called non-structural proteins (nsp). Most of  the 
remaining one-third of  the genome encodes 4 structural proteins. The spike (S) protein is the 
major surface protein (Fig. 1.1A). Neutralizing antibodies are directed against the S protein and it 
is responsible for virus entry and host range. The envelope protein (E) is an integral membrane 
protein and is involved in virus formation and budding. The matrix protein M is the most 
abundant structural protein in the virion whose C-terminus is located at the inside of  the virus 
particle where it interacts with the helical nucleocapsid protein (N), which in turn is associated 
with the viral genome. The M protein is not transported via the Golgi apparatus to the cell 
membrane, but rather stays at the endoplasmatic reticulum during the whole infection cycle. 
There the first steps of  virus assembly are initiated by interactions of  the M and N protein.  
Interspersed between these structural genes are eight accessory genes (Fig. 1.2A, marked in red). 
The encoded proteins share little amino acid identity between genera, formally termed “groups”, 
of  coronaviruses and are therefore called “group-specific”. These proteins are not generally 
required for virus replication in vitro but are thought to have important roles in replication in the 
natural host.  
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Figure 1.2: Genome organization and generation of  subgenomic RNAs of  SARS-CoV. 
(A) Organization of  the SARS-CoV genome. The replicase genes (ORF1a, ORF1b, green) make up two-
third of  the whole genome. Common to all coronaviruses ORFs encoding for the structural proteins are 
located downstream of  ORF1a/b in the order S (spike), E (envelope), M (membrane) and N 
(nucleocapsid) protein (highlighted in blue). Interspersed between the structural genes are the genes 
coding for group-specific accessory proteins (red). (B) A negative-strand copy of  the full-length RNA 
genome serves as template for genome replication (a). Subgenomic mRNAs for translation are transcribed 
from discontinuously transcribed negative-strand subgenomic RNAs. The viral polymerase starts 
transcription at the genomes 3’ end (b) and stops at one of  the transcription regulatory sequences (TRS) 
located upstream of  each ORF. Then the newly synthesized strand dissociates from the template strand 
and fuses to the first TRS at the genomes 5’ end (c). Transcription is continued through the leader 
sequence of  the genome (d). The negative-strand subgenomic RNAs of  various lengths are template for 
transcription of  subgenomic mRNAs (e). [23]  
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1.2.2  SARS-CoV replication cycle 
Binding of  the S protein to the SARS-CoV receptor human angiotensin converting enzyme 2 
(hACE2) mediates fusion of  the virus envelope with the cell membrane. The infectious RNA 
genome is then released into the cytoplasm [21, 22]. Because the RNA genome is positive in 
orientation, it can serve as template for translation. ORF1ab, which codes for proteins involved 
in virus replication, is translated initially. The ORF1ab gene is organized in two partially 
overlapping ORFs (ORF1a and 1b) and translation of  the full polyprotein pp1ab is achieved by a 
-1 ribosomal frame shift. Polyproteins pp1a and pp1ab are co- and post-translationally processed 
by ORF1a-encoded proteinases. These proteinases are autocatalytic and become enzymatically 
active before they are released from the polyprotein by cis-cleavage. All replicase proteins are 
found in membrane-associated “replication complexes”, where viral RNA synthesis takes place. 
For genome replication, a full-length negative-strand genome copy is synthesized, serving as the 
template for synthesis of  full-length positive-strand genome RNA. Negative-strand templates 
make up only 1-2% of  total viral RNA in infected cells. All non-replicase proteins are expressed 
from a set of  “nested” subgenomic mRNAs (Fig. 1.2B). They share common capped 5’ ends 
(“leader sequence”), identical to the sequence of  the 5’ end of  the genome RNA, and common 
poly(A) tailed 3’ ends [24-26]. Usually only the ORF closest to the 5’ end of  subgenomic RNAs is 
translated. Each subgenomic mRNA is transcribed from a corresponding subgenomic negative 
strand RNA. These templates are generated by discontinuous transcription of  the full-length 
positive strand RNA genome. The viral RNA polymerase starts transcription at the 3’ end of  the 
RNA genome until it reaches a transcription regulatory sequence (TRS), located directly upstream 
of  each ORF called body TRS. There the polymerase either continues to the next body TRS or 
stops, dissociates from the template strand and hybridizes to the TRS directly upstream of  the 
“leader sequence”, the leader TRS. There transcription continues through the “leader sequence” 
and synthesis of  the subgenomic negative-strand RNA is completed. This mechanism allows the 
virus to control the abundance of  mRNAs and therefore proteins. The smaller mRNAs, coding 
for structural proteins needed in virus assembly, are most abundant. The assembly of  virions 
takes place at the endoplasmatic reticulum-Golgi intermediate compartment (ERGIC) [23, 27]. M 
and E proteins play major roles in the formation of  virus envelopes, because overexpression of  
both proteins is sufficient for the production of  virus-like particles [28]. Interactions of  M with 
the RNA genome containing nucleocapsid probably ensure incorporation of  only full-length 
genomes into virions [29]. Immature virions are transported through the Golgi apparatus for 
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maturation. Finally, mature virions are transported in vesicles to the plasma membrane and 
released. 
 
 
  
Figure 1.3: Coronavirus replication cycle. 
Binding of  the spike protein to the SARS-CoV specific receptor human angiotensin converting enzyme 2 
(hACE2) mediates virus entry. Following uncoating of  the genomic RNA, proteins necessary for virus 
replication are translated from open reading frame (ORF) 1a and 1ab. The remaining ORFs 2-9 are 
translated from a nested set of  subgenomic RNAs. Virions mature while they are transported through the 
Golgi apparatus. Virus particles are transported in vesicles to the membrane and released by exocytosis. 
Replication cycle adapted from Bergmann et al. [30]. 
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1.2.3  SARS-CoV accessory proteins 
As mentioned above the group-specific ORFs of  SARS-CoV are not absolutely required for in 
vitro replication but may have functions as pathogenicity factors in the natural host. Antibodies 
against all of  these proteins have been found in patients suggesting in vivo expression of  the 
accessory proteins [31-34]. Proteins 3a (p3a) and 3b (p3b) are expressed from subgenomic 
RNA3. P3a with its 274 amino acids is the largest group-specific protein [35] and localizes to the 
Golgi apparatus, the plasma membrane and to intracellular vesicles [36, 37]. Furthermore, p3a 
induces vesicle formation and Golgi fragmentation in full virus context [35]. The p3b, expressed 
from the second ORF of  RNA3, localizes to mitochondria and the nucleus [38, 39] and displays 
IFN-antagonistic properties [40]. The proteins 7a and 7b are expressed from the bicistronic 
RNA7. Protein 7a induces apoptosis [41, 42] and cell cycle arrest [43]. Moreover, p7a inhibits 
cellular protein synthesis [44], seems to act as an RNA silencing suppressor [45] and was 
identified as a structural protein [46]. Protein 7b is a structural virion component [47] and 
localizes to the Golgi compartment during infection [48]. Furthermore, a cell culture adapted 
deletion in ORF7b resulted in attenuation of  the corresponding virus in vitro and in an animal 
model, suggesting a function as an attenuating factor [49]. Protein 9b, expressed from the second 
ORF in the nucleocapsid gene, has been suggested to possess a nuclear export signal, to be 
predominantly localized in the cytoplasm and to induces caspase 3 mediated apoptosis [50, 51]. 
The proteins expressed from ORF6 and ORF8 are described in more detail below. 
 
1.2.3.1  Accessory protein 6 – an IFN antagonist 
The accessory protein 6 (p6) encoded by ORF6 is the best studied protein. P6 was found to be 
expressed in lung and intestine tissues of  SARS patients [52] and localizes in the endoplasmatic 
reticulum (ER)/Golgi membrane. In a first study SARS-CoV p6 was identified as a virulence 
factor, whose genomic insertion turned an attenuated murine hepatitis virus (MHV) into a lethal 
variant. This chimeric virus caused fatal encephalitis in mice and enhanced virus growth in cell 
culture [53]. This enhancement is probably achieved by creating a cellular environment for 
optimal replication [54]. P6 colocalizes with SARS-CoV’s non-structural proteins 3 and 8 [55, 56], 
which are found on double membrane vesicles, the sites of  virus replication [23]. The N-
terminus of  p6 is an amphipathic helix which is able to induce membrane rearrangements to 
from replication complexes. Moreover, the C-terminus of  p6 binds a nuclear import factor and 
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so antagonizes the interferon (IFN) signaling pathway by disruption of  the nuclear import 
machinery [57, 58]. Shuttling of  the IFN stimulated gene factor 3 (ISGF3) into the nucleus relies 
on the binding of  karyopherin α1 (KPNA1) and subsequently to karyopherin β1 (KPNB1). P6 
retains KPNA2 at the ER/Golgi membrane and competes with the ISGF3:KPNA1 complex for 
unbound KPNB1. Depletion of  free KPNB1 by binding to p6:KPNA2 blocks the import of  
ISGF3 and inhibits the induction of  transcription of  IFN-stimulated genes downstream of  the 
JAK/STAT pathway [59]. The suggested model for SARS-CoV p6 IFN antagonism is depicted 
in Fig. 1.4. 
 
The deletion of  ORF6 in recombinant SARS-CoVs did not reduce virus growth in cell culture 
after infection at a high MOI [60]. However, infections at a low MOI revealed disadvantages in 
replication at early time points post infection. Furthermore, although a mechanism for IFN 
antagonism of  p6 has been described, deletion of  ORF6 did not result in an increased IFN 
sensitivity of  the virus [54, 59].  
 
 
Figure 1.4: Model of  SARS-CoV p6 function as an IFN antagonist. 
The STAT1:STAT2:IRF9 complex (ISGF3) is formed after IFN stimulation and recognized by KPNA1 
(Kα1) for nuclear import. Protein 6 (here ORF6) retains KPNA2 (Kα2) at the ER and competes with 
KPNA1 for unbound KPNB1 (Kβ1), which is necessary for nuclear translocation of  ISGF3 [59]. 
 
Introduction 
10 
Despite the rather modest influence of  p6 on virus growth in cell culture, its expression in 
context of  MHV greatly enhanced mortality in mice and implies an important role in virus 
infection in the natural host [53].  
 
1.2.3.2  ORF8 – subject to excessive mutations 
Genetic analysis of  SARS-CoV strains from different phases of  the epidemic revealed that the 
ORF8 region underwent unusually excessive changes within a short time [61]. Strains isolated 
from humans in the early phase of  the pandemic and those isolated from palm civets (Paguma 
larvata) carried either a single full-length ORF8 or showed an 82 nucleotide (nt) deletion [26, 61]. 
SARS-CoV strains isolated in the intermediate phase of  the pandemic displayed a 29nt-deletion 
within ORF8 resulting in two ORFs, ORF8a and ORF8b [61]. This genotype was dominant 
during the rest of  the epidemic. In a very late cluster of  SARS cases a genotype with a 415nt 
deletion resulting in the loss of  ORF8 was isolated from two patients [61]. The deletion 
mutations within ORF8 might either mean that ORF8 is non-coding or codes for a non-
functional protein. Many studies have been conducted comparing the proteins of  the full-length 
ORF8 and the pandemic variants ORF8a and 8b to elucidate their roles in human to animal 
transmission or viral pathogenesis and persistence [62-68]. Recombinant viruses carrying either 
the full-length ORF8 or ORF8 with the 29nt-deletion showed no differences in virus replication 
in cell culture [60]. Both viruses grew to same titers in mice and showed no differences in 
replication efficiency, pathology, or duration of  virus persistence [60]. Experimentally infected 
palm civets were equally susceptible to both viruses, however civets infected with SARS-CoV 
carrying the full-length ORF8 had higher body temperatures and slightly stronger antibody 
responses [69]. The ORF8a protein was found to enhance viral replication and induce apoptosis 
when overexpressed and anti-ORF8a-antibodies were found in patients [62]. Expression of  
ORF8b was questioned because of  its unusual location within ORF8a and its poor context for 
translation initiation [26]. In addition, overexpressed protein 8b degrades in vitro within a few 
hours [67]. Nevertheless, protein 8b was found to be expressed late in viral infection and to 
reduce virus replication by down-regulating the expression of  the envelope protein [63, 64, 66]. 
Whether changes within the ORF8 region are a result of  viral adaptation or genomic instability 
remains unclear. The 29nt-deletion appeared to be unnecessary for human-to-animal 
transmission, because isolates from a second zoonotic transmission after the declared end of  the 
SARS epidemic carried the full-length ORF8 [64].  
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1.3  Bats as the reservoir of emerging viruses 
Bats represent an outstanding reservoir for viral zoonoses because of  their high species diversity, 
broad geographic distribution, ability for long-distance migration and roosting behavior in large 
groups. Bats make up 20% of  the about 4600 species currently classified as mammals [70]. They 
are distributed around the world except for northern and southern polar areas. With their unique 
ability among mammals to fly, bats even cross continents [70]. This ability allows exchange of  
novel viruses between different bat species and other vertebrates. Bats live in great population 
densities with up to several million individuals [70]. This roosting behavior creates optimal 
conditions for intra- and inter-species transmission of  viruses [70].  
Only little is known about the bat immune system and how it supports persistence of  a variety of  
viruses. Because bats share a relatively old common ancestor with other mammals, their immune 
response might have important qualitative and quantitative differences as compared to rodents 
and primates. Similar to other mammals, bats apparently develop a virus-specific adaptive T- and 
B-cell response despite persistent virus infection [70-73].  
In the past years, bats have been demonstrated to be natural reservoirs for an increasing number 
of  emerging zoonotic viruses, e.g. rabies virus [74], filoviruses [73, 75], henipaviruses [71, 76], as 
well as SARS-CoV [10, 72]. 
 
1.3.1  SARS-Coronavirus as a zoonotic agent 
The animal origin of  the SARS pandemic was based, amongst others, on the findings that SARS-
CoV was a new virus without genetic relatedness to known hCoVs. Early case patients lived near 
animal markets or were food traders with animal contact. SARS-CoVs isolated from humans 
were almost identical to isolates from market animals [77]. An initial study found viruses closely 
related to SARS-CoV in palm civets (Paguma larvata), one raccoon dog (Nyctereutes procyonoides) and 
ferret badgers (Melogale moschata) [78]. The question arose, if  other species are also susceptible to 
SARS-CoV, but no systematic studies were conducted. However, a total of  13 mammalian species 
proved to be susceptible in experimental infections [77]. The close genetic relation between 
human and civet SARS-CoV isolates strongly suggested a transmission from civets, but 
interestingly neutralizing antibodies against SARS-CoV were exclusively found in civets from 
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animal markets, not farmed civets [79-81]. So, apparently civets are not generally infected with 
SARS-CoV. Furthermore, it is widely accepted that a reservoir host shows no clinical signs of  an 
infection [82], but experimentally infected palm civets did [69]. Therefore, palm civets definitely 
played an important role in transmission, but were unlikely to be the natural reservoir of  SARS-
CoV. In 2005 bats from the genus Rhinolophus were identified as the most likely reservoir of  
SARS-CoV [10, 72]. The high seroprevalence and wide distribution of  seropositive Rhinolophus 
bats are typical for natural hosts [82]. This finding led to intensive studies on bats and 
coronaviruses around the world. Indeed a huge variety of  alpha- and betacoronaviruses were 
found in many different bat species, suggesting that bats are not only the natural reservoir of  
SARS-CoV but of  most CoVs [83-87]. Furthermore, these studies revealed that bat CoVs seem 
to be specifically associated with their hosts. Different bat species from same locations harbored 
different CoVs, while similar CoVs were found in the same bat species of  geographically distant 
regions [85, 88]. 
This wide distribution of  CoVs in bats, the fact that SARS-CoV entered the human population at 
least two times independently [89] and hints that there is an ongoing evolution of  CoVs in bats 
[85] open the possibility of  future transmissions of  CoVs to the human population and 
emphasize the need to understand reservoir distribution and transmission to prevent future 
outbreaks. 
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1.4  Reverse genetics systems for Coronaviruses 
Reverse genetics provides a valuable tool to study viral protein functions in whole virus context. 
Studies in overexpression systems, looking at only one protein in particular, are rather unreliable 
and leave out virus-host and intra-viral protein interactions. 
First viral reverse genetics systems have already been established in the early 1980s for DNA-
viruses [90-92] and positive-strand RNA-viruses with small genomes [93-95]. All systems for 
positive-strand RNA-viruses are plasmid-based. The cDNA copy of  the whole RNA genome is 
inserted into a vector and maintained in bacteria.  
Coronaviruses possess the largest genomes of  all known RNA-viruses with about 27-32 kb in 
length. The genetic instability of  such large inserts in conventional vectors and the suspected 
toxicity to Escherichia coli (E.coli) of  certain genome regions of  coronaviruses, e.g. replicase genes, 
represent major obstacles in creating a cDNA clone. Different approaches were successfully used 
to overcome these obstacles. Baric and colleagues established a system of  step-wise in vitro 
ligation of  cloned subgenomic cDNAs, completely avoiding the generation of  a full-length 
genome plasmid [96-98]. Here, the coronavirus genome is segmented into 6 fragments, which are 
cloned into conventional vectors. All fragments are cloned using the restriction endonuclease 
BglI, which cuts the sequence GCCNNNN↓NGGC. The unspecified nucleotides represented by 
N leave a statistical variation of  64 different asymmetrical ends, allowing a unidirectional 
assembly of  the fragments. Genomic mutations can be easily inserted into corresponding 
fragments due to their small sizes. Thiel et al. overcame the problems of  cloning of  the large 
cDNA genome by using a poxvirus vector [99]. These vectors are especially suitable for cloning 
of  large fragments, because inserts are kept stable in a non-bacterial host system. Nevertheless, 
subgenomic fragments have to be cloned into plasmids or be prepared as PCR products for 
subsequent insertion into the poxvirus genome. In the end, the cDNA genome of  the 
coronavirus has to be cut out from purified poxvirus DNA. Both mentioned systems use a T7 
promoter, cloned in front of  the coronavirus genome, for in vitro transcription of  infectious 
genomic RNA. The RNA is either electroporated or chemically transfected into eukaryotic cells 
for virus replication. The group of  Enjuanes established the first plasmid-based cloning system 
for the whole coronaviral cDNA genome [100, 101]. Here the cDNA genome is cloned step-wise 
into a bacterial artificial chromosome (BAC) vector. BAC vectors are only present in one or two 
copies per bacterium and inserts are therefore kept stable. The viral genome is under control of  
the cytomegalovirus immediate-early promoter and therefore transcribed in the nucleus of  
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chemically transfected eukaryotic cells. This system avoids potentially error-prone in vitro RNA 
transcription, but exposes the viral genome to RNA modifications and processing, e.g. by 
splicing, within the nucleus. Potential splicing sites can be predicted and deleted by inserting silent 
mutations into the genome. But changing the genome in any way to study modified viral proteins 
might lead to the introduction of  other splicing sites, hence making more modifications of  the 
viral genome necessary. The reverse genetics system established by our group combines BAC 
vector-based cloning of  the coronaviral full-length cDNA genome with in vitro RNA 
transcription of  the genome using the T7 polymerase [49]. The genome is divided into six 
fragments, which are first cloned into high copy vectors. During the step-wise assembly of  the 
full-length genome, the vector backbone is switched to pBeloBAC11, stabilizing the growing 
inserts. Because cDNA inserts are subject to modifications by the bacteria they are maintained in, 
like deletions or nucleotide exchanges, careful handling of  the plasmids and sequencing of  each 
assembly step is necessary. Nevertheless, mutations can be easily introduced on subclone level 
and assembly is straightforward. In contrast to the other systems, recombinant virus does not 
have to be passaged and plaque purified. Four times passaging and three times plaque titration is 
done by other groups leading to increased virus titers [100]. However, this might already be due 
to genome mutations in the course of  cell culture adaptation.  
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1.5  Aim of the thesis 
 
SARS-CoV encodes for an exceptionally high number of  accessory proteins whose features are 
not yet fully characterized. These proteins are dispensable for virus replication in cell culture 
models but are believed to serve important functions in the natural reservoir.  
By sequencing the full-length genome of  a Bulgarian SARS-related bat-CoV new sequence 
information on a reservoir-borne CoV became available.  
The aim of  the present study was to compare accessory proteins from the newly discovered 
SARS-related bat-CoV with their corresponding proteins of  the human pathogenic SARS-CoV. 
The purpose of  this comparison was the evaluation of  the bat-CoV derived proteins to function 
in primate cell culture models, thus assessing their zoonotic potential.  
Protein 6, encoded by ORF6, was chosen because it is a well characterized IFN antagonist. In 
addition, ORF8 was chosen because, intriguingly, it is absent in the Bulgarian SARS-related bat-
CoV, while it is present in Asian SARS-related bat-CoVs and the human pandemic strain. 
Viral proteins derived from a bat-CoV were to be compared to proteins from a human 
pathogenic CoV. In addition to studies on primate cell cultures a cell culture model of  the bat 
reservoir was to be established. Therefore, a Rhinolophus lung cell line was produced and made 
susceptible to SARS-CoV infection.  
.  
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2  Materials and Methods 
2.1  Materials 
2.1.1  Technical equipment 
Equipment Type Source 
Autoclave V120 Systec GmbH, Wettenberg 
Balance SPO 61 Scaltec Instruments GmbH, 
Göttingen 
Blotting system Fastblot B44 Biometra GmbH, Göttingen 
Blue-light transilluminator Flu-O-Blu Biozym Scientific GmbH , Hessisch 
Oldendorf 
Centrifuges Centrifuge 5424 Eppendorf, Hamburg 
 Centrifuge 5810R Eppendorf, Hamburg 
 Sorvall Evolution RC Thermo Fisher Scientific, Schwerte 
Chemiluminescence 
detection system 
FusionFx7 PeqLab/Vilbert Lourmat, Erlangen 
Chemiluminescence reader SynergyTM 2 BioTek, Bad Friedrichshall 
Electrophoresis system Mini-PROTEAN® Tetra 
Cell 
Bio-Rad Laboratories, Munich 
Electroporation system Gene Pulser Xcell Bio-Rad Laboratories, Munich 
Freezer -20°C Liebherr premium Liebherr, Biberbach a. d. Riß 
 -80°C/Typ499 Kaltis Europe GmbH, 
Niederweningen, Switzerland 
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 Liquid Nitrogen LS 750 Taylor Wharton Germany GmbH, 
Husum 
Gel electrophoresis PerfectBlue Gelsystem 
Mini 
PEQLAB Biotechnologie GmbH, 
Erlangen 
Gel electrophoresis 
documentation 
E-Box 3028, WL/26M Vilbert Lourmat, Marne-la-Vallee, 
France 
Heating block Thermomixer comfort Eppendorf, Hamburg 
Hood (Bioflow) Gelaire BSB-4A ICN Biochemicals, Eschwege 
Incubators HERAcell® 240 Thermo Fisher Scientific, St. Leon-
Roth 
 Heraeus® B6126 Thermo Fisher Scientific, St. Leon-
Roth 
Magnetic plate Agencourt SPRIPlate 
Supermagnet Plate 
Beckman Coulter GmbH, Krefeld 
Magnetic stirrer REO basic IKAMAG IKA
®
-Werke GmbH & CO. KG, 
Staufen 
Microscopes TELAVAL31 Carl Zeiss Jena GmbH, Jena 
 IMAGER.M1 Carl Zeiss Jena GmbH, Jena 
PCR cycler Mastercycler epgradient S Eppendorf, Hamburg 
pH meter 766 Calimatic Knick Elektronische Meßgeräte 
GmbH & Co. KG, Berlin 
Photometer NanoDrop 2000c PEQLAB Biotechnologie GmbH, 
Erlangen 
Pipette assistance Accu-jet® pro Brand, Wertheim 
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Pipettes Research, PhysioCare 
(100-1000 µL, 20-200 µL, 
2-20 µL, 0.5-10 µL) 
Eppendorf, Hamburg 
Power supply Standard Power Pack P25 Biometra GmbH, Göttingen 
Real-time PCR cycler LightCycler® 1.5 Roche Diagnostics Deutschland 
GmbH, Mannheim 
 LightCycler® 480 Roche Diagnostics Deutschland 
GmbH, Mannheim 
Rotating incubator GFL-3033 GFL, Burgwedel 
Thermocycler Mastercycler ep Eppendorf, Hamburg 
Vertical shaker Mini Rocker MR.1 PEQLAB Biotechnologie GmbH, 
Erlangen 
Vortexer Vortex VF2 IKA®-Werke GmbH & CO. KG, 
Staufen 
Water purification system Milli-Q® Biocel Millipore GmbH, Schwalbach 
 
2.1.2  Disposables 
Article Source 
Blotting paper Whatman GmbH, Dassel 
C-Chip, Disposable Neubauer improved 
counting chamber 
Biochrom AG, Berlin 
Cell culture flask with filter cap (25, 75, 
175 cm2) 
SARSTEDT AG & Co., Nümbrecht 
Cell culture plates (6well, 24well) SARSTEDT AG & Co., Nümbrecht 
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Cell scraper TPP Techno Plastic Products AG, 
Trasadingen, Switzerland 
Centrifuge tubes (15, 50 mL) SARSTEDT AG & Co., Nümbrecht 
Cover glass slips (13 mm round) Thermo Fisher Scientific, St. Leon-Roth 
Cryotubes SARSTEDT AG & Co., Nümbrecht 
Electroporation cuvettes (1 mm, 2 mm gaps) Biozym Scientific GmbH , Hessisch 
Oldendorf 
Immobilion-PSQ PVDF membrane, 0.2 µm Millipore GmbH, Schwalbach 
LightCycler® Capillaries (20 µL) Roche Diagnostics Deutschland GmbH, 
Mannheim 
Microplates 96-well LUMITRAC, white VWR, Darmstadt 
LightCycler®480 Multiwell Plate 96, white Roche Diagnostics Deutschland GmbH, 
Mannheim 
PCR reaction tubes (0.2 µL) SARSTEDT AG & Co., Nümbrecht 
Petri dishes SARSTEDT AG & Co., Nümbrecht 
Pipette Tips (10, 20, 200, 1000 µL) SARSTEDT AG & Co., Nümbrecht 
Reaction tubes (1.5, 2 mL) SARSTEDT AG & Co., Nümbrecht 
Scalpel Aesculap AG, Tuttlingen 
Serological pipettes (1, 2, 5, 10, 25 mL) SARSTEDT AG & Co., Nümbrecht 
Stericup and Steritop Vacuum Filter Cups 
(500 mL) 
Millipore GmbH, Schwalbach 
Westran® Clear Signal PVDF membrane, 
0.45 µm 
Whatman GmbH, Dassel 
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2.1.3  Chemicals, buffers and solutions 
2.1.3.1  Chemicals 
Chemical Source 
2-Mercaptoethanol (β-Mercaptoethanol) Carl Roth GmbH + Co. KG, Karlsruhe 
2-Propanol ≥99.5% Carl Roth GmbH + Co. KG, Karlsruhe 
30% Acrylamid (Rotiphorese® Gel 30) Carl Roth GmbH + Co. KG, Karlsruhe 
4x NuPAGE® LDS Sample Buffer Life Technologies, Darmstadt 
Acetic acid, 100%, Ph.Eur., reinst Carl Roth GmbH + Co. KG, Karlsruhe 
Agarose Broad Range Carl Roth GmbH + Co. KG, Karlsruhe 
Agarose GTQ Carl Roth GmbH + Co. KG, Karlsruhe 
Ammonium persulfate (APS) Carl Roth GmbH + Co. KG, Karlsruhe 
Ampuwa® (sterile, pyrogen-free water) Fresenius Kabi, Bad Homburg 
Bovine Serum Albumin (special quality for 
molecular biology) 
Roche Diagnostics, Mannheim 
Bovine Serum Albumin (BSA) New England Biolabs GmbH, Frankfurt am 
Main 
Bromphenol blue Sigma-Aldrich Chemie GmbH, Munich 
Calcium Chloride (CaCl2) Carl Roth GmbH + Co. KG, Karlsruhe 
Carrier RNA (Poly A RNA solution, 
10 mg/mL) 
QIAGEN, Hilden 
Chloric acid (HCl) Carl Roth GmbH + Co. KG, Karlsruhe 
Chloroform Carl Roth GmbH + Co. KG, Karlsruhe 
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Crystal Violet Carl Roth GmbH + Co. KG, Karlsruhe 
Dako Fluorescent Mounting Medium Dako North America Inc., Carpineteria, USA 
Diethylpyrocarbonate (DEPC) Carl Roth GmbH + Co. KG, Karlsruhe 
Dithiothreitol (DTT), 0.1 M Life Technologies, Darmstadt 
Disodium hydrogen phosphate - dihydrate 
(Na2HPO4-7H2O) 
Merck KGaA, Darmstadt 
dNTP set (dATP, dTTP, dGTP, dCTP) QIAGEN, Hilden 
Ethanol ≥99.9%, Ph.Eur., reinst Carl Roth GmbH + Co. KG, Karlsruhe 
Ethidium Bromide (10 mg/mL) Carl Roth GmbH + Co. KG, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) SERVA Electrophoresis GmbH, Heidelberg 
EUROIMMUN sample buffer EUROIMMUN AG, Lübeck 
Formaldehyde 37% Carl Roth GmbH + Co. KG, Karlsruhe 
FuGENE® HD Tranfection Reagent Roche Diagnostics, Mannheim 
GelStar® Nucleic Acid Gel Stain Lonza, Rockland, USA 
Glycerol Carl Roth GmbH + Co. KG, Karlsruhe 
Glycin Carl Roth GmbH + Co. KG, Karlsruhe 
IGEPAL® CA-630 Sigma-Aldrich Chemie GmbH, Munich 
Magnesium chloride (MgCl2) Sigma-Aldrich Chemie GmbH, Munich 
Methanol (99%) Carl Roth GmbH + Co. KG, Karlsruhe 
Milk powder Carl Roth GmbH + Co. KG, Karlsruhe 
Phenol (Rotiphenol®) Carl Roth GmbH + Co. KG, Karlsruhe 
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Potassium chloride (KCl) Carl Roth GmbH + Co. KG, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Merck KGaA, Darmstadt 
Protease Inhibitor Cocktail III, EDTA-free Merck KGaA, Darmstadt 
Re-Blot Plus-Strong, 10x Millipore GmbH, Schwalbach 
RNAlater® RNA Stabilization Reagent QIAGEN, Hilden 
Roti®-Histofix 4% (pH7) Carl Roth GmbH + Co. KG, Karlsruhe 
Sodium chloride (NaCl) Carl Roth GmbH + Co. KG, Karlsruhe 
Sodium deoxycholate Carl Roth GmbH + Co. KG, Karlsruhe 
Sodium dodecyl sulfate (SDS), ultra pure Carl Roth GmbH + Co. KG, Karlsruhe 
Sodium hydroxide (NaOH) Carl Roth GmbH + Co. KG, Karlsruhe 
Sucrose Sigma-Aldrich Chemie GmbH, Munich 
SuperSignal® West Chemiluminescent 
Substrate (Pico, Femto) 
Thermo Fisher Scientific p/a Perbio Science 
Deutschland, Bonn 
Tetramethylethylenediamine (TEMED), 99% Carl Roth GmbH + Co. KG, Karlsruhe 
Tris hydroxymethyl aminomethane (Tris) Carl Roth GmbH + Co. KG, Karlsruhe 
Triton X-100 Sigma-Aldrich Chemie GmbH, Munich 
Tween® 20 Sigma-Aldrich Chemie GmbH, Munich 
X-tremeGENE DNA Transfection Reagent Roche Diagnostics, Mannheim 
Xylene cyanol FF Sigma-Aldrich Chemie GmbH, Munich 
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2.1.3.2  Buffers and solutions 
Name Ingredients 
6x Loading Dye 40% Sucrose 
 0.15% Bromphenol blue 
 0.15% Xylene cyanol FF 
 in deionized water 
APS working solution 10% APS 
 in deionizede water 
 store at -20°C 
Crystal violet stock solution 10 g Crystal violet 
 50 mL Formaldehyde (37%) 
 100 mL Ethanol (99.9%) 
 350 mL deionized water 
Crystal violet working solution 100 mL Crystal violet stock solution 
 100 mL Formaldehyde (37%) 
 800 mL deionized water 
DEPC water 1 mL DEPC 
 in 1 L deionized water 
 stir over night, autoclave 
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PBS-Tween 0.1% Tween® 20 
 10% 10x PBS 
 in deionized water 
Phosphate buffered saline (PBS), 10x, pH7.0 80 g NaCl 
 2 g KCl 
 26.8 g Na2HPO4-7H2O 
 2.4 g KH2PO4 
 adjust pH with 37% HCl 
 add 1 L deionized water 
 autoclave 
RIPA lysis buffer 150 mM NaCl 
 1% IGEPAL® CA-630 
 0.5% Sodium deoxycholate 
 0.1% SDS 
 50 mM Tris (pH8.0) 
 in deionized water 
 steril filtrate, store at 4°C 
add freshly before use: 10 µL Proteinase Inhibitor Cocktail 
 1 µL Benzonase 
 50 µL 0.1 mM DTT 
  to 939 µL RIPA lysis buffer 
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SDS working solution, 10% 100 g SDS 
 in 900 mL deionized water 
 heating to 68°C to dissolve SDS 
 adjust pH to 7.2 with HCl 
Transfer buffer, 10x 250 mM Tris-acetate 
 1.5 M Glycin 
 in deionized water 
Transfer buffer working solution 10% Methanol 
 10% Transfer buffer 10x 
 in deionized water 
Tris-acetate-EDTA (TAE) buffer, 50x, pH7.8 2 M Tris-acetate 
 0.05 M EDTA 
 1 M Acetic acid (100%) 
 in deionized water 
Tris-HCl buffer, 1.875 M, pH8.8 227.14 g Tris-acetate 
 adjust pH with 37% HCl 
 Add 1 L deionized water 
Tris-HCl buffer, 0.6 M, pH6.8 72.68 g Tris-acetate 
 adjust pH with 37% HCl 
 add 1 L deionized water 
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Western blot antibody buffer 1% dry milk 
 in PBS-Tween 
Western blot blocking solution 5% dry milk 
 in PBS-Tween 
 
2.1.4  Cell culture media and supplements 
Name Source 
Accutase™ (50 mL) PAA Laboratories GmbH, Cölbe 
Amino Acids Non Essential (100x, 50 mL) PAA Laboratories GmbH, Cölbe 
Avicel® RC581 FCM BioPolymer, Brussels, Belgium 
CryoMaxx S (50 mL) PAA Laboratories GmbH, Cölbe 
Dulbecco's MEM (DMEM) Biochrom AG, Berlin 
Dulbecco's Modified Eagles Medium (high 
glucose, 4.5 g/L, 500 mL) 
PAA Laboratories GmbH, Cölbe 
Dulbecco's PBS (1x, 500 mL) PAA Laboratories GmbH, Cölbe 
Fetal Bovine Serum (FBS) “Gold” (500 mL) PAA Laboratories GmbH, Cölbe 
L-glutamine (100x, 50 mL) PAA Laboratories GmbH, Cölbe 
Opti-MEM® I Reduced-Serum Medium (1x, 
50 mL) 
Life Technologies, Darmstadt 
OptiPRO TM serum-free medium (1 L) Life Technologies, Darmstadt 
Penicillin/Streptomycin (100x, 50 mL) PAA Laboratories GmbH, Cölbe 
Polybrene Sigma-Aldrich Chemie GmbH, Munich 
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Poly-L-Lysine (50 mL) Sigma-Aldrich Chemie GmbH, Munich 
Puromycin Dihydrochloride Ready Made 
Solution (10 mg/mL, 10 mL) 
Sigma-Aldrich Chemie GmbH, Munich 
Sodium pyruvate (100x, 50 mL) PAA Laboratories GmbH, Cölbe 
Trypsin-EDTA (1x, 50 mL) PAA Laboratories GmbH, Cölbe 
 
2.1.5  Cell lines 
Name Source 
293T Human fetal liver cell line (cell culture collection BNIa) 
BHK-J Baby hamster kidney cell line (cell culture collection BNIa) 
Huh7 Human liver cell line (ATCC CCL-185) 
MA104 Monkey kidney cell line (cell culture collection BNIa) 
RhiLu-hACE2 Transgenic embryonic Rhinolophus landeri lung cell line expressing 
human ACE2 (made in house) 
VeroE6 Monkey kidney cell line (ATCC CRL-1586) 
VeroFM Monkey kidney cell line (kind gift of Jindrich Cinatl, Universtiy of  
Frankfurt) 
Legend: aBNI (Bernhard Nocht-Institute for Tropical Medicine, Hamburg) 
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2.1.6  Viruses 
Name Description/Source 
BGO6-rSCV Recombinant SARS Coronavirus strain Frankfurt (NC_004718) with ORF 
6 from BtCoV/BM48-31/BGR/2008 (NC_014470), Doreen Muth 
O8full-rSCV Recombinant SARS Coronavirus strain Frankfurt (NC_004718) with 29 
nucleotide insertion in ORF 8 between position 27882 and 27883, Doreen 
Muth 
delO6-rSCV Recombinant SARS Coronavirus strain Frankfurt (NC_004718) with 2 stop 
codons instead of  amino acid 4 and 5 in ORF 6, Doreen Muth 
delO8-rSCV Recombinant SARS Coronavirus strain Frankfurt (NC_004718) without 
ORFs 8a and 8b, Doreen Muth 
rSCV Recombinant SARS Coronavirus strain Frankfurt (NC_004718), Susanne 
Pfefferle 
RVFV-Luc Renilla Luciferase expressing recombinant Rift Valley fever virus, Prof. Dr. 
Friedemann Weber, University of  Marburg 
SARS-CoV 
FRA1 
SARS Coronavirus strain Frankfurt (NC_004718), Institute of  Virology, 
Bonn 
 
2.1.7  Media and antibiotics 
Name Source 
Ampicillin Sigma-Aldrich Chemie GmbH, Munich 
Chloramphenicol Sigma-Aldrich Chemie GmbH, Munich 
Lysogeny Broth (LB) Broth (Lennox) Carl Roth GmbH + Co. KG, Karlsruhe 
Lysogeny Broth (LB) Agar (Lennox) Carl Roth GmbH + Co. KG, Karlsruhe 
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S.O.C. Medium Life Technologies, Darmstadt 
Recovery Medium Lucigen Corporation, Middleton, USA 
 
2.1.8  Bacteria 
Name Source 
BAC-Optimized Replicator v2.0 
elctrocompetent cells 
Lucigen Corporation, Middleton, USA 
E. cloni 10G (supreme, elite) electrocompetent 
cells 
Lucigen Corporation, Middleton, USA 
One Shot® Stbl3TM chemically competent cells Life Technologies, Darmstadt/made in-house 
One Shot® TOP10 chemically competent 
cells 
Life Technologies, Darmstadt/made in-house 
 
2.1.9  Enzymes 
2.1.9.1  Restriction endonucleases 
Name Source 
BamHI FastDigest® FERMENTAS GmbH, St. Leon-Roth 
EcoRI FastDigest® FERMENTAS GmbH, St. Leon-Roth 
MluI New England Biolabs GmbH, Frankfurt am Main 
NcoI New England Biolabs GmbH, Frankfurt am Main 
NotI FastDigest® FERMENTAS GmbH, St. Leon-Roth 
PspOMI New England Biolabs GmbH, Frankfurt am Main 
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2.1.9.2  Other enzymes 
Name Source 
Antarctic Phosphatase New England Biolabs GmbH, Frankfurt am 
Main 
Benzonase® Nuclease HC, purity >99% Merck KGaA, Darmstadt 
Phusion® High-Fidelity DNA Polymerase Thermo Fisher Scientific (Finnzymes), St. 
Leon-Roth 
RNaseOUTTM Recombinant Ribonuclease 
Inhibitor 
Life Technologies, Darmstadt 
RNase H Life Technologies, Darmstadt 
SuperScriptTM III Reverse Transcriptase Life Technologies, Darmstadt 
T4 DNA Ligase (5 u/µL) Roche Diagnostics, Mannheim 
 
2.1.10  DNA and protein markers 
Name Source 
GeneRulerTM 1 kb DNA Ladder FERMENTAS GmbH, St. Leon-Roth 
GeneRulerTM 1 kb Plus DNA Ladder FERMENTAS GmbH, St. Leon-Roth 
GeneRulerTM 100 bp Plus DNA Ladder FERMENTAS GmbH, St. Leon-Roth 
Supercoiled DNA Ladder New England Biolabs GmbH, Frankfurt am Main 
Supercoiled DNA Marker Set EPICENTRE, Madison, USA 
  
PageRulerTM Prestained Protein Ladder FERMENTAS GmbH, St. Leon-Roth 
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Figure 2.1: DNA and protein markers 
 
2.1.11  Oligonucleotides 
2.1.11.1  Cloning primers 
BGO6 cloning primers 
BG-ORF6-for ATGTTTAGTCTAGTTGCTTTCCA 
BG-ORF6-rev TTAAGGATGATCAATTTCCATAGG 
F 25778 F GAAGGTGACGGCATTTCAAC 
F 29260 R TTTGTATGCGTCAATGTGCTTG 
H-BG-ORF6-rev TGGAAAGCAACTAGACTAAACATCTGTTGTCACTTACTGTACTAG 
H-BG-ORF6-for CCTATGGAAATTGATCATCCTTAAAACGAACATGAAAATTATTCTCTTC 
RT-BG-ORF6 GTTCTGCTGATGCTATACTTAC 
Underlined: BG-CoV sequence 
delO6 cloning primers 
delORF6-for GACAACAGATGTTTCATTAATGAGACTTCCAGGTTACAATAGC 
delORF6-rev ACTTACTGTACTAGCAAAGCAATATTGTCGTTGCTACCG 
Underlined: double stop codon 
O8full cloning primers 
29nt-for CTGGTTACCAACCTGAATGGAATATAAGGTACAACACTAGGGGTAATACT 
29nt-rev TCCATTCAGGTTGGTAACCAGTAGGACAAGGATCTTCAAGCACATGA 
F 26020 F-P CGGCTCTTCAGGAGTTGCTA 
Underlined: additional 29nts 
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delO8 cloning primers 
delORF8-1-for AATGTCTGATAATGGACCCCAATCAAACCAACGTAGTGC 
delORF8-1-rev GTTCGTTTAGACTTTGGTACAAGGTTCTTCTAGATCC 
  
delORF8-2-for TAAAATGTCTGATAATGGACCCCAATCAAACCAACG 
delORF8-2-rev TTGTTCGTTTAGACTTTGGTACAAGGTTCTTCTAGATCC 
Underlined: sequence replacement for ORF8 
SARS-CoV ORF6 with C-terminal HA-tag 
Eco-Koz-SAO6-F ccgccGgaattcGCCACCatgTTTCATCTTGTTGACTTCCAGG 
SAO6-HA-Not-R 
 
atagtttaGCGGCCGCttaagcgtaatctggaacatcgtatgggt
aTGCAGCTGCTGGATAATCTAACTCCATAGGTTCTTC 
 
SARS-related bat-CoV ORF6 with C-terminal HA-tag 
Eco-Koz-BGO6-F ccgccggaattcGCCACCatgTTTAGTCTAGTTGCTTTCCAAGT
TAC 
BGO6-HA-Not-R atagtttaGCGGCCGCttaagcgtaatctggaacatcgtatggg
taTGCAGCTGCAGGATGATCAATTTCCATAGGTTCTTC 
   
Legend: gaattc EcoRI site 
 GCGGCCGC NotI site 
 GCCACCatg Kozak sequence 
 tacccatacgatgttccagattacgct HA-tag 
 GCAGCTGCA 3x alanine spacer 
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2.1.11.2  Sequence PCR primers 
A 2335 F AGGCACTCGAAATGTGCATTG 
    
B 5663 F TACAGCAAGGTACATTCTTATG 
    
C 9013 F TTGTTATGACACTAATTTGCTAG 
    
D 12200 F CAAGTTGGAAAAGATGGCAGATC 
D 15010 F ACTCAAATGAATCTTAAGTATGC 
D 18969 F AATCCAAAGGCTATCAAGTGTG 
    
E 21249 F CAAGCCGAAGGAACAAATTGATG 
E 22748 F TGCCAGATGATTTCATGGGTTG 
    
F 24444 F AGCCTTCAAACCTATGTAACAC 
F 27420 F GGCAATTCACCATTTCACCCTCTTG 
 
A 2860 R CGGATTCAACAGTGTAGACAGAGCA 
    
B 6490 R CAGCCATAAGATCCTCATGA 
    
C 9740 R GCAGCCTCCTCGAAGGTACT 
    
D 13779 R CCTCATCAAAATGACGTAGAGCATAGAC 
D 16166 R CTGCAAGACTGTATGTGGTGTGTACAT 
    
E 19430 R GCATCGTGTAATACACGTAGCAGA 
E 22427 R ATCTCCTGAGGGAACAACCC 
    
F 24481 R GCCCTGATTAGTTGTTGTGTTA 
F 25594 R ATAGAGGTACAAAAATTGCGCC 
F 29260 R TTTGTATGCGTCAATGTGCTTG 
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2.1.11.3  Sequencing primers 
A 324 F GTCCAACTCAGTTTGCCTGTC 
A 1067 F GGGAATGCCCAAAGTTTGTG 
A 1849 F ACATTGGACAACAGAGATCAG 
A 2587 F AATGGAGCTATCGTTGGCAC 
A 3366 F CTCTGTCTACACTGTTGAATC 
A 3970 F AATGGTAAGCTTTACCATGATTC 
    
B 4622 F CTTAAAGCTCCTGCCGTAGTG 
B 5304 F TGCTGGTGATGCTGCTAAC 
B 6022 F CAAATGACAGGCTTCACAAAG 
B 6782 F GAATTAGAGCTTCACTACCTAC 
B 7468 F ACTATTGTTAATGGCATGAAGAG 
B 8185 F GAAGTGACAGGTGACAGTTG 
    
C 8884 F TACACACCTTCCAAACTCATTG 
C 9578 F CATTCTTGGCTCACCTTCAATG 
C 10297 F CGTATCCAACCTGGTCAAAC 
C 11063 F GGTATTATGGCAATTGCTGC 
C 11570 F TAGGCTATTGTTGCTGCTG 
    
D 12200 F CAAGTTGGAAAAGATGGCAGATC 
D 12924 F CTAAATAGAGGTATGGTGCTG 
D 13700 F AAGATTGTCCAGCGGTTGCTGTC 
D 14510 F GTATGCTGCTGATCCAGCTATG 
D 15264 F ATAATGGCCTCTCTTGTTCTTG 
D 16059 F AAGTTACATGATGAGCTTACTG 
D 16779 F TATGGTGATGCTGTTGTGTAC 
D 17532 F TGACACTGTGAGTGCTTTAG 
D 18034 F CATTACTGGTCTTCATCCTACAC 
D 18656 F TTCTGTGGGTTTTGACTATGTC 
    
E 19250 F GTGAATAAGCATGCATTCCAC 
E 19984 F AAGGTTCAGTCAAAGGTCTAAC 
E 20738 F ATGTCGCAAAGTATACTCAACTG 
E 21452 F TGTGGTTTCAAGTGATATTCTTG 
E 22225 F TTCACCTGCTCAAGACATTTG 
E 22900 F CTGCTCTTAATTGTTATTGGCC 
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E 23658 F AAACCTCCGTAGATTGTAATATG 
    
F 24252 F ACAACAACATCAACTGCATTGG 
F 24905 F CAAAGAAGAGCTGGACAAGTACTTC 
F 25462 F GAGCGCTACCAAAATAATTGCGCTC 
F 26176 F TCTTGCTTTCGTGGTATTCTTG 
F 26918 F GATCACTGTGGCTACATCACGAAC 
F 27659 F GACTTCTATTTGTGCTTTTTAGC 
F 28462 F GATGGTACTTCTATTACCTAG 
F 29149 F GATCCACAATTCAAAGACAACG 
 
2.1.11.4  Real-time RT-PCR primers 
SARS-CoV  RNA 
SARS-F CCCGCGAAGAAGCTATTCG 
SARS-P Fam-ACGTTCGTGCGTGGATTGGCTTTG-BHQ 
SARS-R AGTTGCATGACAGCCCTCTACA 
 
2.1.11.5  Vector primers 
pBeloBAC 
pBELOscfwd GCCCTTAAACGCCTGGTTGCTAC 
pBELOscrev CGACAGGTGCTGAAAGCGAGC 
Seq9 CCCGTATTCAGTGTCGCTG 
  
pCAGGS vector 
 
pCAGGS-F_mod GCCTTCTTCTTTTTCCTACAGC 
pCAGGS-R_mod CTTTATTAGCCAGAAGTCAGATGC 
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pEZTM BAC vector 
BEZ-F1 CACTTTATGCTTCCGGCTCGTATG 
BEZ-R1 GGGATGTGCTGCAAGGCGATTAAG 
 
2.1.11.6  Additional primers 
SARS-CoV N PCR 
Ngenefwd GGCCATTTAGGTGACACTATAGATGTCTGATA
ATGGACCCCAATC 
 underlined = SP6 promoter 
Frev TTTTTTTTTTTTTTTTTTTTGTCATTCTCCTA
AGAAGC 
  
SARS CoV real-time RT-PCR standard 
T7-SAR S1 TAATACGACTCACTATATTATCACCCGCGAAG
AAGCT 
 underlined = T7 promoter sequence 
E 19031 R CTGAGCATCGTAGAACTTCC 
  
Forward primers  
F 27626 F GAGAAAGACAGAATGAATGAGC 
  
  
Reverse primers  
F 27900 R CCCTAGTGTTGTACCTTACAAG 
F 27990 R ACCATAGTGTGCCATCTATGA 
F 28182 R GGGTCCACCAAATGTAATGCGG 
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hACE2-puromycin resistance gene 
hACE2 1737F GAATGTAAGGCCACTGCTCAACTA 
pQC.Puro R TCAGGCACCGGGCTTGC 
 
2.1.11.7  Overview of sequencing PCRs and primers 
 
PCR/Amplicon No. Forward primer Reverse Primer Fragment length 
1 Seq9 F 26100 R 5,292 bp 
2 F 25462 F pBELOscfwd 4,423 bp 
Annealing temperature: 60°C, extension time: 80 sec 
Seq. primer PCR No. 1 Seq. primer PCR No. 2 
pBELOscrev F 25462 F 
E 21452 F F 26176 F 
E 22225 F F 26918 F 
E 22900 F F 27659 F 
E 23658 F F 28462 F 
F 24252 F F 29149 F 
F 24905 F  
 
  
Table 2.1: Sequencing PCRs and primers for subclone pEF 
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PCR/Amplicon No. Forward primer Reverse Primer Fragment length 
1 Seq9 D 16166 R 3,369 bp 
2 D 16059 F E 19430 R 3,363 bp 
3 D 18969 F E 22427 R 3,459 bp 
4 E 21249 F F 24481 R 3,255 bp 
5 E 22748 F F 25594 R 2,869 bp 
6 F 24444 F F 29260 R 4,762 bp 
7 F 27420 F pBELOscfwd 2,130 bp 
Annealing temperature: 57°C, extension time: 72 sec 
Seq. primer PCR No. 1 Seq. primer PCR No. 2 Seq. primer PCR No. 3 Seq. primer PCR No. 4 
pBELOscrev D 16059 F D 19250 F E 22225 F 
D 13700 F D 16779 F D 19984 F E 22900 F 
D 14510 F D 17532 F D 20738 F E 23658 F 
D 15264 F D 18034 F E 21452 F  
 D 18656 F  
 
Seq. primer PCR No. 5 Seq. primer PCR No. 6 Seq. primer PCR No. 7  
F 24252 F F 25462 F F 28462 F 
F 24905 F F 26176 F F 29149 F 
 F 26918 F  
F 27659 F 
 
  
Table 2.2: Sequencing PCRs and primers for subclone pDEF 
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PCR/Amplicon No. Forward primer Reverse Primer Fragment length 
1 Seq9 A 2860 R 3,370 bp 
2 A 2335 F B 6490 R 4,182 bp 
3 B 5663 F C 9740 R 4,090 bp 
4 C 9013 F D 13779 R 4,789 bp 
5 D 12200 F D 16166 R 3,975 bp 
6 D 15010 F E 19430 R 4,413 bp 
7 D 18969 F E 22427 R 3,459 bp 
8 E 21249 F F 24481 R 3,255 bp 
9 E 22748 F F 25594 R 2,869 bp 
10 F 24444 F F 29260 R 4,762 bp 
11 F 27420 F pBELOscfwd 2,465 bp 
Annealing temperature: 56°C, extension time: 72 sec 
Seq. primer PCR No. 1 Seq. primer PCR No. 2 Seq. primer PCR No. 3 Seq. primer PCR No. 4 
pBELOscrev A 2587 F B 6022 F C 9578 F 
A 324 F A 3366 F B 6782 F C 10297 F 
A 1067 F A 3970 F B 7468 F C 11063 F 
A 1849 F A 4622 F B 8185 F C 11570 F 
 B 5304 F C 8884 F D 12200 F 
 
Seq. primer PCR No. 5 Seq. primer PCR No. 6 Seq. primer PCR No. 7 Seq. primer PCR No. 8 
D 12924 F D 16059 F D 19250 F E 22225 F 
D 13700 F D 16779 F D 19984 F E 22900 F 
D 14510 F D 17532 F D 20738 F  
D 15264 F D 18034 F E 21452 F 
 D 18656 F  
 
Seq. primer PCR No. 9 Seq. primer PCR No. 
10 
Seq. primer PCR No. 
11 
 
E 23658 F F 24905 F F 27659 F 
F 24252 F F 25462 F F 28462 F 
 F 26176 F F 29149 F 
F 26918 F  
 
  
Table 2.3: Sequencing PCRs and primers for the SARS-CoV full-length clone 
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2.1.12  Plasmids 
Name Source 
pCAGGS-MCS Prof. Dr. Stephan Becker, University of  
Marburg 
pEZ BAC Lucigen Corporation, Middleton, USA 
pBeloBAC11 New England Biolabs GmbH, Frankfurt am 
Main 
  
 
 
  
Figure 2.2: Vector maps. 
PEZ BAC was used for blunt end cloning of  PCR products. PBeloBAC11 was used for cloning of  the 
SARS-CoV cDNA clone. PCAGGS-MCS was used for eukaryotic gene expression. 
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2.1.13  Kits 
Name Source 
Agencourt® AMPure® Beckman Coulter GmbH, Krefeld 
GeneJETTM Plasmid Miniprep Kit FERMENTAS GmbH, St. Leon-Roth 
mMESSAGE mMACHINE® Kit Ambion/Applied Biosystems, Darmstadt 
MEGAscript® Kit Ambion/Applied Biosystems, Darmstadt 
NucleoBond® Xtra Midi Macherey-Nagel, Düren 
PhusionTM Site-Directed Mutagenesis Kit Thermo Fisher Scientific (Finnzymes), St. Leon-
Roth 
QIAamp DNA Blood Mini Kit QIAGEN, Hilden 
QIAamp® Viral RNA Mini Kit QIAGEN, Hilden 
QIAEXX II® Gel Extraction Kit QIAGEN, Hilden 
Renilla Luciferase Assay System Promega, Mannheim 
RNeasy® Mini Kit QIAGEN, Hilden 
SuperScriptTM III One-Step RT-PCR 
System with Platinum® Taq DNA 
Polymerase 
Life Technologies, Darmstadt 
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2.1.14  Antibodies 
Primary antibodies 
Name Target (antigen) Species Dilution 
(Application) 
Source 
β-actin β-actin mouse 1:2000 (WB) Sigma-Aldrich, 
Munich 
anti-FLAG FLAG-tag epitope mouse/ 
rabbit 
1:5000 (WB),          
1:100 (IF) 
Sigma-Aldrich, 
Munich 
anti-Golgi 58K Golgi protein 58K/ 
cytoplasmic part 
mouse 1:100 (IF) Sigma-Aldrich, 
Munich 
anti-HA HA-tag epitope mouse/ 
rabbit 
1:5000 (WB),          
1:100 (IF) 
Sigma-Aldrich, 
Munich 
Delseith serum SARS-CoV human 1:100 (IF) BNI 
Legend: Western blot (WB), Immunofluorescence assay (IF), Bernhard Nocht-Institute (BNI) 
 
Secondary antibodies 
Name Label Species Dilution (Application) Source 
anti-human Cy2 goat 1:200 (IF) Dianova, Hamburg 
anti-mouse Cy3 goat 1:200 (IF) Dianova, Hamburg 
anti-mouse HRP goat 1:20,000 (WB) Dianova, Hamburg 
anti-rabbit Cy2 goat 1:200 (IF) Dianova, Hamburg 
anti-rabbit HRP goat 1:20,000 (WB) Millipore GmbH, Schwalbach 
Legend: Immunofluorescence assay (IF), horseradish peroxidas (HRP), Western blot (WB) 
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2.1.15  Software 
Name 
AxioVision Rel. 4.8 
BioEdit Sequence Alignment Editor version 7.0.9.0 
DNASTAR Lasergene 7 (EditSeq, SeqMan) 
SigmaPlot 11.0 
Vector NTI 10.3.0 
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2.2  Methods 
2.2.1  Cell culture and virus propagation 
2.2.1.1  General cell culture methods 
All cells were maintained in DMEM with high glucose (4.5 g/L) supplemented with 5% 
Penicillin/Streptomycin, 5% non-essential amino acids, 5% sodium pyruvate, 5% L-glutamine 
and 10% FBS in an incubator with a 5% CO2 environment at 37°C. Passaging was done 
dependent on cell growth. Confluent cells were washed once with PBS and treated with Trypsin 
(or Accutase™ in case of  RhiLu-hACE2 cells) at 37°C until detachment was completed. Cells 
were then suspended in supplemented DMEM and seeded in a new cell culture flask at a dilution 
according to their growth between 1:3 and 1:10. Cell culture flasks were filled with supplemented 
DMEM according to their sizes (T25 = 6 mL, T75 = 12 mL, T175 = 25 mL) 
For cryopreservation cells were detached as described above and counted. Cell amount was 
adjusted to 5x 106 cells/cryo tube, the cell suspension was centrifuged at 300x g for 3 min. The 
cleared supernatant was discarded, the cell pellet was resuspended in 1 mL CryoMaxx/cryo tube 
and cells were aliquoted. In order to freeze cells controlled at 1°C/min cryo tubes were placed in 
an insulated box filled with isopropanol and placed in a -70°C freezer. After 16 h cells were 
transferred to liquid nitrogen. 
 
2.2.1.2  Transfection of eukaryotic cells 
Eukaryotic cells were transfected using Roches FuGENE® HD or X-tremeGENE Transfection 
Reagent for analysis of  protein expression in Western blot analysis or Immunofluorescence 
assays. 
Cells were seeded according to their size and speed of  growth between 1x 105 and 
3x 105 cells/mL, seeding 500 µL/24well or 2 mL/6well. Confluency between 70-80% is desired 
for optimal transfection efficiency with FuGENE® HD or X-tremeGENE. After cultivation over 
night in an incubator, medium was exchanged by fresh supplemented DMEM, 400 µL/24well or 
1.5 mL/6well and the transfection complex was set up. The amount of  plasmid DNA and the 
ratio of  transfection reagent to DNA used varied in accordance to the cell lines transfection 
efficiency and downstream application. The transfection complex was prepared according to 
manufacturer’s instructions. Briefly, plasmid DNA was diluted in OptiPROTM serum-free medium 
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in a 1.5 mL reaction tube, 100 µL/24well or 500 µL/6well. FuGENE® HD was pipetted into the 
diluted plasmid DNA without getting in contact with the plastic wall of  the reaction tube. The 
transfection complex was then vortexed, briefly centrifuged and incubated at room temperature 
for 15 min. Thereafter, the transfection complex was pipetted drop-wise into the fresh 
supplemented DMEM. Cells were further incubated for 24h and subsequently used for Western 
blot analysis or Immunofluorescence assay. 
 
2.2.1.3  Generation of recombinant virus 
The generation of  recombinant SARS-CoV and all cell culture works with them were carried out 
under biosafety level 4 conditions. 
For generation of  recombinant viruses 7-methyl guanosine capped, poly-A-tailed in vitro 
transcribed SARS-CoV genomic full-length RNA was used (2.2.2.11). In order to improve 
translation efficiency of  viral proteins [96] capped nucleocapsid transcript was co-electroporated. 
BHK-J and Vero FM cells were grown to confluency and detached as described above. 
Resuspended cells were counted in a Neubauer improved counting chamber. 4x 106 BHK-J cells 
were needed for one electroporation reaction. The amount of  cells was adjusted according to the 
number of  electroporations, cells were centrifuged at 300x g for 3 min at 4°C and washed twice 
in 20 mL ice cold PBS. Cells were then resuspended in 1 mL OptiMEMTM and centrifuged again 
as described above. OptiMEMTM was discarded qualitatively and the BHK-J cells were 
resuspended in 100 µL OptiMEM per electroporation reaction. Cells were kept on ice until 
further use. 
2 mm electroporation cuvettes and 1.5 mL reaction tubes were placed on ice for cooling. RNA in 
vitro transcripts were thawed on ice. Per electroporation reaction 10 µg of  SARS-CoV genomic 
full-length RNA and 2 µg of  nucleocapsid transcript were pipetted into one pre-cooled 1.5 mL 
reaction tube. 100 µL cell suspension was mixed with the in vitro transcripts by carefully pipetting 
up and down twice, and then the RNA-cell-suspension was transferred to a pre-cooled 
electroporation cuvette and placed on ice until electroporation. The cuvette containing the RNA-
cell-suspension was placed in the shock pod of  the Gene Pulser XcellTM and one pulse was 
applied (pre-set protocol for BHK-J cells; 25 msec, 140 V, exponential decay). The cells were left 
at room temperature for 10 min. Thereafter, the cells were resuspended in 12 mL supplemented 
DMEM, seeded in a T75 cell culture flask and transferred to the incubator. 
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5-6x 106 VeroFM cells were seeded in a T175 cell culture flask in 20 mL supplemented DMEM 
and cultured overnight in an incubator for virus recovery. 
After 24h electroporated BHK-J cells were scraped off  and cells and recombinant virus 
containing cell culture supernatant were decanted into a 50 mL centrifuge tube and spun at 
300x g for 3 min. 2.5 mL of  the cleared supernatant was transferred to the T175 cell culture flask 
containing VeroFM cells, the remaining supernatant and cells were stored at -70°C if  retry was 
necessary. The infected cell culture flask was transferred to an incubator for virus growth for 3-4 
days. At day 0, 2, 3 and if  necessary 4, 140 µL supernatant were sampled for isolation of  viral 
RNA (2.2.2.1) to monitor virus replication in real-time RT-PCR (2.2.3.3). When virus growth 
could be confirmed the virus containing supernatant was decanted into a 50 mL centrifuge tube, 
cleared from cell debris at 300x g for 3 min and aliquoted á 500 µL in cryo tubes. Recombinant 
virus was stored at -70°C. Plaque assays were done for determining the amount of  infectious 
particles in plaque forming units per mL (2.2.1.6). 
When virus growth was not sufficient after 3 days, the cell culture was incubated for another day 
before harvesting the supernatant. 
 
2.2.1.4  Production of virus stock 
5-6x 105 VeroFM cells were seeded in a T175 cell culture flask in 25 mL supplemented DMEM 
and cultivated overnight in an incubator. Cells were infected at a multiplicity of  infection (MOI) 
of  0.0001 (50-60 PFU per flask) for 1 h at 37°C in a total volume of  10 mL. Thereafter, the cell 
culture flask was filled up with 10 mL fresh supplemented DMEM and the infected cell culture 
was further incubated for 3 days. 140 µL cell culture supernatant were sampled at day 0 and 3 for 
isolation of  viral RNA (2.2.2.1) and verification of  virus growth in real-time RT-PCR (2.2.3.3). 
3 days after infection the virus containing supernatant was harvested and centrifuged at 300x g 
for 3 min. The cleared supernatant was aliquoted á 500 µL in cryo tubes, virus stocks were stored 
at -70°C. After confirmation of  virus growth in real-time RT-PCR the amount of  infectious 
particles was determined by plaque titration (2.2.1.6). 
 
2.2.1.5  Virus infection 
For virus infection studies cells were detached and counted in a Neubauer improved counting 
chamber as described above. The cell concentration was adjusted to 4x 105 cells/mL. Cells were 
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seeded in 24- or 6-well plates á 500 µL or 2 mL, respectively and cultivated overnight in an 
incubator. 
Virus stocks were diluted in OptiPROTM according to the desired MOI prior to infection (e.g. 
800 PFU/mL for an MOI of  0.001). 
Cell culture supernatant was removed from the cells and 250 µL or 1 mL virus master mix were 
pipetted to one 24-well or 6-well, respectively. After 1 h virus adsorption in an incubator the virus 
master mix was removed, cells were washed once with PBS and wells were refilled with 
supplemented DMEM (250 µL/24-well, 2 mL/6-well). Cell culture plates were placed back in an 
incubator for cultivation. 
 
2.2.1.6  Plaque titration assay 
The amount of  infectious particles in plaque forming units per mL (PFU/mL) was determined 
with the help of  a plaque titration assay. This method is based on the assumption that one virus 
particle upon infection of  a single cell only spreads horizontally to neighboring cells when 
overlayed with high viscous medium. So one infectious particle creates a hole in a confluent cell 
monolayer (plaque) and the amount of  PFU in a given volume can be calculated. In case of  
SARS-CoV the optimal high viscous overlay proved to be a 1:2 dilution of  2.4% Avicel in 
2xDMEM. 
500 µL VeroE6 cells were seeded per 24-well at a concentration of  3x 105 cells/mL 16-24h prior 
to titration. 
The virus containing samples were serially diluted 1:10 (60 µL sample in 540 µL supplemented 
DMEM). Each dilution step was titrated in duplicates. After removal of  the cell culture 
supernatant from the VeroE6 plates, 200 µL of  diluted sample were pipetted into one 24-well, 
the plate was placed back into an incubator for 1 h for virus adsorption. Next, the diluted virus 
samples were removed and the cells overlayed with 500 µL Avicel-2xDMEM per 24-well. After 
3 days of  incubation the overlay was removed and cells were fixated for at least 20 min in 6% 
Formaldehyde. Cells were washed once with 1x PBS and stained with 500 µL crystal violet 
working solution for 15 min. Following removal of  crystal violet the stained cell layer was washed 
with water and left for drying until analysis. All dilutions with distinct plaques were counted and 
PFU/mL calculated according to the following equation: 
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2.2.1.7  Lentiviral Transduction 
Lentiviral transduction is a highly efficient method for the transfer of  genes into a broad variety 
of  cell lines [102]. The major characteristic of  lentiviruses is their ability to integrate their genetic 
information into the genome of  an infected cell. This way, foreign genes can be permanently 
transferred into host cells. 
The method of  lentiviral transduction utilizes the ability of  Vesicular stomatitis virus 
glycoprotein (VSV-G) pseudotyped lentiviruses to infect most mammalian cell cultures and to 
integrate a transgene (here hACE2 or viral genes and a puromycin selection marker) into the 
genome of  the infected cell [100]. The G protein thereby mediates receptor-independent virus 
entry. For safety reasons the structural proteins of  the lentiviruses are provided in trans to 
produce single-cycle infectious particles. Therefore a packaging cell line is transfected with three 
different plasmids encoding proteins for assembly of  the lentiviruses, which are subsequently 
released into the cell culture supernatant. The packaging plasmid encodes the lentiviral 
polymerase and the group-specific antigens but lacks the envelope protein. This is substituted by 
VSV-G located on a second plasmid. The third plasmid carries the gene of  interest. Upon cellular 
entry of  the lentiviral vector the viral RNA genome is reverse transcribed and the produced 
cDNA is integrated into the cell genome. Integration occurs randomly and can lead to the 
disruption of  cellular genes. 
All used lentiviruses were kindly provided by Alexander Pfeifer (Institute of  Pharmacology and 
Toxicology, University of  Bonn).  
 
 Generation of a bat cell line stably expressing human ACE2 
In order to establish reservoir-related cell culture models for SARS-CoV infection studies, a new 
bat cell line from the reservoir host had to be generated. All Rhinolophus bats are environmentally 
protected. Since our working group had an exemption license for bat catching in Ghana, the 
endemic species Rhinolophus landeri was caught. 
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The generation of  a SARS-CoV susceptible bat cell line stably expressing human ACE2 was done 
in the course of  the bachelor thesis of  Hanna Roth [103]. Briefly, immortalized RhiLu cells were 
seeded at a concentration of  2x 105 cells/mL in a 6-well and cultivated overnight. Cells were then 
infected with lentiviruses carrying the sequence information of  hACE2 at an MOI of  0.0005 
(determination of  the biological titer is described in the reference). Infection was done in 800 µL 
supplemented DMEM containing 12 mg/mL polybrene, for better attachment of  viruses to the 
cellular membrane. 24h p.i. 1.2 mL fresh supplemented DMEM was added to the 6-well and cells 
were further incubated. 48h p.i. virus containing medium was removed, cells were washed twice 
with PBS and 2 mL selection medium (supplemented DMEM containing 4 µg/mL puromycin) 
were added to the well. The use of  selection medium leads to the die off  of  cells which did not 
successfully integrate hACE2 and the attached puromycin resistance gene into their genome. The 
selection medium was changed every 3 days while the puromycin concentration was gradually 
increased to 6 µg/mL in order to increase the selection pressure. 10 days p.i. cells were detached 
with Accutase™, seeded in a fresh 6-well and further incubated in selection medium. When the 
cells reached confluency, they were expanded into a T25 culture flask. The so generated mixed 
culture of  RhiLu cells stably expressing hACE2 was propagated by using selection medium 
containing only 4 µg/mL puromycin only after every second passage.  
 
 Transduction of primate and bat cells for transient 
expression of a transgene 
Lentiviral transduction can also be used for the temporary expression of  a foreign gene for 
example in the context of  a tans-complementation experiment. Here cells are not selected for 
successful genome integration. Therefore, within the produced cell culture not all cells express 
the transduced gene. This method is generally used for short termed experiments, since 
expression levels of  the transduced gene gradually ceases. In this work lentiviral transduction was 
used for the transient expression of  the proteins encoded by SARS-CoVs ORF8. 
VeroFM and MA104 cells were seeded at a concentration of  1x 105 /mL, RhiLu-hACE2 cells at a 
concentration of  3x 105 /mL in 24-well plates and cultivated overnight. Cells were infected with a 
physiological titer of  50 ng reverse-transcriptase activity per 24-well in supplemented DMEM and 
cultivated for 48h, when protein expression generally reaches its maximum.  
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2.2.2  Molecular biological methods 
2.2.2.1  Isolation of viral RNA 
Viral RNA from cell culture supernatant was extracted with QIAGENs QIAamp® Viral RNA kit 
according to manufacturer’s instructions. Briefly, 70 µL or 140 µL virus containing cell culture 
supernatant were added to 560 µL AVL containing carrier RNA, puls-vortexed and incubated for 
10 min at room temperature. Samples were stored at -20°C or immediately processed. 560 µL 
ethanol were added to the samples and puls-vortexed again for 15 sec. Samples were then applied 
to a QIAamp Mini column and RNA bound to the columns membrane by brief  centrifugation. 
Bound RNA was washed with Buffer AW1 and AW2. To eliminate all residual buffer, the column 
was spun at full speed for 3 min. RNA was eluted in 60 µL AVE pre-heated to 80°C. The eluate 
was stored at -20°C. 
 
2.2.2.2  cDNA synthesis 
Transcription of  RNA into cDNA was done with Invitrogens SuperScriptTM III Reverse 
Transcriptase according to manufacturer’s instructions, generally using specific reverse primers. 
Master mix I and II were prepared according to the following reaction set up: 
dNTPs (10 mM each) 0.5 µL 
Reverse primer (10 µM) 0.5 µL 
RNase-free water 2.0 µL 
BSA (Roche, 1 mg/mL) 0.5 µL 
Template RNA 2.5 µL 
Total 6.0 µL 
 
 
 
 
 
Master mix I for cDNA synthesis 
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5x First-Strand Buffer 2.0 µL 
DTT (0.1 M) 0.5 µL 
SuperScriptTM III Reverse Transcriptase 1.0 µL 
RNaseOUTTM 0.5 µL 
Total 4.0 µL 
 
 
Reverse Transcription was done according to the following temperature profile: 
Denaturation 65°C 5 min Master mix I 
Primer annealing 4°C 1 min  
cDNA synthesis 55°C 60 min After 1 min add master mix II 
Inactivation 70°C 5 min  
Storage 4°C ∞ Add 0.5 µL RNaseH 
Elimination of  template RNA 37°C 15 min  
Storage 4°C ∞  
 
CDNAs were stored at -20°C until used in downstream applications. 
 
2.2.2.3  Isolation of genomic DNA 
Cellular genomic DNA was extracted using QIAGENs QIAamp® DNA Blood Mini Kit 
according to manufacturer’s instructions. Briefly, cells were washed once with PBS and detached 
using trypsin or Accutase™. Detached cells were resuspended in PBS and pelleted for 3 min at 
1000x g. Supernatant was removed and cells resuspended again in 200 µL PBS. 20 µL protease 
and 200 µL Buffer AL were added. The sample was incubated at 56°C for 10 min for cell lysis 
and protein degradation. 200 µL ethanol were added to the sample and the mixture was applied 
to a QIAamp Mini spin column. DNA was bound to the membrane by centrifugation at 6000x g 
Master mix II for cDNA synthesis 
Temperature profile for cDNA synthesis 
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for 1 min. Bound DNA was washed with Buffer AW1 and AW2, the membrane was dried by 
centrifugation at 16,100x g for 3 min. DNA was eluted in 100 µL Buffer AE pre-heated to 80°C. 
Extracted DNA was stored at -20°C. 
 
2.2.2.4  Isolation of plasmid DNA 
Plasmid DNA was isolated in small scale with Fermentas' GeneJETTM Plasmid Miniprep Kit or in 
medium scale with MACHEREY-NAGELs NucleoBond® Xtra Midi kit according to the 
manufacturer’s instructions. 
 
For small scale plasmid preparations overnight cultures of  a quarter petri dish plate of  bacteria 
carrying low copy plasmids or ⅛ of  a petri dish plate of  bacteria carrying high copy plasmids 
were used. The culture was scraped and resuspended by vigorous vortexing in 250 µL 
Resuspension Solution. 250 µL of  Lysis Solution were added for cell lysis. After addition of  
350 µL Neutralization Solution cell debris were pelleted at 11,000x g for 5 min and the 
supernatant was transferred to a GeneJETTM spin column by decanting. Plasmid DNA was 
bound to the filter membrane by centrifugation. The column washed twice with 500 µL Wash 
Solution. In order to eliminate residual buffer the column was spun dry at full speed for 2 min. 
Plasmid DNA was eluted in 50 µL Elution Buffer. For elution of  low copy plasmids the 
membrane was incubated twice with 25 µL 37°C pre-warmed Elution Buffer. Plasmid DNA 
containing eluate was stored at -20°C. Integrity of  the plasmids was verified by agarose gel 
electrophoresis (2.2.2.8) of  20 µL low copy plasmid or 5 µL high copy plasmid. 
 
For medium scale plasmid preparations 5-10 petri dishes of  an overnight culture were used. The 
bacteria were scraped off  and resuspended in 8-16 mL Buffer RES by vortexing in a 50 mL 
centrifuge tube. The bacteria were lysed with 8-16 mL Buffer LYS for 5 min at room 
temperature. Meanwhile, the NucleoBond® Xtra column and column filter were equilibrated with 
Buffer EQU. 8-16 mL Buffer NEU were added to the lysed bacteria and the bacteria suspension 
was applied to the NucleoBond® Xtra column filter. Following loading of  the whole bacteria 
suspension the column filter was washed with Buffer EQU and afterwards discarded. Next, the 
column was washed with Buffer WASH. After washing the plasmid DNA was eluted from the 
column with 5 mL Buffer ELU and precipitated out of  the eluate by addition of  3.5 mL 100% 
isopropanol and centrifugation at 15,000x g and 4°C for 30min. The plasmid DNA pellet was 
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washed once with 70% ethanol, centrifuged again at 15,000x g and room temperature for 5 min 
and air dried. The pellet was resuspended in an appropriate amount of  Ampuwa® (100-200 µL). 
Plasmid DNA was stored at -20°C. 
 
2.2.2.5  Purification of PCR products 
PCR products were routinely purified with Beckman Coulters Agencourt® AMPure® XP in order 
to remove excess primers, dNTPs, salts and enzymes. 
The procedure was done according to the manufacturer’s instructions. Briefly, Agencourt® 
AMPure® XP was resuspended by vortexing and 1.8x the volume of  the PCR reaction was mixed 
with the PCR product by pipetting. The mixed sample was incubated at room temperature for 
10 min, then the sample containing PCR tube was placed on an Agencourt SPRIPlate 96 Super 
Magnet Plate for 10 min.  The magnetic beads carrying the bound PCR products separate from 
the solution. The cleared solution was discarded and the beads washed twice with 70% ethanol. 
All residual ethanol was removed and the beads were left at room temperature for complete 
drying. The dried magnetic beads were resuspended in an appropriate volume of  Ampuwa® and 
PCR products were eluted by repeated pipetting.. Magnetic beads were either left in the 
suspension and the purified PCR product was stored at 4°C or the PCR tube was placed on the 
magnetic plate to separate beads from PCR products, cleared PCR product was transferred to a 
fresh tube and stored at 4°C for short term or at -20°C for long term. 
 
2.2.2.6  Gel extraction of DNA fragments 
In order to eliminate undesired DNA fragments after digestion of  plasmid DNA or unspecific 
PCR products, restriction or PCR reactions were separated on an Roti®garose Broad Range gel, 
DNA fragments or PCR products of  interest were cut out of  the gel with a scalpel and purified 
using QIAGENs QIAEX II® Gel Extraction Kit according to manufacturer’s instructions. 
Briefly, excised gel slices were put in a 1.5 mL reaction tube and weighed. Depending on the size 
of  the fragments 3 volumes of  Buffer QX1 or 3 volumes of  Buffer QX1 and 2 volumes of  
Ampuwa® for fragments of  100 bp – 4 kb or > 4 kb respectively were added to the tube (100 mg 
gel = 100 µL). QIAEX II® silica particles were resuspended by vortexing for 30 sec and 15 µL 
were added to the gel containing buffer. Agarose was solubilized and DNA bound to QIAEX II® 
silica particles by incubation for 10 min at 50°C on a thermo shaker rotating at 1400 rpm. 
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Thereafter, samples were centrifuged and the supernatant was removed carefully. The pellet was 
washed once with Buffer QX1 and twice with Buffer PE. Resuspension of  the pellets was done 
by inverting and flicking the tube in order to minimize shear forces on large DNA fragments. 
After washing, the pellet was air-dried until it became white. DNA fragments were eluted in 
20 µL Ampuwa® by incubation for 5 min at room temperature, 5 min at 50°C, or 10 min at 50°C 
according to fragment sizes of  ≤ 4 kb, 4 – 10 kb, or ≥ 10 kb, respectively. After incubation the 
samples were centrifuged and the supernatant was transferred to a clean 1.5 mL reaction tube. 
DNA fragments were ideally used immediately for downstream applications or stored at -20°C. 
 
2.2.2.7  Phenol-chloroform extraction and alcohol precipitation 
of nucleic acids 
Since in vitro transcriptions require very clean templates for optimal yields, linearized SARS-CoV 
full-length plasmids were purified by phenol-chloroform extraction. In vitro transcribed RNAs 
used in cell culture for electroporation were also phenol-chloroform extracted for optimal purity. 
Briefly, 1 volume of  phenol-chloroform was added to one reaction, mixed by inversion and 
phases were separated by centrifugation for 5 min at 4°C and 11,000x g. The upper nucleic acid 
containing aqueous phase was transferred to a clean 1.5 mL reaction tube and 1 volume of  
chloroform was added. Phase separation was done by centrifugation for 5 min at 4°C and 
11,000x g. The upper nucleic acid containing phase was again transferred into a fresh 1.5 mL 
reaction tube and the nucleic acids were precipitated by ethanol precipitation. 
 
Alcohol precipitation is a standard method for eliminating proteins, salts and small nucleotides 
such as enzymes, buffers, or primers from nucleic acids in restriction or PCR reactions and can 
be done with ethanol or isopropanol. 
Ethanol precipitation was done by adding 0.1 volume of  3 M sodium acetate (pH 6.6) and 
2.5 volumes of  99.9% ethanol to the reaction and centrifugation at 4°C and 11,000x g for 
30 min. The pellet was washed once or twice with 70% ethanol, centrifuged at room temperature 
and 11,000x g for 5 min, air dried and resuspended in an appropriate volume of  Ampuwa®. 
Isopropanol precipitation was done by adding 0.7 volume of  99.9% isopropanol to the reaction 
and centrifugation at 4°C and 11,000x g for 30 min. The pellet was washed once or twice with 
70% ethanol, centrifuged at room temperature and 11,000x g for 5 min, air dried and 
resuspended in an appropriate volume of  Ampuwa®. 
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When precipitating RNAs all steps were carried out at 4°C, DEPC treated water was used for 
diluting ethanol and pellets were resuspended in RNase-free water. 
 
2.2.2.8  Agarose gel electrophoresis of DNA 
Electrophoretic analysis of  DNAs on agarose gels was done to verify successful restriction or 
PCR amplification and to separate DNA fragments within a reaction for subsequent extraction. 
The percentage of  agarose in the gel varied between 0.8 and 2% for very large and very small 
DNA fragments, respectively. Roti®garose GTQ was used for standard gel electrophoresis, 
Roti®garose Broad Range for preparative gels. In addition, 50x TAE was sterile filtrated for 
preparative gels. 
The appropriate amount of  agarose was weighed and dissolved in 1x TAE buffer by heating in a 
microwave oven. After complete dissolving the agarose was cooled down without letting it 
solidify again and 1.5 µL of  1% ethidium bromide were added per 50 mL agarose. The agarose 
was poured under a fume hood into the gel tray and left for solidification. 
An appropriate amount of  DNA (200-300 ng plasmid DNA, 5 µL PCR product) was mixed with 
6x loading dye and applied to one lane. 500 ng per lane of  a suitable DNA marker were used to 
determine the size of  DNA fragments. 
Separation of  DNA fragments was done applying 80-120 V, depending on the size of  the 
electrophoresis chamber. 
Preparative gels were not stained with ethidium bromide but incubated after electrophoresis with 
Lonzas GelStar® Nucleic Acid Gel Stain (diluted 1:1000 in 1x TAE). 
 
2.2.2.9  Photometric determination of nucleic acid concentration 
Nucleic acid concentrations were determined using PeqLabs NanoDrop 2000c. The instrument 
was blanked with the liquid the nucleic acid was dissolved in, usually Ampuwa® or AVE. Then 
1 µL of  nucleic acid sample was applied and measured 3 times. The mean value was calculated 
and accepted as the concentration. 
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2.2.2.10  Sequencing of DNA 
Agencourt® AMPure® XP purified PCR products (2.2.2.5) or plasmid minipreparations (2.2.2.4) 
were sent to SeqLab Sequence Laboratories Göttingen for sequencing. 
Sequencing primer (10 mM) 1.0 µL 
DNA 400 ng 
Ampuwa® add to 7.0 µL 
 
Sequence data was viewed with BioEdit 7.0.9.0 and sequence alignments were generated with 
DNASTER Lasergene 7. 
 
2.2.2.11  Generation of capped RNA transcripts 
In vitro transcription of  capped full-length SARS-CoV genomic RNAs was done with Ambions 
mMESSAGE mMACHINE® Kit according to manufacturer’s instructions with minor changes 
for the transcription of  long templates. 
In front of  the SARS-CoV genome the minimum T7 promoter sequence needed for 
transcription was added. A NotI restriction site, directly following the poly-A-tail, was used for 
linearization of  the plasmid containing the full-length SARS-CoV genome. 
6 µg of  full-length SARS-CoV plasmid were linearized with 5 µL Fermentas FastDigest® NotI for 
at least 30 min in a total volume of  200 µL (2.2.2.13). Completeness of  linearization was checked 
by agarose gel electrophoresis (2.2.2.8). Linearized plasmid was purified by phenol-chloroform 
extraction (2.2.2.7). The plasmid was resuspended in 20 µL RNase-free water; the plasmid 
concentration was determined (2.2.2.9) and adjusted to 1 µg/5 µL. The in vitro transcription 
reaction was pipetted on ice according to the following set up: 
 
 
 
 
 
Sequence reaction set up 
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2x NTP/CAP 15 µL 
10x Reaction Buffer 3 µL 
GTP 4 µL 
Enzyme Mix 3 µL 
Linearized plasmid (1 µg) 5 µL 
Total 30 µL 
 
The reaction was placed in a thermo mixer and incubated at 37°C for 3 h. After 3 h 1 µL of  
TURBO DNase was added to the reaction and residual DNA template was degraded at 37°C for 
15 min. Thereafter, 15 µL Ammonium Acetate Stop Solution and 105 µL nuclease-free water 
were added to the reaction and the in vitro transcript was phenol-chloroform extracted (2.2.2.7). 
Isopropanol precipitation was started only after incubation of  RNA with isopropanol at -20°C 
overnight. The RNA pellet was resuspended in 20 µL nuclease-free water, concentration was 
determined and adjusted to 5 µg/µL. In vitro transcripts were stored at -70°C. 
 
For generation of  capped nucleocapsid RNA the template for in vitro transcription was generated 
by PCR using the primer Ngenefwd, which contains the minimum SP6 promoter sequence and 
Frev with PhusionTM polymerase (2.2.3.1). The PCR product was purified with Agencourt® 
AMPure® XP (2.2.2.5) and adjusted to a concentration of  1 µg/7 µL. 
  
Reaction set up for in vitro transcription of  SARS-CoV genomic RNA 
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The in vitro transcription reaction was pipetted on ice according to the following set up: 
2x NTP/CAP 15 µL 
10x Reaction Buffer 3 µL 
GTP 2 µL 
Enzyme Mix 3 µL 
PCR product (1 µg) 7 µL 
Total 30 µL 
 
The reaction was placed in a thermo mixer and incubated at 37°C for 2 h. 
Degradation of  DNA template and purification of  RNA by phenol-chloroform extraction were 
done as described for full-length SARS-CoV genomic RNA. Concentration of  nucleocapsid 
transcript was determined and adjusted to 2 µg/µL. Nucleocapsid RNA was stored at -70°C. 
 
2.2.2.12  Generation of an RNA standard for quantification of 
SARS-CoV genomic RNA 
The real-time RT-PCR for detection of  SARS-CoV genomic RNA amplifies a region within 
nsp14. In order to absolutely quantify SARS-CoV RNA in cell culture supernatants an RNA 
standard was generated. A PCR product was amplified using primers T7-SAR-S1, carrying the 
minimal T7 promoter sequence and E 19031 R. These primers generate an 865 bp amplicon 
much longer than that generated during real-time PCR, guaranteeing optimal annealing of  the 
real-time primers. The PCR product was purified with Agencourt® AMPure® XP (2.2.2.5) and 
adjusted to a concentration of  1 µg/8 µL. Uncapped in vitro transcript was generated with 
Ambions MEGAscript® Kit. 
  
Reaction set up for in vitro transcription of  capped nucleocapsid RNA 
Materials and Methods 
59 
The in vitro transcription reaction was pipetted on ice according to the following set up: 
ATP 2 µL 
CTP 2 µL 
GTP 2 µL 
UTP 2 µL 
Enzyme Mix 2 µL 
10x Reaction Buffer 2 µL 
PCR product (1 µg) 8 µL 
Total 20 µL 
 
The reaction was placed in a thermo mixer and incubated at 37°C for 4 h. After 4 h 1 µL of  
TURBO DNase was added to the reaction and residual DNA template was degraded at 37°C for 
15 min. The in vitro transcript was purified using QIAGENs RNeasy® Mini Kit protocol for RNA 
clean up. Briefly, the in vitro transcription reaction was filled up with 80 µL RNase-free water and 
350 µL RLT Buffer containing 1% β-mercaptoethanol were added and mixed vigorously. 250 µL 
100% ethanol were added and mixed vigorously again. The sample was loaded on an RNeasy® 
spin column and centrifuged for 15 sec at 8000x g. The flow through was discarded and the 
column washed twice with 500 µL Buffer RPE. The column was dried by centrifugation at full 
speed for 1 min. RNA was eluted in 30 µL RNase-free water for 1 min at 8000x g. In order to 
increase RNA yield, the eluate was used to elute the column again. Afterwards the RNA 
concentration was determined (2.2.2.9) and RNA copies/µL were calculated using the following 
equation: 
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 N = 6.022x 1023/µL 
 c = RNA concentration in ng/µL 
 M = molecular weight of  RNA transcript in g/mol 
 
Reaction set up for uncapped in vitro transcripts 
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The in vitro transcript was immediately diluted 1:10 in AVE buffer (QIAamp® Viral RNA Mini 
Kit) containing sodium azide as a preservative. Subsequent dilutions were done in nuclease free 
water containing 10 µg/mL carrier RNA for stabilization of  the in vitro transcript. The stock and 
all dilutions were stored at -20°C. 
Successful in vitro transcription was verified by real-time RT-PCR (2.2.3.3) of  a dilution series 
ranging from 108 to 103 RNA copies per reaction. 
 
2.2.2.13  Restriction endonuclease digestion and 
dephosphorylation of DNA 
Plasmids and PCR products were digested with New England BioLabs® restriction endonucleases 
or Fermentas FastDigest® restriction endonucleases according to manufacturer’s instructions. 
Briefly, 6-10 µg of  plasmid DNA or PCR product were digested in a total volume of  100-200 µL 
with up to 50 u of  restriction enzyme for 4-8h at optimal temperature for the corresponding 
enzyme. Successful digestion was verified by agarose gel electrophoresis of  200-300 ng DNA 
(2.2.2.8). A high amount of  template was used in order to compensate loss during ethanol 
precipitation (2.2.2.7) and gel purification (2.2.2.6). An excess of  restriction enzymes and pro-
longed incubation times were used to assure completeness of  restriction. Frequently, templates 
were digested with two enzymes needing different reaction conditions, which made it necessary 
to ethanol precipitate the template after the first digestion. 
When complete digestion was achieved, the template containing most part of  the vector 
backbone (and/or the resistance gene) was dephosphorylated to avoid religation and creating 
false positive clones. Dephosphorylation was done with 5 µL Antarctic Phosphatase and 10% 
Antarctic Phosphatase Buffer in the restriction reaction without prior ethanol precipitation for 
15 min at 37°C. 
Digested fragments were usually ethanol precipitated prior to immediate downstream 
applications like separation on preparative agarose gel and subsequent ligation. If  storage was 
necessary, fragments were stored under ethanol and ammonium acetate at -20°C. 
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2.2.2.14  Ligation of nucleic acid fragments 
Ligation of  digested DNA fragments was usually done using Roches T4 DNA Ligase according 
to the following reaction set up: 
10x Ligation Buffer 1.0 µL 
T4 DNA Ligase (5 U/µL) 1.5 µL (1:10 diluted) 
Template DNA 7.5 µL 
Total 10.0 µL 
 
Prior to ligation DNA fragments from restriction reactions were separated on a preparative broad 
range agarose gel (2.2.2.8). Wanted DNA fragments were excised from the gel using a scalpel and 
extracted (2.2.2.6). The extracted fragments were quantified (2.2.2.9) and their molecular mass 
was determined. Ligation of  large DNA fragments in the process of  assembly the SARS-CoV 
full-length clone was usually done using equal molecule amounts of  each fragment. Small DNA 
fragments of  only several hundred base pairs were applied in a 5-fold excess to vector molecules 
in the ligation reaction. The molecule concentration was determined using the following 
equation: 
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 N = 6.022x 1023/µL 
 c = RNA concentration in ng/µL 
 M = molecular weight of  DNA fragment in g/mol 
 
Ligation reactions were incubated overnight at 14°C and stored at 4°C for short term or at -20°C 
for long term. 
 
Ligation reaction set up for T4 ligase 
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2.2.3  Polymerase chain reaction 
Polymerase chain reaction (PCR) is generally used for exponential amplification of  DNA 
fragments using a DNA polymerase and specific forward and reverse primers, which ultimately 
determine the range of  the DNA fragment. 
2.2.3.1  Phusion® PCR 
DNA amplification for subsequent use in restriction reactions or sequencing was done with 
Phusion® High-Fidelity DNA Polymerase with the following PCR reaction set up: 
5x Phusion® HF-buffer 5.0 µL 
dNTPs (10 mM each) 0.5 µL 
Forward primer (10 µM) 0.5 µL 
Reverse primer (10 µM) 0.5 µL 
Phusion® DNA polymerase 0.25 µL 
Template DNA (10-50 ng) 1.0 µL 
Ampuwa® 17.25 µL 
Total 25.0 µL 
 
Cycling was done according to the following temperature profile in an Eppendorf  Mastercycler: 
Initial Denaturation 98°C 20 sec  
Denaturation 98°C 10 sec 
35x Annealing X°C* 20 sec 
Extension 72°C 15 sec/kb 
Storage 4°C ∞  
* primer melting temperature salt adjusted  
(Oligo Calc, http://www.basic.northwestern.edu) 
Reaction set up for Phusion® PCR 
Temperature profile for Phusion® PCR 
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2.2.3.1.1 Overlap extension-PCR 
Overlap extension-PCRs were used to generate DNA fragments for insertion of  mutations of  
several base pairs in length or the exchange of  whole ORFs within SARS-CoV subclones. 
Phusion® High-Fidelity DNA Polymerase was generally used because of  its extremely low error 
rate and high processivity. 
Extensions were done in a 2-step or 3-step approach. 
 
The 2-step approach was used for small insertions. Two partially overlapping PCR products are 
generated, where the overlapping regions contain the insertion and are introduced via appropriate 
primers (Fig. 2.3). After ensuring successful amplification by agarose gel electrophoresis (2.2.2.8), 
the PCR products are purified with Agencourt® AMPure® XP (2.2.2.5) and the actual extension-
PCR is done. As primers both outmost primers (F1 and R2) of  the preceding PCRs are used. As 
templates both fragments are mixed in equal volumes and serially diluted 1:10 and 1:100. Dilution 
of  the templates proved to be essential, because high concentrated templates do not necessarily 
result in optimal extension. After amplification, the PCR product was checked for expected 
length and absence of  undesired amplicons by agarose gel electrophoresis. Distinct PCR 
products are purified with Agencourt® AMPure® XP and used for downstream application. If  the 
amplicon is contaminated by unspecific PCR products, the PCR reaction is separated on an 
agarose gel and the desired PCR fragment extracted (2.2.2.6). 
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The 3-step approach was used to exchange whole ORFs by connecting the new ORF with 
flanking SARS-CoV wild type sequences in order to facilitate introduction into the appropriate 
SARS-CoV subclone. 
In a first PCR (PCR1 in Fig. 2.4) the whole new insert is amplified. Next, the flanking sequences 
around the position where the new insert should be introduced are amplified (PCR2 and PCR3 in 
Fig. 2.4). Primer R2 of  PCR2 and primer F3 of  PCR3 consist of  backbone specific sequences 
and additionally specific sequences of  the new insert creating overlapping regions. Extension is 
done step wise or all at once resulting in 3 possible approaches leading to the final extended PCR 
product: 
 PCR1 + PCR2 = PCR4.1 + PCR3 = PCR5 
 PCR1 + PCR3 = PCR4.2 + PCR2 = PCR5 
 PCR1 + PCR2 + PCR3 = PCR5 
Generally, templates are mixed in equal volumes and subsequently diluted 1:10 and 1:100. The 3 
approaches are usually done simultaneously and the method chosen, which leads to success. All 
PCR products are purified with Agencourt® AMPure® XP (2.2.2.5) or if  necessary extracted from 
an agarose gel (2.2.2.6) prior to the next PCR amplification. 
Figure 2.3: 2-step overlap extension PCR. 
PCR1 is amplified using primers F1 and R1. PCR2 is generated with primers F2 and R2. Primers R1 and 
F2 carry the sequence of  the insertions and create overlapping ends. During extension PCR using 
outmost primers F1 and R2 the overlapping region anneals and the template strand is extended. 
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Figure 2.4: 3-step overlap extension PCR. 
Three fragments are generated by PCR using primers as indicated. PCR1 (primers F1 and R1) is the 
sequence to be exchanged in the backbone. PCR2 and PCR3 are tagged with insert specific sequences 
added by primers R2 and F3, respectively. So, PCR2 and PCR3 contain overlapping sequences to PCR1 
which are used in subsequent PCRs for annealing of  the template fragments. 
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2.2.3.2  Real-time RT-PCR for quantification of genomic SARS-
CoV RNA 
Quantification of  genomic SARS-CoV RNA was done by amplifying a region within nsp14 using 
Invitrogens SuperScriptTM III One-Step RT-PCR System with Platinum® Taq DNA Polymerase 
according to the following reaction set up: 
RNase-free water 3.0 µL 
2x Reaction Mix 6.25 µL 
BSA (10 µg/mL) 0.5 µL 
SuperScriptTM III RT/ Platinum® Taq Mix 0.5 µL 
Forward primer SARS F (10 µM) 0.5 µL 
Reverse primer SARS R (10 µM) 0.5 µL 
Probe SARS P (10 µM) 0.25 µL 
RNA (5 fg-0.5 µg) 1.0 µL 
Total 12.5 µL 
 
Amplification and detection was done according to the following temperature profile: 
Reverse transcription 55°C 15 min  
Initial denaturation 95°C 2 min  
Denaturation 95°C 15 sec 
45x 
Annealing/Extension* 58°C 30 sec 
Cooling 40°C 10 sec  
 
*Detection 
 
Reaction set up for real-time RT-PCR 
Temperature profile for real-time RT-PCR 
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2.2.3.3  Site-Directed Mutagenesis 
Small insertions, deletions or point mutations were introduced into plasmids using Finnzymes 
PhusionTM Site-Directed Mutagenesis Kit according to manufacturer’s instructions. Briefly, 
primers were designed in accordance to the mutation as shown in figure 2.5. 
 
http://www.abgene.com/images/products-fz/fz-1084_1.gif 
 
All primers needed to be phosphorylated at the 5' end and were about 30 nt in length. Due to the 
length of  the primers, their salt adjusted melting temperature usually was about 70°C. The 
following reaction set up was used for mutagenesis: 
5x PhusionTM HF-buffer 5.0 µL 
dNTPs (10 mM each) 0.5 µL 
Forward primer (10 µM) 0.5 µL 
Reverse primer (10 µM) 0.5 µL 
PhusionTM Hot Start DNA Polymerase (2 U/µL) 0.25 µL 
Template DNA (10 pg-50 ng) 1.0 µL 
Ampuwa® 17.25 µL 
Total 25.0 µL 
 
 
 
 
 
Reaction set up for PhusionTM Site-Directed Mutagenesis 
Figure 2.5: Primer design for PhusionTM Site-Directed Mutagenesis 
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Cycling conditions for mutagenesis were as follows: 
Initial denaturation 98°C 30 sec  
Denaturation 98°C 10 sec 
25x Annealing X°C * 20 sec 
Extension 72°C 30 sec/kb 
Final Extension† 72°C 10 min  
Storage 4°C ∞  
 
* Primer melting temperature according to Oligo Calcs (http://www.basic.northwestern.edu) salt 
adjusted TM, annealing was done 3°C cooler than melting temperature. If  no PCR product could 
be detected, annealing temperature was lowered to 56°C. 
† Final extension was omitted when extension time during cycling exceeded 10 min. 
 
Successful amplification of  template DNA was verified by agarose gel electrophoresis (2.2.2.8). 
If  no amplification could be detected, PCR was redone using Finnzymes Phusion® High-Fidelity 
DNA Polymerase (2.2.3.1). 
 
Circularization of  PCR products was done using Quick T4 DNA Ligase without purifying the 
PCR products prior to ligation. The amount of  PCR product used was evaluated from the gel, 
using 1-5 µL depending on the quantity seen in the agarose gel. Ligation was done according to 
the following reaction set up: 
PCR product 1-5 µL 
2x Quick Ligation Buffer 5 µL 
Quick T4 DNA Ligase 0.5 µL 
Ampuwa® Add to 10.5 µL 
 
The ligation reaction was incubated for 30 min at room temperature and stored on ice or -20°C 
until transformation. 
Temperature profile for Site-Directed Mutagenesis PCR 
Ligation reaction set up for Site-Directed Mutagenesis 
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The circularized plasmids were transformed into suitable chemically or electrocompetent E.coli as 
described in chapter 2.2.6. 
 
2.2.4  Cloning of PCR products into pEZTM BAC vector 
Lucigens pEZTM BAC vector is blunt end linearized and dephosphorylated. This allows cloning 
of  PCR products amplified with 5' phosphorylated primers without restriction digestion. 
PCR products were generated using Phusion® High-Fidelity Polymerase (2.2.3.1) and 
amplification was verified by gel electrophoresis (2.2.2.8). The PCR product was purified with 
AMPure® (2.2.2.5) and the DNA concentration was determined (2.2.2.9). Ligation reaction was 
set up according to the following protocol: 
5x Ligation Buffer 2 µL 
pEZTM BAC vector 1 µL 
Clone Smart Ligase 1 µL 
PCR product (100 ng) 6 µL 
Total 10 µL 
 
Ligation was done for 2 h at room temperature. Thereafter, the ligation reaction was heat 
inactivated for 15 min at 70°C and immediately placed on ice. 
Transformation of  the ligation reaction was done by electroporation into BAC-Optimized 
Replicator™ v2.0 Electrocompetent Cells. 20 µL electrocompetent cells were transferred to a 
pre-cooled 1.5 mL reaction and 1 µL ligation reaction was added. The cell-ligation reaction mix 
was then pipetted into a pre-cooled 1 mm gap cuvette and a pulse was applied. Pulse settings 
were: 1800 V, 25 µF, 200 Ω. Cells were resuspended in 500 µL recovery medium and incubated 
for 1 h at 37°C in a shaking incubator. Thereafter, transformed cells were plated on YT-agar 
plates containing 12.5 µg/mL chloramphenicol and incubated at 37°C overnight. 
 
Ligation reaction set up for cloning into pEZTM BAC vector 
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2.2.5  Production of chemically competent E.coli 
A 5 mL overnight culture of  glycerol stocked One Shot® Stbl3TM was prepared in LB medium. 
250 µL of  overnight culture were used to inoculate 250 mL LB medium and grown at 37°C in a 
shaker at 100 rpm. After 1 h a sample was taken and OD600 determined. If  OD600 was was not 
within the range of  0.5-0.7 the culture was further incubated and samples were taken every 
30 min. When OD600 reached the correct value the culture was transferred to an ice bath and 
cooled to 4°C under constant shaking. The culture was then incubated for another 15 min at 4°C. 
Afterwards the bacteria were pelletized for 15 min at 3000 rpm at 4°C. The supernatant was 
carefully discarded, the pellet resuspended in 50 mL 80 mM CaCl2 and incubated for 40 min at 
4°C. Bacteria were pelletized again for 15 min at 3000 rpm and 4°C. Supernatant was carefully 
discarded, the pellet resuspended in 5 mL 80 mM CaCl2 + 20% glycerol and aliquoted á 100 µL 
in pre-cooled 1.5 mL reaction tubes. The bacteria were shock frozen in liquid nitrogen and stored 
at -70°C. 
 
2.2.6  Transformation of chemically and 
electrocompetent E.coli and preparation of glycerol 
stocks 
Ligation reactions were usually transformed first into chemically competent TOP10 (Invitrogen) 
or One Shot® Stbl3TM (Invitrogen or self-made) according to manufacturer’s instructions. Briefly, 
50 µL of  bacteria were thawed on ice, mixed gently by stirring with the pipette tip with 8 µL 
ligation reaction and the transformation reaction was incubated on ice for 30 min. Heat shock 
was performed at 42°C for 30 sec (TOP10) or 45 sec (One Shot® Stbl3TM ). After heat shock One 
Shot® Stbl3TM were placed on ice for 2 min before adding S.O.C. medium, while 250 µL S.O.C. 
medium were added immediately to TOP10 cells. The bacteria were then incubated at 37°C for 
1 h at 300rpm. Cells were spread on LB plates containing the appropriate antibiotic according to 
the transformed vector (50 µg/mL Ampicillin for pCAGGS, 12.5 µg/mL Chloramphenicol for 
pBeloBAC11 and pEZTM BAC) and incubated overnight at 37°C in an incubator. 
 
Ligation reactions yielding no colonies in chemically competent cells were additionally 
transformed into electrocompetent E.cloni® 10G SUPREME or E.cloni® 10G ELITE (Lucigen®) 
according to manufacturer’s instructions. Briefly, 1-2 µL ligation reaction were pipetted into a 
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pre-cooled 1 mm electroporation cuvette and 25 µL E.cloni® were added. The cells were electro 
shocked with one pulse of  10 µF, 600 Ω and 1800 V. 975 µL of  Recovery Medium were 
immediately added to the cuvette, the cells were transferred to a 1.5 mL reaction tube and 
incubated at 37°C for 1 h at 300 rpm. Thereafter, cells were spread on LB plates containing the 
appropriate antibiotic according to the transformed vector and incubated overnight at 37°C in an 
incubator. 
 
Glycerol stocks of  sequenced plasmids were produced to conveniently produce high amounts of  
overnight cultures for plasmid midipreparations. An inoculating loop of  bacteria was 
resuspended in 900 µL LB medium and mixed with 900 µL glycerol. The mixture was aliquoted á 
600 µL and stored at -70°C. 
 
2.2.7  Protein biochemical methods and 
immunodetection assays 
 
2.2.7.1  Protein isolation from eukaryotic cells 
Cells were washed thrice with ice cold 1x PBS in order to fixate their current state of  protein 
expression and to remove FBS. The cells were then scraped of  in 500 µL 1x PBS, transferred to a 
1.5 mL reaction tube and centrifuged for 5 min at 300x g and 4°C. The supernatant was 
discarded, the pellet resuspended in an appropriate volume of  RIPA lysis buffer (25 µL/24-well 
or 100 µL/6-well) and the lysed cells were incubated on ice for 20 min. Optionally cells were 
centrifuged for 10 min at full speed and 4°C in order to remove nuclei. The supernatant was then 
transferred to a fresh 1.5 mL reaction tube. Protein samples were stored at -80°C until use. 
 
2.2.7.2  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Prior to Western blot analysis protein samples were separated according to their mass by 
denaturating SDS-PAGE. SDS-PAGE gels were prepared depending on the mass of  the proteins 
to be analyzed between 12 and 14% acrylamide (table 2.17). 
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2 mini gels Separation gel Stacking gel 
12% 14%  
30% Acrylamide 4.00 mL 4.67 mL 0.50 mL 
1.875 mM Tris (pH8.8) 2.00 mL 2.00 mL  
0.6 M Tris (pH6.8)   0.60 mL 
Water 3.85 mL 3.18 mL 1.85 mL 
10% SDS 0.10 mL 0.10 mL 0.03 mL 
10% APS 0.05 mL 0.05 mL 0.015 mL 
TEMED 0.01 mL 0.01 mL 0.003 mL 
 
After complete polymerization of  the gel it was placed into the Mini-PROTEAN electrophoresis 
module (Bio-Rad) and the module was filled with 1x SDS-PAGE running buffer. Gel slots were 
rinsed vigorously by pipetting running buffer in order to remove gel residuals. Protein samples 
were mixed with 4x NuPAGE® LDS Sample Buffer (Invitrogen) and boiled for 5 min at 95°C if  
necessary prior to loading the gel. 8 µL of  Fermentas PageRulerTM Prestained Protein Ladder 
were used as mass reference. Separation was achieved by applying 100 V. 
 
2.2.7.3  Western blot analysis 
Following separation of  protein samples by SDS-PAGE proteins can be visualized on 
polyvinylidenfluorid (PVDF) membranes. Therefore, proteins are transferred from an SDS gel 
onto the membrane via application of  electric current in a semi-dry blotting system. Transferred 
proteins are then specifically detected by a primary antibody which again is detected by a 
secondary antibody that is coupled to horse radish peroxidase (HRP). Detection is done by 
conversion of  a chemiluminescent substrate and pictured in Peqlabs FUSION FX7TM imaging 
system. 
6 Whatman papers were equilibrated in 1x transfer buffer and the PVDF membrane was 
activated by short incubation in 100% methanol. Afterwards the PVDF membrane is rinsed in 
water and transferred to 1x transfer buffer to avoid drying-out. The electrode of  the blotting 
system was assembled with 3 Whatman paper, activated PVDF membrane, SDS gel and again 3 
Composition of  SDS-polyacrylamide gels 
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Whatman paper. Air bubbles were smoothed out, the second electrode placed on top and the 
proteins were transferred applying 150 mA per blot for 1.5 h. After successful protein transfer 
the membrane was blocked with 5% dry milk in PBS-Tween for 1 h at room temperature or 
overnight at 4°C. Following blocking and 3 times washing with PBS-Tween for 5 min the 
membrane was incubated for 1 h at room temperature with the primary antibody diluted in 1% 
dry milk in PBS-Tween. Afterwards the membrane was again washed thrice with PBS-Tween and 
incubated for 1 h at room temperature with the secondary antibody diluted 1:20,000 in 1% dry 
milk in PBS-Tween. Finally, the membrane was washed 6 times with PBS-Tween and detection 
was done with SuperSignal® West Pico or Femto Chemiluminescent Substrate. 
When a second protein needed to be detected on a membrane (e.g. β-actin as loading control), 
already bound primary and secondary antibody had to be removed first. Therefore, the 
membrane was incubated in Re-Blot Plus-Strong solution (diluted 1:10 in water) for 20 min at 
room temperature. The membrane was washed 3 times with PBS-Tween and was then ready for 
incubation with new antibodies. 
 
2.2.7.4  Immunofluorescence assay (IF) 
For visualization of  overexpressed proteins within cells the immunofluorescence assay was used. 
A cell monolayer is fixed with paraformaldehyde maintaining cell structures and protein epitopes. 
Fixed cells are then incubated with a primary antibody directed against the protein of  interest and 
a secondary antibody coupled to a fluorescent dye. Detection is done by fluorescence 
microscopy. 
Cells were seeded according to their size and speed of  growth between 1x 105 and 3x 105 cells on 
round glass cover slips in 24-wells. Cells were then transfected as described in chapter 2.2.1.2. 
Usually 24h after transfection supernatant was removed and the cells were washed once with ice 
cold 1x PBS. The cells were fixed with 500 µL Roti®-Histofix per 24-well for 20 min at room 
temperature. Thereafter, cells were washed twice with PBS-Tween and cell membranes were 
permeabilized with 200 µL freshly made 0.1% Trition® X-100 in PBS-Tween for 10 min at room 
temperature. After washing twice with PBS-Tween cells were incubated with the primary 
antibody diluted in EUROIMMUN sample buffer for 1 h at 37°C in a wet chamber. Next, cells 
were washed again twice with PBS-Tween and incubated with the secondary antibody diluted in 
1x PBS for 30 min at 37°C in a wet chamber. After washing the cells twice with PBS-Tween cell 
nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) diluted 1:1000 in 1x PBS for 
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2 min in the dark at room temperature. Cells were finally washed twice with 1x PBS and once 
with water. Cover slips were then placed with the cell layer facing down onto microscope slides 
and the cover slips were sealed with Dako Fluorescence Mounting Medium. After drying of  the 
mounting medium for at least 8h at 4°C cells were ready for microscopy. 
 
2.2.8  RVFV-Renilla bioassay 
In order to determine cell line-specific pan-species IFN effective concentrations (EC) an RVFV-
Ren bioassay was performed. Here a genetically modified Rift Valley fever virus is used that 
carries a Renilla luciferase (RVFV-Ren) instead of  its IFN antagonist NSs making it highly 
sensitive to IFN treatment. Renilla luciferase expressed in infected cells can be measured with 
Promegas Renilla luciferase assay system and gives a direct correlation between virus growth and 
biologically active IFN. 
For determination of  pan-species IFN EC values 100 µL/96-well of  a cell suspension with a 
concentration of  6x105 cells/mL were seeded and cultivated overnight. Medium was removed 
and replaced by 100 µL/well of  pan-species IFN diluted in DMEM. Cells were further incubated 
for 7 h. Thereafter, IFN containing medium was removed and cells were infected with 100 µL 
RVFV-Ren at an MOI of  0.01. Virus containing supernatant was not taken off  during infection. 
For each assay 2 controls were needed. A positive control, were cells were not incubated with 
IFN but infected with virus, resembling maximal virus growth/luciferase expression. A negative 
control, were cells were neither incubated with IFN nor infected with virus, for determination of  
background signal. 16 h post infection the supernatant was removed completely and cells lysed in 
50 µL passive lysis buffer per well by shaking at room temperature in the dark. Cell lysis was 
controlled by microscopy. Incompletely detached cells were scraped off. 10 µL cell lysate were 
transferred to one well of  a read-out plate, the plate was covered with aluminium foil until read-
out was performed. Luciferase activity was determined as relative light units (RLU) after addition 
of  50 µL luciferase substrate per well by a luminescent reader. 
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3  Results 
3.1  Technical preliminary work 
3.1.1  Generation of recombinant SARS-CoVs 
3.1.1.1  SARS-CoV reverse genetics system 
In order to investigate the influence of  mutations of  the SARS-CoV genome on the virus’ 
phenotype, a reverse genetic system was established in our working group [49]. The full-length 
SARS-CoV genome was split into 6 overlapping parts (A-F) of  about 4.4 to 6.9 kb in length and 
cloned into high copy vectors (Fig. 3.1). Within these vectors silent mutations were inserted into 
the genome to delete restriction sites and to create a cloning strategy that made it possible to re-
assemble the whole genome stepwise. Fragment A and B were ligated to subclone pAB 
(14,415 bp), B, C and D were combined to subclone pBCD (16,245 bp), D and E were fused to 
pDE (15,900 bp) and E and F to subclone pEF (15,376 bp). Due to instability of  large fragments 
in high copy vectors, the vector backbone was changed during assembly of  the subclones to the 
low copy bacterial artificial chromosome (BAC) vector pBeloBAC11. The 5’-half  of  the full-
length genome was then assembled after restriction of  pAB and pBCD with restriction enzymes 
PspOMI, cutting within the vector backbone and Bsu36I, cutting within nsp3 of  the SARS-CoV 
genome, resulting in the half-clone pABCD (22,807 bp). 
Subclone pEF and half-clone pDEF carried the 3’-end of  the SARS-CoV genome including all 
accessory genes. Since the focus of  this thesis was the characterization of  the accessory genes 
ORF6 and ORF8 the subclones pEF and pDEF were used to introduce mutations and deletions. 
Assembly of  pDEF from pDE and pEF and the subsequent assembly of  the full-length SARS-
CoV clone are described in more detail below. 
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Figure 3.1 Assembly of  the full-length SARS-CoV clone. 
After cloning of  SARS-CoV genome fragments A-F into high copy vectors, a stepwise assembly and a 
change of  the vector backbone to pBeloBAC11 was done. Fragment A was cut out of  its vector with BglI 
and PspOMI. Fragment B was excised using BglI and NotI. The new vector backbone pBeloBAC11 was 
cut in two by NotI and EcoRI. All four fragments were ligated at once to create subclone pAB. NotI and 
PspOMI produce compatible ends, ligation thus deletes both restriction sites. For assembly of  subclone 
pBCD, fragment B was cut out using NotI and BglI, C was excised by BglI and D using BglI and BclI. 
Vector pBeloBAC11 was digested by NotI, EcoRI and BamHI. All four fragments were ligated at once. 
BclI and BamHI create compatible ends; upon ligation both restriction sites are consequently deleted. 
Fragment D was cut out with AclI and BglI, while E was excised using BglI and PstI for assembly of  
pDE. PBeloBAC11 was cut in two by BsaHI, EcoRI and NsiI. The four fragments were ligated. BsaHI 
and AscI as well as PstI and NsiI create compatible ends. Ligation results in deletion of  the restriction 
sites. Subclone pEF was built up of  fragment E, cut with SphI and BglI and fragment F, cut with BglI and 
NotI. The vector backbone was digested with SphI, EcoRI and NotI. Plasmids pAB and pBCD were 
digested with Bsu36I and PspOMI to create pABCD. To create pDEF subclone pDE and pEF were 
digested with NcoI only. The full-length SARS clone was finally assembled by ligation of  fragments 
ABCD and DEF, which were cut using PspOMI and MluI. Figure taken from Pfefferle et al., 2009 [49]  
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3.1.1.2  Assembly of half-clone pDEF 
Subclone pEF contained all structural and accessory genes of  the SARS-CoV genome and the 3’-
terminal 227 bp of  nsp16 (Fig. 3.2A). The complete clone comprised 15.4 kb with an insert of  
8.5 kb. One possibility to mutate single ORFs was the generation of  mutated PCR amplicons by 
overlap extension PCR (2.2.3.2) and subsequent introduction of  the fragment into pEF via 
restriction sites SwaI or BamHI and NotI. All three enzymes cut only once within the subclone, 
as indicated in Fig. 3.2A. Due to its relatively small size pEF could be used for site-directed 
mutagenesis (2.2.3.4). This technique allowed introducing mutations by primers followed by the 
complete amplification of  the plasmid by PCR. 
Subclone pDE contained 99% of  the RNA polymerase (nsp12) sequence, nsp13 to nsp16 and a 
small part of  the ORF coding for the spike protein including the NcoI site for assembly with 
pEF (Fig. 3.3A). 
Assembly of  half-clone pDEF was achieved by a single digestion of  pDE and pEF with NcoI. 
As indicated in the vector maps in Fig. 3.2A pDE and pEF shared an overlapping region within 
the 5’-end of  the spike ORF including the naturally occurring NcoI site, which was used to fuse 
the SARS-CoV genome sequence. Digestion of  pDE with NcoI resulted in the fragmentation of  
the plasmid into two fragments of  9,630 bp and 6,270 bp in length. The difference in fragment 
length was sufficient to distinguish both fragments on an agarose gel and enabled efficient 
excision from a preparative gel (Fig. 3.2B). Digestion of  pEF with restriction enzyme NcoI cut 
the plasmid into two fragments of  13,753 bp and 1,623 bp in length (Fig. 3.2B). Of  each 
subclone only the large fragments were needed for ligation. 
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The fragment of  pEF used for ligation contained the major part of  the pBeloBAC11 vector 
backbone including the chloramphenicol resistance gene. Dephosphorylation of  this fragment 
was necessary in order to minimize religation and growth of  false positive colonies (2.2.2.13). 
After dephosphorylation, both restriction reactions were applied on a preparative agarose gel 
(2.2.2.8). The desired DNA fragments were extracted from an agarose gel and ligated as 
described (2.2.2.6; 2.2.2.14). Chemically competent E. coli cells were transformed with the ligation 
reaction (2.2.6). Grown colonies were picked and plated on LB agar for small scale plasmid 
preparations (2.2.2.4). Plasmids were applied on an agarose gel and their sizes determined in 
comparison to a supercoiled DNA marker. Plasmids with a size of  about 23 kb were first 
screened for correct orientation of  the ligation product. Since pDE and pEF were only cut with 
Figure 3.2: NcoI digestion of  pDE and pEF for assembly of  pDEF. 
(A) Vector maps of  subclones pDE and pEF, restriction sites of  NcoI are indicated. (B) Digestion of  
pDE with NcoI yielded fragments of  9,630 bp and 6,270 bp, while pEF was cut into fragments of  
13,753 bp and 1,623 bp. M = 1 kb DNA ladder; “-” indicates uncut plasmid; “+” indicates digestion with 
NcoI. 200 ng of  plasmid were applied per lane. 
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one restriction enzyme, there were two possibilities of  ligation. Incorrect ligation resulted in a 
discontinuous SARS-CoV genome fragment that could not be used for further cloning. In order 
to prove correct cloning a subset of  sequencing PCR reactions was done covering the complete 
construct (Table 2.2). PCR No. 3 amplified a region of  the insert carrying the naturally occurring 
NcoI site within the SARS-CoV genome. Amplification could only be achieved when the ligation 
was successful and in the correct orientation. An amplification product (amplicon 3) proved right 
ligation, while an indistinct PCR product indicates incorrect ligation. 
 
After successful generation of  amplicon 3 and verification of  an intact NcoI restriction site by 
sequencing with primer E 21452 F, all remaining sequencing PCRs (see table 2.2 for primer pairs 
and cycling conditions) were done using the standard reaction set up for Phusion® High-Fidelity 
Polymerase (2.2.3.1). PCR products were controlled by gel electrophoresis, purified and 
sequenced with suitable sequencing primers as listed in table 2.2 (2.2.2.5; 2.2.2.10). When the 
complete DEF insert was sequenced and no undesired mutations were detected, the plasmid was 
prepared in midi-scale for use in assembly of  the full-length clone. 
 
3.1.1.3  Assembly of the full-length SARS-CoV clone 
In this working step half-clone pDEF had to be fused to half-clone pABCD, containing the 5’-
half  of  the SARS-CoV genome, in order to obtain a full-length continuous SARS-CoV genome. 
The non-structural proteins nsp1-10 and 80% of  the RNA polymerase (nsp12) were included in 
pABCD (Fig. 3.3A). The inserts ABCD and DEF overlapped in nsp12, where the naturally 
occurring MluI site was located. This MluI site was used to fuse both inserts and generate the 
complete genome. A second MluI site, present in nsp3 of  the SARS-CoV genome, was deleted 
by introduction of  a silent mutation in subclone pB as indicated in Fig. 3.1. 
First, both half-clones, pABCD and pDEF, were linearized with restriction enzyme PspOMI, 
which cut within the vector backbone as indicated in Fig. 3.3A. Successful linearization was 
indicated by reduction of  two bands, representing supercoiled and open circle forms of  the 
plasmid (Fig. 3.4B), to only one band, representing a linear DNA fragment. A typical agarose gel 
of  a supercoiled plasmid in comparison to its linearized form is shown in Fig. 3.5A. Digestion of  
half-clone pABCD with the second restriction enzyme MluI resulted in two fragments of  
15,130 bp and 7,677 bp in length. The half-clone pDEF was cut with the same enzyme in 
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fragments of  21,567 bp and 1,816 bp. The typical fragmentation pattern of  the plasmids after 
digestion with PspOMI and MluI is shown in Fig. 3.3B. 
 
 
 
 
 
Only the large fragments of  each half-clone were needed for ligation. The large fragment of  
pDEF contained most of  the pBeloBAC11 vector backbone including the chloramphenicol 
resistance gene and was therefore dephosphorylated (2.2.2.13). The fragments needed for ligation 
were extracted from a preparative gel (2.2.2.8; 2.2.2.6). Ligation was done with equal amounts of  
Figure 3.3: Digestion of  pABCD and pDEF for assembly of  full-length SARS-CoV clone. 
(A) Vector maps of  pABCD and pDEF, restriction sites of  PspOMI and MluI needed for restriction and 
assembly of  the full-length clone are indicated. (B) Digestion of  pABCD with PspOMI and MluI yielded 
fragments of  15,130 bp and 7,677 bp, while pDEF was cut into fragments of  21,567 bp and 1,816 bp. M 
= 1 kb DNA ladder; “-” indicates undigested plasmid; “+” indicates digestion with both enzymes. 200 ng 
plasmid were applied per lane of  a 0.8% agarose gel. 
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each fragment (2.2.2.14). E. coli cells were chemically transformed with the ligation reaction and 
resulting colonies were picked and used for plasmid minipreparations (2.2.6; 2.2.2.4). Plasmids 
were screened for correct size by agarose gel electrophoresis in comparison to a supercoiled 
DNA marker. Plasmids with sizes of  about 37 kb (Fig. 3.4B) were first screened with PCR No. 5 
as listed in table 2.3. PCR 5 amplified a fragment containing the MluI site, which was only 
generated by successful ligation.  
Integrity of  the MluI site was then verified by sequencing of  the PCR product with primer 
D 13700 F. After confirmation of  the integrity of  the MluI site, all remaining sequencing PCRs 
were done using the standard Phusion® High-Fidelity Polymerase reaction set up (2.2.3.1; see 
table 2.3 for primer pairs and cycling conditions). PCR products were controlled by agarose gel 
electrophoresis, purified and sequenced with the appropriate primers listed in table 2.3 (2.2.2.8; 
2.2.2.10). After ruling out mutations, the plasmid was prepared in midi-scale (2.2.2.4). The 
resulting full-length SARS-CoV clone is depicted in Fig. 3.4A. A minimal T7 promoter sequence 
was inserted directly upstream of  the genome for in vitro transcription into infectious full-length 
genomic RNA (2.2.2.11). A NotI site located directly downstream of  the poly-A tail and was 
used to linearize the full-length clone making it accessible to the T7 polymerase.  
The generated SARS-CoV full-length clone was then used for the rescue of  recombinant SARS 
coronavirus (rSCV) as described in the following (3.2.1.4). 
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Figure 3.4: Full-length SARS-CoV clone. 
(A) Vector map of  the full-length SARS-CoV clone. (B) Separation characteristics of  the full-length 
SARS-CoV clone on a 0.8% GTQ agarose gel. M = Supercoiled DNA marker set. The upper band 
represents the supercoiled form of  the plasmid. 
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3.1.1.4  Rescue of recombinant SARS-CoVs 
The full-length SARS-CoV clone served as a template for the generation of  infectious viral RNA. 
Since T7 polymerase needs linear DNA templates for in vitro transcription the plasmid was first 
linearized by digestion with NotI (2.2.2.11). The restriction site was located downstream of  the 
genome’s poly-A tail as shown on the vector map of  the plasmid in Fig. 3.4A. Complete 
linearization of  the plasmid was checked by agarose gel electrophoresis (2.2.2.8). The differences 
in migration patterns of  linearized full-length plasmid in comparison to supercoiled plasmid in 
the gel are shown in Fig. 3.5A. The linearized plasmid was then purified by phenol-chloroform 
extraction and ethanol precipitation in order to generate highly pure template for in vitro 
transcription (2.2.2.7). In vitro transcription of  full-length genomic RNA was then done as 
described in chapter 2.2.2.11. The resulting in vitro transcript was again phenol-chloroform 
extracted and ethanol precipitated to yield highly pure RNA. Replication of  coronaviruses 
initiated from pure genomic RNA proved to be enhanced by co-electroporation of  capped 
nucleocapsid RNA [96]. Therefore, the nucleocapsid sequence of  SARS-CoV was amplified from 
subclone pEF using a forward primer that binds to the nucleocapsid’s start codon and contains 
the minimal SP6 promoter sequence adding it to the PCR amplicon (2.2.3.1). The reverse primer 
bound within the 3’-end of  the 3’-UTR of  the SARS-CoV genome and contained a poly-A tail. 
The modified PCR product (Fig. 3.5B) could be used for the in vitro transcription (2.2.2.11) of  
capped and poly-A tailed RNA that is directly translated in the cytoplasm of  electroporated cells.  
Capped viral genomic RNA and capped nucleocapsid were electroporated into BHK-J cells 
(2.2.1.3). BHK-J cells are not susceptible to SARS-CoV, because they lack the SARS-CoV 
receptor hACE2. However, they can be efficiently electroporated and produce viable viruses that 
are released into the cell culture supernatant. Therefore, virus-containing supernatant was 
harvested 24h post electroporation and was transferred to the SARS-CoV-susceptible primate cell 
line, VeroFM. Virus replication was documented as the increase of  viral RNA in the cell culture 
supernatant by real-time RT-PCR (2.2.3.3). A typical growth kinetic of  recombinant virus is 
shown in Fig. 3.5C. 
Production of  virus stock was generally terminated after 3d, because it was experimentally shown 
that virus replication was optimal at this time point. Further incubation yielded only a small 
additional increase in viral RNA but led to a decreased yield in infectious virus particles (data not 
shown). 
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Aliquoted virus stock was quantified for the presence of  viable, infectious particles by plaque 
titration (2.2.1.6). In addition, the morphology of  plaques was analyzed (Fig. 3.5D). Generally, a 
virus titer of  106 PFU/mL was achieved.  
In order to verify that the virus stock contained recombinant SARS-CoV and was not produced 
by contamination from a patient isolate, the marker mutation deleting the second MluI site within 
nsp3 was sequenced. While the MluI site was present in the patient’s isolate, it was not detectable 
in the newly generated virus stock (Fig. 3.5E). All recombinant viruses used in the present thesis 
were characterized in this manner. 
 
 
  
 
Figure 3.5: Rescue of  recombinant SARS-CoVs. 
Linearized full-length SARS-CoV plasmid (A) and a PCR amplicon of  SARS-CoVs nucleocapsid (B) were 
in vitro transcribed into capped and poly-A tailed RNA. Both RNAs were co-electroporated into BHK-J 
cells. 24h post electroporation, cell culture supernatant was transferred to susceptible VeroFM cells and 
virus replication was monitored by real-time RT-PCR (C). The produced virus stock was quantified by 
plaque titration (D) and an introduced marker mutation, deleting an MluI site within nsp3, was sequenced 
to verify the origin of  the virus stock being the SARS-CoV full-length clone. 
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3.1.2  Generation of a SARS-CoV-susceptible bat cell 
line 
Horseshoe bats (Rhinolophus sp.) have been described as the putative reservoir of  SARS-related 
coronaviruses [10, 72]. To date there are only two bat cell lines commercially available, Tb1-Lu 
derived from Tadaria brasiliensis and Mvi/It derived from Myotis velifer incautus [104], both of  which 
do not belong to the SARS-related CoVs reservoir genus. Because the full-length genome of  the 
SARS-related bat-CoV from Bulgaria was sequenced from bat feces sampled from Rhinolophus 
blasii, a cell line from this genus was chosen to be generated. Primary cell cultures from 
Rhinolophus landeri embryonic lungs (RhiLu) were prepared and cells were immortalized by 
lentiviral transduction of  the simian virus 40 large T-antigen as previously described [105, 106]. 
However, this cell line was not susceptible to human SARS-CoV (data not shown), presumably 
because it lacked the SARS-CoV receptor hACE2. In the course of  the Bachelor project of  
Hanna Roth, the immortalized cell line was made susceptible to SARS-CoV infection by lentiviral 
transduction of  hACE2 [103].  
The VSV-G pseudotyped lentiviruses used for transduction of  RhiLu cells with hACE2 were 
kindly provided by Alexander Pfeifer (Institute of  Pharmacology and Toxicology, University of  
Bonn). Transduction of  RhiLu cells was done as described in chapter 2.2.1.7.2. During expansion 
of  the newly generated cell line, samples were taken and analyzed for genomic integration of  
hACE2 and expression of  hACE2.  
Genomic integration of  hACE2 was verified by PCR (2.2.3.1). Genomic DNA was extracted 
(2.2.2.3) and PCR performed with a forward primer binding within the hACE gene and a reverse 
primer binding within the puromycin resistance gene, yielding a 1.9 kb amplicon (Fig. 3.6B). The 
pCR4® vector containing the hACE2-puromycin resistance gene construct was used as a PCR 
positive control. 
Expression of  hACE2 was confirmed by SDS-PAGE and Western blot analysis (2.2.7.2; 2.2.7.3) 
as shown in Fig. 3.6C. No expression of  hACE2 was detected in native, immortalized RhiLu 
cells. However, RhiLu-hACE2 cells showed expression of  the transgene with similar amounts as 
in the naturally hACE2-expressing MA104 cells. β-actin was additionally detected to ensure that 
similar amounts of  each sample were applied. It is noteworthy that the β-actin antibody used here 
was, in addition to other species reactivity specified by the manufacturer, also cross-reactive with 
bat β-actin. 
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Finally, the newly generated RhiLu-hACE2 cells were tested for susceptibility to SARS-CoV 
infection in comparison to MA104 cells. Cells were infected with SARS-CoV Frankfurt-1 at two 
different MOIs (2.2.1.5) and virus replication was determined at different time points p.i. by 
plaque titration of  the supernatant (2.2.1.6). RhiLu-hACE2 cells clearly supported SARS-CoV 
replication, although not as efficiently as MA104 cells (Fig. 3.6D). 
With the generation of  this cell line, a valuable tool to study SARS-CoV in the context of  its 
natural reservoir was established. Together with the genetic information obtained from the full 
genome sequence of  the SARS-related bat-CoV it was now possible to compare human and bat 
coronaviral proteins in their respective hosts.  
 
Results 
87 
 
 
Figure 3.6: Generation of  a SARS-CoV susceptible bat cell line. 
(A) Primary cell culture and immortalization of  Rhinolophus landeri embryonic lung cells was done as 
previously described [105, 106]. Immortalized cells were transduced with hACE2 by lentiviruses. (B) 
Integration of  hACE2 into the genome of  the cells was verified by PCR. The vector containing the 
hACE2-puromycin resistance gene construct was used as a PCR positive control. (C) Expression of  
hACE2 was confirmed by Western blot analysis using mouse-anti-hACE2 (1:1000). In addition, β-actin 
was detected using mouse-anti-β-actin (1:2000) to ensure that similar protein amounts were applied. 
MA104 cells, expressing hACE2 naturally, served as positive control. (D) Susceptibility to SARS-CoV of  
the newly generated cell line was confirmed by infection of  RhiLu-hACE2 in comparison to MA104 with 
SARS-CoV Frankfurt-1 at MOIs 1 and 0.001. At 8, 24 and 48h p.i. supernatants were sampled and virus 
titers determined by plaque titration.  
Results 
88 
3.1.3  Determination of pan-species IFN EC50 on 
primate and bat cell culture 
In order to investigate the ability of  a virus to cope with intracellular countermeasures, an 
antiviral state was induced in the cells before infection. This antiviral state is a result of  the 
upregulation of  IFN-stimulated genes (ISGs) caused by pretreatment with IFN. The species-
specific IFN receptor is a limiting factor in this case. SARS-CoV was shown to be highly sensitive 
to IFN [107], however, the responsible ISGs or other underlying factors have not yet been 
identified [108-110]. A comparison of  SARS-CoV mutants in primate and bat cell cultures was to 
be done in this thesis. This included IFN treatment of  cells to characterize host-specific 
interactions with the respective mutants. Therefore it was necessary to identify the particular 
amount of  a pan-species universal IFN to induce a comparable antiviral state in the different 
primate and bat cell cultures.  
In order to test the bat cell line RhiLu-hACE2 along with the primate cell lines VeroFM and 
MA104, the universal type I IFN (pan-species IFN) was used on all cell lines. It was expected that 
the ability of  this pan-species IFN to induce an antiviral state differed among the three cell lines. 
In order to quantify this difference, the IFN concentration required to reduce viral replication of  
a Rift Valley fever virus (RFVF) to 50% (EC50) was determined for each cell line. The RVFV 
(RVFV-Ren) is a mutant expressing Renilla luciferase instead of  its IFN antagonist, the non-
structural protein NSs, making it highly IFN-sensitive [111]. Expression of  Renilla luciferase was 
measured with a luciferase assay and was consistent with virus replication patterns [111]. 
VeroFM, MA104 and RhiLu-hACE2 cells were seeded, preincubated with different 
concentrations of  pan-species IFN and infected with RVFV-Ren as described in chapter 2.2.8. 
Thereafter, cells were lysed and expression of  luciferase was determined in relative light units 
(RLU). 
To determine the EC50 values, IFN concentrations in log10 U/mL were plotted against the 
percentages of  emitted RLU (Fig. 3.7). Background signals (cells treated with neither IFN nor 
virus) were subtracted from all values. The maximal signal of  the positive control (cells not 
preincubated with IFN but infected with RVFV-Ren) was normalized to 100%. A linear equation 
was calculated based on the exponential progression of  the plotted curve. Cell specific EC50 
values were set at 50% RLU. 
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Cell line-specific pan-species IFN EC50 values were 31.8, 8.5 and 5.6 U/mL for VeroFM, MA104 
and RhiLu-hACE2, respectively. 
 
 
 
3.2  Assessment of putative virulence factors of 
SARS-CoV and SARS-related bat-CoV  
The SARS-related bat-CoV Bt-CoV/BM48-31 (BG-CoV) was identified by our working group in 
Rhinolophus bats from Bulgaria, thereby providing valuable genome sequence information on a 
SARS-related CoV in its natural host and leading to the imminent question of  whether this virus 
poses a threat to humans [88]. Initially BG-CoV and human SARS-CoV Tor2 were compared on 
genomic level by alignments. As shown in Fig. 3.8 the nucleic acid identity exceeded 90% in most 
parts of  the genome. Major differences were found in genes encoding IFN antagonists, like 
ORF6 coding for p6. Strikingly, ORF8 was entirely absent.  
An amino acid alignment of  SARS-CoV p6 (SA-p6) and BG-CoV p6 (BG-p6) shown in Fig. 3.9 
revealed that both proteins shared 50% amino acid identity and 78.1% amino acid similarity. 
Screening of  more bats of  the genus Rhinolophus from other countries revealed that none of  the 
European SARS-related bat-CoVs carry an ORF8 [Drexler et al., unpublished data], while all 
SARS-CoVs isolated from Chinese animals (civets and bats) carry the full-length ORF8 [10, 72, 
78].  
Figure 3.7: Determination of  cell line-specific pan-species IFN EC50. 
VeroFM (A), MA104 (B), and RhiLu-hACE2 (C) were seeded in 96-well plates, incubated with pan-
species IFN concentrations between 0 and 100 U/mL for 7h, and then infected with a Renilla luciferase 
expressing Rift Valley fever virus (RVFV-Ren) at an MOI of  0.01 for 16 h. Cells were lyzed and luciferase 
expression measured with a luciferase assay in relative light units (RLU). RLU in % were plotted against 
log rIFN concentrations and EC50 values determined at 50% RLU. rIFN = recombinant pan-species IFN. 
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ORF6 and ORF8 were chosen for detailed investigations on their potential to serve as putative 
virulence factors that might play a role in interspecies transmission. Therefore, overexpression 
analysis and studies addressing the function of  these proteins in the context of  the virus 
replication cycle were conducted. 
 
 
 
 
3.2.1  Characterization of SARS-CoV and SARS-related 
bat-CoV p6 
The mechanism by which SA-p6 inhibits the transport of  STAT1 into the nucleus and thus the 
transcriptional initiation of  IFN-stimulated genes was already described by Frieman et al. [59]. 
The C-terminal 10 amino acids of  p6 directly interact with KPNA2, retaining it at the rough 
ER/Golgi apparatus, which in turn binds to KPNB1, thus depleting the pool of  free KPNB1 
that is necessary for the transport of  the ISGF3:KPNA1 complex into the nucleus [59]. As 
shown in Fig. 3.9A the C-terminal region of  p6 is exposed to the cytosol thus allowing the 
binding of  KPNA2. The amino acid alignment of  SA-p6 and BG-p6 in Fig. 3.9B shows that the 
C-terminal 10 amino acids of  both proteins are highly similar. Therefore, BG-p6 might be able to 
bind human KPNA2. This hypothesis was first investigated in overexpression systems.  
Figure 3.8: Nucleic acid percent identity plot. The genome of  the the SARS-related bat CoV 
BtCoV/BM48-31 was aligned with the human SARS-CoV Tor2 and the percentage of  identical nucleic 
acids were plotted against their genome position. 
Results 
91 
 
 
3.2.1.1  Cloning of SARS-CoV and SARS-related bat-CoV ORF6 
into expression vector pCAGGS 
In order to compare SA-p6 to BG-p6 the corresponding ORF6 were cloned into the pCAGGS 
expression vector. Both ORF6 were PCR amplified (2.2.3.1) using gene specific primers listed in 
chapter 2.1.11.1. Each forward primer included an HA-tag, the Kozak consensus sequence and 
an EcoRI restriction site, while the reverse primers included the NotI restriction site (Fig. 3.10A). 
The generated PCR product and the expression vector pCAGGS were digested with NotI and 
EcoRI (2.2.2.13). Digested pCAGGS was dephosphorylated in order to minimize vector 
religation. All restriction reactions were applied on a preparative agarose gel from which the 
desired fragments were excised and purified (2.2.2.8; 2.2.2.6). Ligation was done with a 5-fold 
excess of  insert molecules as compared to the vector (2.2.2.14). Transformation of  the ligation 
reaction and plasmid preparations of  selected and subcultured colonies was done as described 
(2.2.6; 2.2.2.4). The size of  prepared plasmids was compared to empty pCAGGS vector on an 
agarose gel (2.2.2.8). Plasmids larger than the empty vector were directly sequenced with specific 
vector primers (2.1.11.5) for a correct insert. Correct insertion of  ORF6 including Kozak 
sequence and HA-tag is exemplarily shown for SARS-CoV ORF6 in Fig. 3.10A. For each 
construct of  C-terminally HA-tagged ORF6, one plasmid was picked and prepared in midi-scale 
Figure 3.9: SARS-CoV p6 putative conformation and amino acid alignment with bat-CoV p6. 
(A) Schematic diagram of  the putative conformation of  p6 relative to intracellular membranes as 
described by Zhou et al. [56]. The C-terminus, responsible for the interaction with KPNA2 is exposed to 
the cytosol, while the N-terminal region, inducing membrane rearrangements is embedded in the 
membrane. (B) Amino acid alignment of  p6 of  SARS-CoV and p6 of  the SARS-related bat-CoV found in 
European Rhinolophus. 
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(SARS-CoV ORF6 vector construct “SAO6-pCAGGS” and BG-CoV ORF6 vector construct 
“BGO6-pCAGGS”). 
Expression and cellular localization of  tagged proteins might be altered by the tag in comparison 
to the untagged proteins. Successful C-terminal HA-tagging of  SARS-CoV p6 has already been 
described [59] but was verified again for the constructs produced here. SAO6- and BGO6-
pCAGGS were therefore chemically transfected into 293T and Huh7 cells (2.2.1.2). 293T cells 
 
Figure 3.10: Generation and validation of  ORF6 expression vector constructs. 
Restriction sites EcoRI and NotI as well as the Kozak consensus sequence (Koz) and an HA-tag sequence 
were added to the ORF6 sequences of  SARS-CoV and BG-CoV by PCR. After cloning of  the PCR 
products into pCAGGS vector the constructs were sequenced for correct insertion. The partial 
chromatogram of  the SARS-CoV ORF6 construct is shown (A). Successful expression of  SA-p6 and 
BG-p6 was verified by Western blot analysis (B) and immunofluorescence (C). (B) 293T cells were
transfected with 3 µg of  either ORF6 expression vector constructs at a 1:2 ratio of  FugeneHD.  Cells 
were harvested 24h post transfection and protein expression was detected by Western blot using rabbit-
anti-HA primary antibody (1:5000). M = PageRulerTM Prestained Protein Ladder (C) Huh7 cells were 
seeded on cover glass slips and transfected with 500 ng SAO6- or BGO6-pCAGGS at a 1:3 ratio of  
FugeneHD. P6 expression was visualized with primary rabbit-anti-HA antibody (1:100) and secondary 
goat-anti-rabbit-Cy2 antibody (1:200). Nuclei were stained with DAPI (1:1000). 
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were used for Western blot analysis because of  their high transfection efficiency. The predicted 
molecular masses of  SA-p6 and BG-p6 are 8.6 and 8.4 kDa, respectively. Both proteins were 
detected by Western blot analysis though at masses lower than 17 kDa but higher than 10 kDa 
when compared to the protein marker. Proteins detected at masses other than predicted is a 
common phenomenon and is frequently due to the fact that protein markers only provide 
approximate protein masses. Huh7 cells were used for IF due to their relatively large size, which 
facilitates the visualization of  expressed proteins. As shown in Fig. 3.10C both p6 were strongly 
expressed in the cytoplasm of  transfected cells. 
After verification of  the functionality of  the plasmids SA-p6 and BG-p6 could be compared in 
different overexpression experiments. 
 
3.2.1.2  Cellular localization of SA-p6 and BG-p6 in human and 
bat cells 
SA-p6 is known to localize at the endoplasmatic reticulum/Golgi membrane of  primate cells 
[59]. In order to determine if  this is also true for BG-p6 a subcellular colocalization study was 
performed by IF assay in human cells. In addition, bat cells were included to investigate 
differences in subcellular localizations. Human hepatocarcinoma (Huh7) cells and RhiLu-hACE2 
cells were transfected with SAO6- and BGO6-pCAGGS as described in chapter 2.2.1.2 and 
prepared for IF (2.2.7.4) 24h post transfection.  
Both proteins SA-p6 and BG-p6 were expressed in the cytoplasm of  transfected human and bat 
cells as shown in Fig 3.11. The Golgi apparatus of  Huh7 cells was visualized by co-staining with 
a Golgi protein marker antibody showing a characteristic perinuclear distribution. SA-p6 and BG-
p6 partially overlapped with the Golgi staining. In RhiLu-hACE2 cells proteins SA-p6 and BG-p6 
appeared to localize more clearly to single regions which could be co-stained with the Golgi 
marker. However, it was shown that both proteins partially colocalize with a Golgi marker in 
Huh7 and RhiLu-hACE2 cells. Because both proteins showed a similar expression pattern in 
human cells and because sequence data on bat cellular proteins were lacking, further 
overexpression studies on SA-p6 and BG-p6 were done in primate cells only.  
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3.2.1.3  Colocalization of SA-p6 and BG-p6 with human 
karyopherins 
It has been described that SA-p6 binds directly to cellular KPNA2 thus inhibiting the nuclear 
import of  ISGF3 [59]. In the following experiment the question was addressed, of  whether BG-
p6 also retains KPNA2 at the ER/Golgi. The cell line was changed to primate kidney cells 
(VeroFM) as follow-up studies with recombinant SARS-CoV (3.2.2) would be done in those 
highly susceptible cells. VeroFM cells were cotransfected with either SAO6- or BGO6-pCAGGS 
in addition to FLAG-tagged KPNA1- or KPNA2-pCAGGS (a kind gift from Megan Shaw, 
Mount Sinai Medical Center, New York) as described in chapter 2.2.1.2. 
As expected, KPNA2 was retained in the cytoplasm of  the cell in presence of  SA-p6 (second 
row of  Fig. 3.12). According to published data, KPNA1 had a nuclear distribution (Fig. 3.12 first 
row). In fact, BG-p6 was similarly able to inhibit the nuclear translocation of  human KPNA2 
(Fig. 3.12 third row), but not of  KPNA1 (Fig. 3.12 fourth row). 
Figure 3.11: Colocalization of  SA-p6 and BG-p6 with the Golgi apparatus of  human and bat cells. 
To investigate the subcellular distribution of  SA-p6 and BG-p6 in human Huh7 cells in comparison to bat 
RhiLu-hACE2 both cell lines were transfected with 500 ng of  each HA-tagged O6 plasmid at a 1:3 ratio 
of  FugeneHD. 24h post transfection, cells were fixed and labeled with primary rabbit-anti-HA antibody 
(1:100) and secondary goat-anti-rabbit-Cy2 antibody (1:200) for localization of  p6 and mouse-anti-Golgi 
(1:100) and goat-anti-mouse_Cy3 (1:200) for visualization of  the Golgi apparatus. Nuclei were stained 
with DAPI (1:1000). 
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These results indicate that p6 derived from a bat CoV is able to interfere with the same human 
transport protein as its hCoV counterpart, suggesting a potentially similar mechanism in 
antagonizing the cellular IFN signaling pathway.  
 
 
 
 
Figure 3.12: Colocalization of  SA-p6 and BGp6 with KPNA2. 
For colocalization of  p6 with human karyopherins VeroFM cells were transfected with 250 ng HA-tagged 
SAO6 or BGO6 plasmid and 250 ng FLAG-tagged KPNA1 or KPNA2 plasmid with FugeneHD at a 
ratio of  1:3. 24h post transfection, cells were fixed in 4% PFA and labeled with rabbit-anti-HA (1:100) 
and mouse-anti-FLAG (1:100). Anti-HA antibody was visualized with goat-anti-rabbit-Cy2 (1:200) 
secondary antibody. Anti-FLAG antibody was visualized with goat-anti-mouse-Cy3 antibody (1:200) 
secondary antibody. Nuclei were stained with DAPI (1:1000). 
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3.2.1.4  Inhibition of STAT1 nuclear translocation upon IFN 
stimulation by SA-p6 and BG-p6 in primate cells 
In order to quantify and compare the IFN-antagonistic abilities of  SA-p6 and BG-p6 a STAT1-
translocation assay was performed. STAT1 is part of  the ISGF3 complex and is rapidly 
transferred to the nucleus upon IFN stimulation. In this assay the capability of  SA-p6 and BG-p6 
to inhibit this STAT1 translocation after IFN stimulation was determined. VeroFM cells were 
transfected with SAO6-, BGO6-, or empty pCAGGS vector together with GFP-tagged STAT1 
(2.2.1.2). 24h post transfection cells were stimulated with pan-species IFN or left untreated as a 
negative control. As shown in Fig. 3.13A STAT1 was evenly distributed in the cytoplasm and 
nucleus of  IFN-untreated cells in the absence of  either types of  p6. Upon IFN treatment STAT1 
was more concentrated within the nucleus. In the presence of  SA-p6 and BG-p6 STAT1 was 
clearly retained in the cytoplasm. In order to quantify this effect three IF pictures were taken 
randomly from each setting at low magnification. A total of  50 positively transfected cells per 
picture were counted and analyzed for STAT1 translocation. Cells where STAT1 was found 
evenly distributed between nucleus and cytoplasm were defined as “STAT1 translocated”. Cells 
where STAT1 was found only in the cytoplasm were defined as “no STAT1 translocation”. The 
percentage of  cells without STAT1 translocation was calculated and compared for each setting 
(Fig. 3.13B). After IFN stimulation almost all cells showed a translocation of  STAT1 into the 
nucleus. In the presence of  either protein STAT1 translocation after IFN stimulation was greatly 
reduced. It appeared that BG-p6 was slightly more efficient than SA-p6 in inhibiting the 
transport of  STAT1. These results further support the previous finding that the bat CoV-derived 
BG-p6 is equally functional in primate cells as its hCoV counterpart SA-p6. 
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Figure 3.13: Inhibition of  nuclear translocation of  STAT1-GFP by SA-p6 and BG-p6. 
(A) VeroFM cells were transfected with 250 ng SAO6, BGO6, or empty pCAGGS plasmid in addition to 
250 ng STAT1-GFP plasmid with X-tremeGENE transfection reagent at a ratio of  1:3. 24h post 
transfection, cells were treated with 1000 U/mL pan-species IFN for 1 h. Cells were then fixed in 4% 
PFA and labeled with rabbit-anti-HA (1:100) primary antibody and goat-anti-rabbit-Cy3 (1:200) secondary 
antibody. Nuclei were stained with DAPI (1:1000). (B) Pictures were taken from three sections of  each 
setting, a total of  50 cells per picture were counted for translocation of  STAT1-GFP into the nucleus. 
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3.2.2  Characterization of BG-p6 in the full virus 
context 
In overexpression analysis BG-p6 exhibited similar functions as its counterpart SA-p6. With the 
help of  the SARS-CoV reverse genetics system a chimeric recombinant SARS-CoV carrying 
ORF6 from the SARS-related bat-CoV was generated next, BGO6-rSCV. In addition, a 
recombinant SARS-CoV lacking ORF6 was constructed to serve as a control virus. This was 
done to give evidence that observed effects can be allocated exclusively to ORF6. 
 
3.2.2.1  Generation of an rSCV carrying the SARS-related bat 
CoV ORF6 
SARS-CoV ORF6 is located within subclone pEF as shown in Fig. 3.14B. To exchange SARS-
CoV ORF6 with its homologue from the SARS related bat-CoV an overlap extension PCR was 
designed. The generated amplicon consisted of  the BG-CoV ORF6 and flanking SARS-CoV 
wild type sequences. This new chimeric sequence was introduced into subclone pEF via two 
unique restriction sites (BamHI and NotI). The strategy of  the overlap extension PCR is depicted 
in Fig. 3.14A. Primers used in these PCRs are listed in chapter 2.1.11.1. Fig. 3.14B shows the 
vector map of  subclone pEF and the unique restriction sites of  BamHI and NotI for 
introduction of  the PCR product. 
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For cloning of  the BG-CoV ORF6 the ORF6 sequence was required to be generated from bat 
feces. Therefore, viral RNA was extracted from bat feces stored in RNA later and cDNA was 
synthesized with a specific RT primer binding 55 nts downstream of  the ORF6 stop codon 
(2.2.2.1; 2.2.2.2). The cDNA was used for amplification of  the entire ORF6 represented by 
amplicon PCR1 from the overlap extension PCR shown in Fig. 3.14A (2.2.3.1). The flanking 
sequences were amplified directly from subclone pEF. Amplicon PCR2, upstream of  SARS-CoV 
ORF6, was generated with a SARS-CoV specific reverse primer that added BG-CoV ORF6 
sequence to the 3’-end of  the PCR product. Amplicon PCR3, which lay downstream of  SARS-
CoV ORF6, was generated with a SARS-CoV specific forward primer that added BG-CoV ORF6 
sequence to the 5’-end of  the PCR product. These newly added BG-CoV ORF6 sequences 
created overlapping regions to the PCR1 that were used for binding in the subsequent overlap 
extension PCRs. Template amplicons for the overlap extension PCRs are shown in Fig. 3.15A. 
Three different amplicons should be generated in the first round of  overlap extension PCR. 
Amplicon PCR4.1 should be generated with templates PCR1 and PCR2. Amplicon PCR4.2 was 
to be produced with PCR1 and PCR3 as templates. In addition, it was attempted to create 
amplicon PCR5 by directly fusing PCR1, PCR2 and PCR3. As described in chapter 2.2.3.1.1 
templates were combined and serially diluted. Primers for the corresponding amplicons were 
used as depicted in the cloning strategy in Fig. 3.14A. The results of  the extension PCRs are 
Figure 3.14: BGO6-rSCV cloning strategy. 
(A) Overview of  the BGO6 cloning strategy. PCR1 amplified the complete BGO6, while PCR2 and 
PCR3 were done with primers that added additional BG specific sequences to the 3' and 5' ends of  the 
amplicons. Amplicons from PCR4.1 and PCR4.2 could be amplified using products of  PCR1 and PCR2 
or PCR1 and PCR3. PCR5 amplicons were generated with either PCR4.1 and PCR3 or PCR4.2 and 
PCR2. (B) Vector map of  subclone pEF with single cutters NotI and BamHI for introduction of  the 
overlap extension PCR product. 
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shown in Fig. 3.15B. PCR4.1 was successfully amplified without the generation of  non-specific 
fragments. PCR4.2 was only generated in minor amounts and a by-product of  about 300 bp 
appeared in relatively large quantities. A direct amplification of  PCR5 was not achieved. 
Therefore, PCR4.1 was used for the second round of  overlap extension PCR. 
PCR4.1 and PCR3 were combined, serially diluted and subjected to PCR amplification. 
Amplicons are shown in Fig. 3.15C. The amplicon PCR5 was successfully generated. The yield of  
the desired amplicon and the reduction of  non-specific PCR products were optimal when the 
templates were diluted 1:10. This PCR setup was used to generate high amounts of  PCR5 for 
enzymatic digestion. 
Amplicon PCR5 and subclone pEF were digested with BamHI and NotI (2.2.2.13). In the case 
of  amplicon PCR5 this led to fragments with predicted lengths of  3,702 bp, 267 bp and 111 bp. 
Subclone pEF was cut into fragments of  11,671 bp and 3,705 bp in length. Successful digestion 
was verified by gel electrophoresis (2.2.2.8) shown in Fig. 3.15D. The 11.7 kb fragment of  pEF 
contained the entire pBeloBAC11 backbone including the resistance gene. To avoid false positive 
clones due to relegation, the backbone was dephosphorylated (2.2.2.13). The BG-CoV ORF6 is 
one codon shorter than that of  SARS-CoV ORF6. Therefore the insert from PCR5 comprised 
only 3,702 bp, while the fragment cut out from pEF was 3,705 bp in length. Both restriction 
reactions were separated on a preparative agarose gel and the correct fragments for ligation were 
excised and extracted (2.2.2.6; 2.2.2.14). Colonies grown after transformation were prepared for 
plasmid isolation in mini-scale (2.2.6; 2.2.2.4). Plasmids were analyzed for their size on an agarose 
gel in comparison to subclone pEF. All analyzed plasmids showed the same length as pEF (data 
not shown) but eventually only one plasmid was chosen for sequencing (sequencing PCRs, PCR 
conditions and sequencing primers are listed in table 2.1). Special attention was paid to the region 
between BamHI and NotI. The introduced fragment was exclusively generated by PCR and was 
therefore subjected to several amplification cycles. The probability of  PCR-based mutations was 
thereby increased. The selected plasmid “BGO6-pEF-K1” showed no undesired mutations and 
was prepared in midi-scale for the assembly of  a full-length clone as described in chapters 3.1.1.2 
and 3.1.1.3. 
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Figure 3.15: Overlap extension PCRs and restriction digests for the cloning of  BGO6 into 
subclone pEF. 
(A) Generation of  templates for overlap extension PCR. PCR1 (189 bp) was amplified using BGO6 
specific primers. Template cDNA was synthesized from viral RNA isolated out of  bat feces. PCR2 
(1.3 kb) and PCR3 (2.6 kb) were directly amplified from subclone pEF. (B) First round extension PCR. 
PCR1 and PCR2 were mixed 1+1 and serially diluted 10-1 and 10-2 to serve as template in the extension 
PCR generating PCR4.1 (1.5 kb). PCR1 and PCR3 were used as templates for PCR4.2 (2.8 kb) and 
PCR1+PCR2+PCR3 were used as templates for PCR5 (4.1 kb). (C) Second round extension PCR: 
PCR4.1 and PCR3 were mixed 1+1 and serially diluted 10-1 and 10-2 to serve as template in the second 
round extension PCR generating PCR5 (4.1 kb). (D) Digestion of  pEF and PCR5 for introduction of  
BGO6 into subclone pEF. PCR5 and pEF were digested with BamHI and NotI. The 11.7 kb fragment of  
pEF and the 3.7 kb fragment of  PCR5 were used for subsequent ligation. “-“ = undigested DNA; “+” = 
double digested DNA. Generally, 5 µL PCR product or 200 ng plasmid DNA were applied on one lane of  
a 0.8% agarose gel. M1 = 100 bp DNA ladder plus; M2 = 1 kb DNA ladder plus; M3 = 1 kb DNA 
ladder. 
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3.2.2.2  Generation of an rSCV with a deleted ORF6 
It was shown for CoVs that up- and downstream elements of  the TRS are important for virus 
replication and transcription [24, 112]. In particular the generation of  subgenomic mRNAs relies 
on a correct genomic context. By deleting a complete ORF the transcription of  subgenomic 
mRNAs of  neighboring ORFs might be ablated. In case of  ORF6, transcription regulation of  
the membrane coding ORF5 and ORF7 might be altered by deleting the ORF6 sequence. 
Therefore ORF6 was not completely deleted but provided with a double stop codon at amino 
acid positions 5 and 6 as shown in Fig. 3.16A, leading to the translation of  a shortened non-sense 
peptide.  
The double-stop codon was introduced into subclone pEF by site-directed mutagenesis (2.2.3.3). 
Mutation primers were designed as shown in Fig. 3.16A. The 5' phosphorylated forward primer 
contained the double-stop codon in the middle of  its 43nt sequence. It was essential that the 
forward and reverse primers were placed end-to-end in correspondence with the template strand. 
Nucleotide gaps between both primers would result in deletion mutations. Using this primer 
Figure 3.16: Deletion of  ORF6 within subclone pEF by site-directed mutagenesis PCR. 
(A) Codons 4 and 5 of  SARS-CoV ORF6 were exchanged by a double stop codon via site-directed 
mutagenesis to prevent translation of  protein 6, thus generating an ORF6 deletion mutant. (B) 5' 
phosphorylated primers, of  which the forward primer carried the double-stop codon, were used for 
amplification of  the entire pEF yielding an amplicon of  15.4 kb. Annealing temperatures of  58°C and 
66°C were compared in order to minimize non-specific PCR products. (C) Ligation of  the PCR product 
yielded a high number of  plasmids with the same size as the reference plasmid (R) pEF. Plasmids of  
correct size are marked with “*”. 
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design the whole pEF was amplified. Primer annealing temperatures of  58°C and 66°C were 
compared. It was expected that a higher annealing temperature would result in more specific 
primer binding and therefore less non-specific PCR products. Conversely, at the low temperature 
the PCR product of  15,376 bp was generated more efficiently and with lesser non-specific 
products (Fig. 3.16B). It was assumed that the non-specific product did not contain enough 
sequence information to give rise to false positive colonies. The amplicon was therefore not 
purified. Ligation of  the unpurified amplicon was done as described (2.2.3.3). Plasmids of  
selected and subcultured colonies were screened for correct size in comparison to pEF. As shown 
in Fig. 3.16C, the yield of  plasmids with the correct size was reasonably high. Prepared plasmids 
were first screened for the presence of  the double-stop codon with PCR2 from the sequencing 
PCRs listed in table 2.1 and primer F 26918 F binding upstream of  ORF6. Only one plasmid 
carried the mutation.  
This was most likely due to the presence of  pEF in the PCR reaction, since it had not been 
purified and therefore probably contained some residual amount of  pEF. It is also possible that 
the primer design was not optimal, resulting in the double-stop codon only being incorporated 
into a small number of  amplicons. Due to the high probability of  PCR-based undesired 
mutations within the 15.4 kb amplicon, the whole plasmid was sequenced. No additional 
mutations were detected and the plasmid (delO6-pEF-K12) was prepared in midi-scale for 
assembly of  the corresponding full-length clone as described in chapters 3.1.1.2 and 3.1.1.3. 
 
3.2.2.3  Rescue and quantification of ORF6 mutant rSCVs 
Both ORF6 mutant rSCVs, BGO6-rSCV and delO6-rSCV, were rescued as described in chapter 
3.1.1.4. Virus growth was monitored by real-time RT-PCR quantification of  viral RNA (2.2.2.1; 
2.2.3.2) in a VeroFM cell culture infected with supernatant of  electroporated BHK-J cells. The 
increase of  viral RNA over three days of  infection is shown in Fig. 3.17A.  
Both virus stocks were sequenced for correct mutations. The cDNA was synthesized from viral 
RNA (2.2.2.2) with a SARS-CoV specific reverse primer and was used as template for a PCR 
amplifying the genome region around ORF6 (2.2.3.1). Finally, the amplicons were sequenced with 
primer F 26918 F. Both virus stocks contained recombinant virus with the desired mutation.  
Following verification of  correct mutations, the newly generated virus stocks were quantified by 
plaque titration (2.2.1.6). Although both stocks contained equal amounts of  viral RNA 
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(Fig. 3.17A), the quantity of  infectious particles of  BGO6-rSCV was increased by 10-fold in 
comparison to delO6-rSCV (data not shown). Genotypically different viruses could give rise to 
altered plaque morphologies on account of  a different phenotype. As shown in Fig. 3.17B 
plaques produced by BGO6-rSCV were considerably smaller than that of  wild type rSCV. On the 
contrary, plaques of  delO6-rSCV were slightly enlarged in comparison to plaques of  rSCV. These 
initial findings on the varying plaque morphology of  the ORF6 mutant viruses indicated that the 
viruses may display further altered phenotypic characteristics. Therefore, both mutant viruses 
were compared to wild type rSCV for replication differences in a growth kinetic. 
 
3.2.2.4  Growth kinetics of ORF6 mutant viruses 
Yount et al. showed that an rSCV lacking ORF6 had no replication disadvantages as compared to 
wild type rSCV after infection at a high MOI of  1 [60]. On the contrary Zhao et al. reported that 
the absence of  p6 results in decreased virus growth when infection is done at a low MOI of  0.01 
[54]. In the present study an MOI of  0.001 was chosen in order to emphasize replication 
differences between the three ORF6 variants more clearly than previous studies. In addition, this 
scenario was expected to imitate the early phase of  an infection and/or the first animal to human 
transmission, where virus concentrations would still be low. This scenario was considered 
representative for the characterization of  potential zoonotic risk markers. 
VeroFM cells were infected with rSCV, BGO6-rSCV and delO6-rSCV (2.2.1.5). Supernatant was 
sampled at indicated time points and plaque titrated (2.2.1.6). Results of  plaque titration are 
shown in Fig. 3.18. At 8 and 24h p.i. all three viruses grew to almost identical titers of  2-5x 
 
Figure 3.17: Rescue of  ORF6 mutant viruses. 
(A) Supernatant of  BHK-J cells electroporated with in vitro transcribed RNA of  ORF6 mutated viral 
genomes was transferred to VeroFM cells for rescue of  recombinant virus. Virus growth was measured 
by real-time RT-PCR. (B) Plaque morphology of  BGO6- and delO6-rSCV was compared to rSCV. 
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102 PFU/mL and 1x 105 PFU/mL, respectively. At 48h p.i. BGO6-rSCV exhibited a 6.5-fold 
increase of  infectious particles as compared to wild type rSCV. At 72 h p.i. replication differences 
between the three viruses had leveled out. 
These results suggested a replication advantage of  the recombinant virus expressing p6 of  the 
SARS-related bat-CoV. 
 
3.2.2.5  Growth of ORF6 mutant viruses in primate and bat cells 
in an anti-viral state 
An influence on replication of  viruses mutated within the IFN antagonist expressing ORF6 was 
expected to be seen best in IFN-competent cells put into an anti-viral state by IFN stimulation. 
VeroFM cells do not secrete IFN but still have functional type I IFN receptors and therefore 
respond normally to externally applied IFN [113]. MA104 cells possess an intact IFN system 
[114]. So VeroFM and MA104 cells were chosen as representative primate cell lines. In addition 
to comparing the three ORF6 variants on primate cells, each virus was compared for its ability to 
replicate in a bat cell line in comparison to the primate cells. For this purpose the SARS-CoV 
susceptible and IFN-competent bat cell line RhiLu-hACE2 (3.1.2) was included in the following 
experiment. 
 
Figure 3.18: Growth kinetics of  ORF6 mutant viruses. 
VeroFM cells were infected with rSCV, BGO6-rSCV, and delO6-rSCV at an MOI of  0.001. Supernatant 
was sampled at 8, 24, 48, and 72 h p.i. and virus titers were determined by plaque titration.  
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In order to induce an anti-viral state cultures were incubated with their cell line-specific pan-
species IFN concentrations. Previous experiments showed that MA104 cells preincubated with 
600 U/mL pan-species IFN allowed virus growth which was clearly reduced as compared to 
untreated cells (data not shown). The corresponding cell line-specific pan-species IFN 
concentrations for VeroFM and RhiLu-hACE2 cells were calculated with the help of  the 
determined EC50 values (3.1.3). The EC50 value of  VeroFM cells is 3.7-fold higher, while the 
EC50 value of  RhiLu-hACE2 cells is 1.5-fold lower than that of  MA104 cells. Therefore, 
VeroFM cells were treated with 2245 U/mL and RhiLu-hACE2 cells with 395 U/mL pan-species 
IFN.  
The above-described growth kinetic done in VeroFM cells exhibited replication differences at 
48h p.i. Kinetics done by other groups rather found differences at earlier time points p.i. This 
might be due to higher MOIs used in these experiments. However, in order not to bypass the 
optimal time point, samples were taken at 24 and 48h p.i. 
The supernatants sampled at 48h p.i. were first analyzed by real-time RT-PCR (2.2.3.2). The 
results presented in Fig. 3.19 show that IFN-induced reduction of  virus replication had already 
leveled out in VeroFM and MA104 cells. However, differences in viral RNA load were still 
obvious on RhiLu-hACE2 cells. Based on these findings supernatants sampled 24h p.i. were 
plaque titrated for quantification of  infectious virus particles 2.2.1.6). 
 
 
Figure 3.19: Viral RNA load of  ORF6 mutant viruses 48h p.i on VeroFM, MA104 and RhiLu-
hACE2. 
(A) VeroFM, (B) MA104 and (C) RhiLu-hACE2 were infected at an MOI of  0.001 with rSCV, BGO6-
rSCV and delO6-rSCV. Viral RNA was extracted from supernatants at 48h p.i. Replication differences of  
the ORF6 mutant viruses had already disappeared. 
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Plaque titration, as shown in Fig. 3.20, revealed different overall levels of  virus replication in the 
three cell lines. Virus titers were highest in VeroFM cells, while titers of  the same virus in MA104 
cells were 10 to 100-fold lower. Virus titers obtained from RhiLu-hACE2 cells were up to 1000-
fold lower than from VeroFM cells. Reduced virus growth in MA104 cells as compared to 
VeroFM cells might be explained by their intact IFN system. Although SARS-CoV is known to 
antagonize the type I IFN pathway, type III IFNs which use a distinct signaling pathway were 
found to play a critical role in managing virus replication [115]. A possible explanation could be 
that MA104 cells with intact type I and III IFN pathways reduced SARS-CoV replication more 
efficiently than VeroFM cells having only an intact type III IFN system [116]. Reduced overall 
virus replication in RhiLu-hACE2 cells was already observed during the course of  their 
generation. It is most likely that differences in the cellular processing machinery between bat cells 
and primate cells could be the cause of  inefficient post-translational modifications of  viral 
proteins and virus maturation of  a virus that is adapted to primate cells. 
 
 
Notably, in all three cell lines wild type rSCV grew to higher titers than BGO6-rSCV and delO6-
rSCV. BGO6-rSCV and delO6-rSCV grew to similar titers in both primate cell lines. Interestingly, 
in RhiLu-hACE2 cells delO6-rSCV grew to lower titers than BGO6-rSCV. This replication 
pattern could be seen even more distinctly at 48h p.i. as shown in Fig. 3.21.  
Preincubation of  VeroFM cells with pan-species IFN led to a 150- and 100-fold decreased virus 
growth of  rSCV and BGO6-rSCV, respectively. DelO6-rSCV replication was even 260-fold 
lower. IFN stimulated MA104 cells yielded reduced virus replication of  rSCV, BGO6-rSCV and 
Figure 3.20: Virus growth of  ORF6 mutant viruses on primate and bat cells. 
VeroFM (A), MA104 (B) and RhiLu-hACE2 (C) were preincubated with cell line-specific pan-species IFN 
concentrations or medium only for 16 h and infected with rSCV, BGO6-rSCV and delO6-rSCV at an 
MOI of  0.001 for 24h. Supernatants were plaque titrated for determination of  virus titers. Wild type 
rSCV grew to highest titers on all three cell lines. 
 
 
Results 
108 
delO6-rSCV by 15-, 7- and 3-fold, respectively, as compared to un-stimulated cells. This clearly 
showed that the influence of  externally applied IFN on reduction of  virus replication was more 
distinct in IFN-deficient VeroFM cells than in IFN-competent MA104 cells. It was likely that the 
already reduced virus replication in MA104 cells could only be slightly reduced by additional IFN. 
Consequently, in VeroFM cells, having a supposedly diminished IFN response to virus infection, 
the presence of  external IFN resulted in a strong response and therefore had a comparably high 
impact on virus replication.  
 
 
 
The impact of  IFN treatment prior to infection was the highest in VeroFM cells, but in this 
scenario not relevant because viruses were to be compared within one cell line and not between 
different cell lines.  
In summary, growth of  the three viruses was equally inhibited in VeroFM cells by IFN 
pretreatment. In MA104 cells replication of  rSCV was reduced to a greater extent than that of  
BGO6-rSCV and delO6-rSCV. However, pretreatment with IFN of  RhiLu-hACE2 cells led to a 
drastic inhibition of  BGO6-rSCV replication as compared to wild type rSCV, which could be 
seen best 48h p.i (Fig. 3.21). Replication of  delO6-rSCV was inhibited more efficiently than rSCV 
but to a lesser extent than BGO6-rSCV. These data suggest a general attenuating effect when the 
BG-p6 was expressed in the context of  viral replication. 
  
Figure 3.21: Virus replication of  ORF6 mutants on RhiLu-hACE2 cells 48h p.i. 
RhiLu-hACE2 cells were preincubated with their cell line-specific pan-species IFN concentration and 
infected with the three ORF6 mutant viruses as described above. Supernatants were sampled 48h p.i. and 
plaque titrated. 48h p.i. wild type rSCV grew to the highest titer, while delO6-rSCV replicated the least 
efficiently.  
Results 
109 
3.2.3  Impact of ORF8 integrity on virus replication 
The most obvious difference in genome organization between Asian SARS-related bat-CoVs, the 
human pandemic SARS-CoV and the Bulgarian SARS-related bat-CoV (Bt-CoV/BM48-31) 
sequenced by our group is the integrity of  ORF8 [88]. While Asian bat-CoVs and early human 
isolates carry one single full-length ORF8, ORF8 isolated during the human pandemic adapted a 
29nt-deletion thereby splitting it into two separate open reading frames, ORF8a and 8b [10, 72, 
78]. In the Bulgarian bat-CoV ORF8 is entirely absent. Sampling of  more Rhinolophus bats from 
Spain, Italy and Slovenia revealed that ORF8 was missing in all European SARS-related bat-CoVs 
(Fig. 3.22, unpublished data). 
A gene and its respective protein, undergoing such drastic mutations might serve as a virulence 
factor and was therefore studied in the context of  viral replication. With the help of  the SARS-
CoV reverse genetics system, two ORF8 mutants were generated. O8full-rSCV carried the 
untruncated ORF8 without the 29nt-deletion while delO8-rSCV lacked the entire ORF8 
sequence.  
 
Figure 3.22: ORF8 integrity of  European SARS-related bat-CoVs. Feces from Rhinolophus bats from 
Spain, Italy, Slovenia and Bulgaria were sampled. PCR amplification of  the ORF8 region revealed that all 
SARS-related bat-CoVs lack ORF8. R.hip = Rhinolophus hipposideros, R.fer = Rhinolophus ferrumequinum, 
R.bla = Rhinolophus blasii, R.eur = Rhinolophus euryale. 
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3.2.3.1  Completion of ORF8 for the generation of O8full-rSCV 
The missing 29nts that reconstitute SARS-CoVs ORF8a and ORF8b to a single ORF8 were 
introduced by a two-step overlap extension PCR (2.2.3.1.1) as depicted in the cloning strategy in 
Fig. 3.23A. The reverse primer of  PCR1 and the forward primer of  PCR2 contain the additional 
29nts which partially overlap for annealing in the subsequent extension PCR (Fig. 3.23B). The 
extended PCR product covered the region between restriction sites BamHI and NotI enabling 
the introduction of  the mutated SARS-CoV sequence into subclone pEF as described for 
BGO6-pEF in chapter 3.3.1. 
Amplicons PCR1 and PCR2, shown in Fig. 3.24A, were generated from subclone pEF. The 
forward primer of  PCR1 and the reverse primer of  PCR2 were 5’ phosphorylated for subsequent 
cloning of  the extension PCR product into pEZTM BAC as described in chapter 2.2.4. For the 
fusion of  amplicons PCR1 and PCR2 to amplicon PCR3, both template PCRs were combined in 
equal amounts and serially diluted before performing PCR amplification. Generation of  
Figure 3.23: Cloning strategy for generation O8full. 
(A) The 29 nucleotides (nt), fusing SARS-CoVs ORF8a and 8b to one single full-length ORF8, were 
introduced by overlap extension PCR. PCR1 amplicon was generated using primer F 26020 F and the 
reverse primer 29nt-rev, which carried 24 of  the 29nts. PCR2 amplicon was generated with the forward 
primer 29nt-for, which carried 25 of  the 29nts, and pBELOscfwd. The overlapping region of  21 nt was 
used for annealing of  PCR1 and PCR2 in the subsequent extension PCR. Introduction of  the mutated 
fragment into subclone pEF was done via restriction sites BamHI and NotI. (B) The alignment illustrates 
the primer design for the O8full cloning strategy. 
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amplicon PCR3 was successful in each dilution as shown in Fig. 3.24B. Subclone pEF served as a 
PCR positive control. Amplicon PCR3 obtained from the template PCR 10-2 dilution was used 
for cloning into pEZTM BAC vector (2.2.4). The vector insert was sequenced (2.2.2.10) and the 
plasmid “O8full-pEZ-K1” prepared in midi-scale (2.2.2.4) for introduction of  the full-length 
ORF8 into subclone pEF. Therefore, plasmids O8full-pEZ-K1 and pEF were successively 
digested with BamHI and NotI as shown in Fig. 3.24C (2.2.2.13). The pEZ vector contained one 
additional BamHI site and two additional NotI sites up- and downstream of  its multiple cloning 
site. The digestion with BamHI had already released the complete insert from the vector because 
the vector-included restriction site is positioned only 46 bp downstream of  the insert. This 
fragment comprising 3,891 bp is shown in the control gel in Fig. 3.24C. After restriction with 
NotI subclone pEF was dephosphorylated. The 11.7 kb fragment of  pEF and the 3.7 kb 
fragment of  O8full-pEZ were excised from a preparative gel, extracted and ligated (2.2.2.8; 
2.2.2.6; 2.2.2.14). Colonies selected after transformation were prepared for plasmid isolation in 
mini-scale (2.2.6; 2.2.2.4). Plasmids were analyzed for their size on an agarose gel in comparison 
to subclone pEF. Plasmids of  the same size as pEF were used as templates for sequencing PCR2 
in table 2.1. The PCR products were sequenced for correct mutation of  ORF8. All plasmids 
carried the introduced 29nts within ORF8. One plasmid, O8full-pEF-K1, was fully sequenced 
 
Figure 3.24: O8full extension PCR and cloning into pEZ-BAC. 
(A) PCR1 (1.9 kb) and PCR2 (2.0 kb) were combined in equal amounts and serially diluted 10-1 and 10-2 to 
serve as templates to generate extension PCR product PCR3 of  3.9 kb (B). Subclone pEF served as PCR 
positive control. 5 µL of  each PCR product were applied per lane on a 0.8% agarose gel to verify 
successful amplification. (C) PCR3 was first cloned into pEZTM-BAC. Thereafter, the mutated insert was 
cut out with restriction enzymes BamHI and NotI and inserted into pEF. “+” indicates digestion with 
BamHI; “++” indicates additional digestion with NotI; M = 1 kb DNA ladder. 
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using sequencing PCRs and sequencing primers listed in table 2.1. No undesired mutations were 
found and the plasmid was prepared in midi-scale (2.2.2.4) and used for assembly of  the full-
length clone as described in chapters 3.1.1.2 and 3.1.1.3. 
 
3.2.3.2  Deletion of ORF8 for the generation of delO8-rSCV 
ORF8a and 8b were deleted from the SARS-CoV genome in two different ways. In the first 
approach both reading frames were cut out from ORF8as ATG to ORF8bs TAA (variant delO8-
1). In the second approach both ORFs were exchanged by the sequence AATAA according to 
the sequence around the missing ORF8 in the BtCoV/BM48-31 genome (variant delO8-2). The 
mutations were introduced into a suitable subclone by site-directed mutagenesis as generally 
described in chapter 2.2.3.3. 5' phosphorylated primers were designed in a way that the forward 
primers (delORF8-1-for and delORF8-2-for) bound directly downstream of  ORF8bs TAA and 
the reverse primers (delORF8-1-rev and delORF8-2-rev) hybridized directly upstream of  
ORF8as ATG, amplifying the complete subclone except ORFs 8a and 8b (see Fig. 3.25A). 
In order to minimize cloning steps after deletion of  ORF8a/b, site directed mutagenesis was 
done with subclone pDEF and the full-length SARS-CoV clone instead of  pEF. In addition, 
PhusionTM Hot Start DNA Polymerase was compared to Phusion® High-Fidelity DNA 
Polymerase concerning the enzymes processivities. Therefore, reactions were set up as described 
in chapter 2.2.3.1 and 2.2.3.3 for the corresponding enzymes. PCR products were applied on an 
agarose gel shown in Fig. 3.25B. PhusionTM Hot Start DNA Polymerase was not able to amplify 
any of  the templates; while Phusion® High-Fidelity DNA Polymerase yielded distinct amplicons 
of  pDEF (see Fig. 3.25B). Although the hot start DNA polymerase is part of  the site-directed 
mutagenesis kit, its processivity was reduced as compared to the high-fidelity polymerase. When 
mutating large plasmids it is therefore recommended to switch enzymes. PCR products from 
template pDEF of  both ORF8 deletion variants were used for ligation as per the manufacturer’s 
recommendations in the site-directed mutagenesis kit. 
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Transformation of  the ligation reactions into in-house produced stbl3 cells (2.2.6) yielded only 5 
colonies for the delO8-1 variant and 3 colonies for the delO8-2 variant. This was likely due to the 
low competence of  self-made bacteria but probably also reflects the difficulty of  handling of  
Figure 3.25: DelO8 cloning strategy and mutagenesis PCR. 
(A) Alignment of  ORF8a/b from SARS-CoV strain Frankfurt-1 with the SARS-related bat-CoV BtCoV-
BM48-31. Primers illustrate the two different cloning strategies for the deletion of  ORF8a/b. Site-
directed mutagenesis PCR with primer pair delORF8-1 entirely deletes ORF8a/b, while primer pair 
delORF8-2 exchanges ORF8a/b with the sequence “AATAA”. (B) Site-directed mutagenesis PCRs with 
primer pairs delORF8-1 (delO8-1) and delORF8-2 (delO8-2). Mutagenesis PCRs were done on subclone 
pDEF (1) and the full-length SARS-CoV clone (2). Comparatively, Phusion Hot Start and High Fidelity 
polymerase were used for amplification. Only the high fidelity polymerase was able to generate PCR 
amplicons. M = 1 kb DNA ladder. 
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large DNA fragments. Here, ligation of  the PCR product might not have been efficient. All 8 
colonies were picked and their plasmids prepared in mini-scale (2.2.2.4). Gel electrophoresis, as 
shown in Fig. 3.26A, revealed that only 3 colonies of  the del-O8-1 variant and 1 colony of  the 
delO8-2 variant carried plasmids of  the same size as the pDEF reference plasmid. The shorter 
plasmids were most likely a result of  the ligation of  shortened PCR products generated during 
mutagenesis. One way to circumvent the generation of  false positive colonies would be the 
purification of  the mutated PCR product from an agarose gel. This was not done because it was 
assumed that non-specific PCR products would not contain enough vector sequence for 
propagation in bacteria.  
Plasmids of  the correct size were screened by PCR with appropriate primers amplifying the 
genome region around ORF8. Amplicons would be 5,417 bp for wild type sequence or 5,077 bp 
and 5,082 bp for delO8-1 and delO8-2, respectively. Two of  three delO8-1 plasmids and the 
single delO8-2 plasmid yielded shortened PCR products as compared to the amplicon from wild 
type subclone pDEF (Fig. 3.26B). Sequencing of  the shortened PCR products revealed that all 
plasmids were correctly deleted of  ORF8. Plasmids “delO8-1-pDEF-K3” and “delO8-2-pDEF-
K3” were sequenced using sequencing PCRs and primers as listed in table 2.1. Both plasmids 
were free of  PCR-based undesired mutations and thus prepared in midi-scale (2.2.2.4) for the 
assembly of  the full-length clones as described in chapter 3.1.1.3. 
 
 
Figure 3.26: DelO8-pDEF plasmid minipreparations and screening PCRs. 
(A) Ligation and transformation of  the two mutagenesis PCR products yielded only a total of  8 colonies. 
All colonies were picked and prepared for plasmid minipreparations. 200 ng of  each plasmid were applied 
on one lane of  a 0.8% agarose gel and sizes were compared to unmutated pDEF (R). Mutated plasmids 
of  the same size as pDEF are marked “*”. (B) These four plasmids were screened in a PCR amplifying 
the ORF8a/b region. Amplicons would be about 5.1 kb in length when ORF8a/b was deleted 
successfully and would comprise 5.4 kb when the wild type sequence was used as template (R). Two 
plasmids of  delO8-1 and the single delO8-2 plasmid yielded shortened amplicons (marked “*”). M = 1 kb 
DNA ladder. 
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3.2.3.3  Rescue and quantification of ORF8 mutant rSCVs 
All ORF8 mutants, O8full-rSCV, delO8-1-rSCV and delO8-2-rSCV, were rescued as described in 
chapter 3.1.1.4. Virus growth was confirmed by real-time RT-PCR quantification of  viral RNA 
(2.2.2.1; 2.2.3.2). The increase of  viral RNA after infection of  VeroFM cells with supernatant of  
electroporated BHK-J cells is shown in Fig. 3.27A. Most interestingly, virus growth of  delO8-1-
rSCV was greatly delayed as compared to the other viruses. Infection was therefore extended for 
1 day. Nonetheless, the amount of  viral RNA was still lower as compared to the second ORF8 
deletion variant delO8-2-rSCV. 
For sequencing of  the virus stocks cDNA was synthesized from viral RNA (2.2.2.2) using a 
specific reverse primer binding downstream of  ORF8. The produced cDNA was used in a PCR 
with a forward primer binding at the downstream end of  ORF7a and a reverse primer binding 
within ORF9 as depicted in Fig. 3.27C. The generated amplicons already provided evidence for 
either the presence or absence of  the correct mutation. As shown in Fig. 3.27C the length of  the 
PCR product was determined by the corresponding ORF8 mutation. Amplicons generated from 
the respective virus stocks (Fig. 3.27D) were of  correct size and their sequence was verified.  
Quantification of  the newly generated virus stocks was done by plaque titration (2.2.1.6). 
Morphologies of  O8full-rSCV and wild type rSCV plaques were similar as shown in the upper 
panel of  Fig. 3.27B. Notably, the deletion of  ORF8 greatly altered the plaque morphology of  the 
rSCVs. As shown in Fig. 3.27B plaques of  delO8-1-rSCV are much smaller than those of  wild 
type rSCV. In addition, the discrepancy between viral RNA and infectious particles was 
considerably higher. Typically, the amount of  viral RNA/mL is 104-fold higher than PFU/mL. 
Correspondingly, the first countable amount of  plaques of  delO8-1-rSCV was expected at a 
dilution of  10-4 but was in fact determined at a dilution of  10-2. Plaques of  delO8-2-rSCV were 
also smaller in size as compared to wild type rSCV but not as small as delO8-1-rSCV plaques. 
Moreover, the discrepancy between viral RNA and PFU was similar to that of  wild type rSCV. 
These findings strongly suggested that the sequence context around an ORF is of  considerable 
importance to the viability and fitness of  SARS-CoV. The virus with a simple deletion of  
ORF8a/b displayed an impaired growth. But the virus, designed according to the genome 
organization of  the bat-related SARS-CoV, where ORF8a/b was replaced by a short context 
sequence, exhibited robust virus growth. 
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Because of  the better fitness and the more profound genome organization, further cell culture 
experiments were only done with delO8-2-rSCV, which is in the following text only referred to as 
delO8-rSCV. 
 
 
  
Figure 3.27: Rescue of  ORF8 mutant rSCVs. 
VeroFM cells were infected with supernatant of  BHK-J cells electroporated with the in vitro transcribed 
full-length RNA of  the three different ORF8 mutants. Virus growth was monitored by real-time RT-PCR 
(A). Plaque morphology of  the newly generated ORF8 mutant viruses were determined (B) and the 
genomic region around ORF8 was PCR amplified and sequenced for correct mutation. M = 100 bp Plus 
DNA Ladder. 
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3.2.3.4  Comparative growth kinetics of ORF8 variants 
Differences in ORF8 mutant virus plaque morphology were already observed during virus rescue 
(3.2.3.3). In further experiments the influence of  the integrity of  ORF8 on virus replication was 
investigated. VeroFM cells were infected at a very low MOI of  0.001 and virus replication was 
determined by plaque titration of  cell culture supernatant. A low MOI was chosen because this 
would magnify small replication differences and would best resemble the early phase of  a 
zoonotic transmission event. As shown in Fig. 3.28 already at 8h p.i. O8full-rSCV grew to higher 
titers than rSCV and delO8-rSCV. At 24h p.i. this replication pattern had noticeably developed. 
Virus titers decreased with reduced integrity of  ORF8. O8full-rSCV, with a single full-length 
ORF8, yielded highest titers. The wild type rSCV, with a truncated ORF8a and a potentially 
nonfunctional ORF8b, grew to intermediate titers, while delO8-rSCV, entirely lacking ORF8, 
yielded the lowest titers. Replication differences disappeared by 48h p.i., by which time the 
replication plateau of  all three viruses was reached. 
 
 
These results confirmed that infections at low MOIs show replication differences of  the ORF8 
variants, which could not be seen after infections at high MOIs [60]. 
 
Figure 3.28: Virus growth of  ORF8 variants on VeroFM cells. 
VeroFM cells were infected with the three ORF8 variants, O8full-rSCV, rSCV, and delO8-rSCV, at an 
MOI of  0.001. Supernatants were sampled at 8, 24, 48, and 72 h p.i. and virus titers were determined by 
plaque titration. 24h p.i. O8full-rSCV grew to highest titers, while delO8-rSCV displayed delayed virus 
growth. 
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3.2.3.5  Replication of ORF8 mutant viruses on IFN stimulated 
primate and bat cell lines 
In addition to a second primate cell line, virus replication was again analyzed on the bat cell line 
RhiLu-hACE2. The virus variant delO8-rSCV was detected in samples from European 
Rhinolophus bats. The truncated version of  ORF8 was exclusively found in the human pandemic 
virus. The single full-length ORF8 was identified in Asian Rhinolophus bats, amplifying hosts and 
human isolates from the early phase of  the pandemic. For these reasons the question arose of  
whether ORF8 influenced the adaptation to a new host and served as a virulence factor. 
According to the results from the previous experiments (3.2.2.4), cells were infected at a low 
MOI and supernatants sampled 24h p.i. were plaque titrated. In addition to comparing virus 
growth on different cell lines, a potential antagonism with the IFN signaling pathway should be 
investigated. Therefore, cells were preincubated with their cell line-specific pan-species IFN 
concentrations prior to infection as described for the ORF6 mutant viruses in chapter 3.3.5. 
In all three cell lines the same replication pattern as found in the previous experiment was 
identified (Fig. 3.29). Virus titers decreased with reduced integrity of  ORF8. Especially distinct 
were the growth differences between O8full-rSCV and delO8-rSCV. Virus titers were 25- to 272-
fold increased when the virus encoded the full-length ORF8 depending on the cell line used. 
Furthermore, as already seen in ORF6 mutant experiments, similar virus replication differences 
between the analyzed cell lines were detected (3.2.2.5). Generally, virus titers obtained in VeroFM 
cells were higher than those obtained in MA104 cells. Release of  infectious particles from RhiLu-
hACE2 cells was lower as compared to primate cells. 
Preincubation of  the cells with IFN reduced the general replication level of  all three viruses. This 
suggested an IFN-independent mechanism of  ORF8 influenced virus replication. 
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3.2.3.6  Trans-complementation of ORF8 variants 
To verify that the observed differences in virus replication were due to expression of  the ORF8-
encoded protein (p8) only, a trans-complementation assay was performed. Cells overexpressing 
p8 were infected with delO8-rSCV in order to determine if  replication efficiency can be 
enhanced by the presence of  the protein. Lentiviral transduction was chosen as the optimal 
method for gene transfer since it guarantees high protein expression levels in most cell lines 
(2.2.1.7). In this experiment a transient expression of  the protein was sufficient. Therefore, cells 
were not subjected to selection pressure as done in the course of  generating the bat cell line 
RhiLu-hACE2 (3.2.2). 
Cells were transduced with lentiviruses carrying either the full-length ORF8 (O8full) or ORF8a. 
Overexpression of  p8b was left out as it is most likely not expressed during virus infection [26, 
63]. 
VeroFM, MA104 and RhiLu-hACE2 cells were transduced as described in chapter 2.2.1.7.2. 
Infection with delO8-rSCV was done 48h post transduction since expression of  the transgenes 
was shown to reach highest expression levels at that time point (data not shown). Cells were 
infected with an MOI of  0.001. Samples were taken 24h p.i. Supernatants were plaque titrated for 
the determination of  infectious particles. Cells were lysed for quantification of  protein 
expression in Western blot analysis (2.2.7) and used in an IF (2.2.7.4) for localization of  the 
expressed proteins. Proteins p8full and p8a were FLAG-tagged for detection. 
Figure 3.29: Replication of  ORF8 variants on IFN stimulated cells. 
VeroFM (A), MA104 (B), and RhiLu-hACE2 (C) were preincubated with cell line-specific pan-species 
IFN concentrations or medium as a control 16 h prior to infection with O8full-rSCV, rSCV, and delO8-
rSCV at an MOI of  0.001. Supernatants were sampled 24h p.i. and virus titers were determined by plaque 
titration. 
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As shown in Fig. 3.30A expression of  p8full and p8a was especially strong in MA104 cells. 
VeroFM cells also expressed both proteins but to a considerably reduced extent. For unknown 
reasons RhiLu-hACE2 cells did not express either of  the proteins. A transduction failure due to 
lack of  entry of  VSV-G pseudotyped lentiviruses can be ruled out as RhiLu-hACE2 cells were 
made hACE2-transgenic by the same method (3.2.2). However, to exclude this possibility, the 
expression plasmids were transfected transiently (2.2.1.2). Again both proteins were not 
expressed (data not shown). This suggests either a malfunction of  the CMV promoter in bat cells 
or that the proteins might have been prone to degradation as already shown in case of  p8b [67]. 
Because of  the lack of  p8full and p8a in RhiLu-hACE2 cells in Western blot analysis, bat cell 
samples were not further analyzed.  
The IF revealed a different distribution of  p8full as compared to p8a (Fig. 3.30C). In VeroFM 
cells as well as in MA104 cells p8full was evenly distributed throughout the whole cytoplasm. In 
contrast p8a formed small granules in both cell lines. These differences between p8full and p8a 
expression have already been described by Keng, et al. and are thought to be a result of  different 
protein conformations [63]. 
Plaque titration of  the supernatants revealed that expression of  p8full and p8a was able to 
enhance replication of  delO8-rSCV (Fig. 3.30B). Expression of  p8a in MA104 cells was 
especially strong and enhanced virus replication by 10-fold as compared to cells not expressing 
any p8. It was assumed that p8full overexpression would reconstitute virus replication most 
efficiently. This effect was not observed but was most likely due to the low expression level of  
p8full. Nevertheless, even a low expression level of  p8full resulted in a 3-fold enhanced virus 
replication on MA104 cells. The same trans-complementation effects were observed in VeroFM 
cells, although to a lesser extent. This was most likely caused by the considerable lower 
expression level of  p8full and p8a in VeroFM as compared to MA104 cells.  
In conclusion, virus growth of  delO8-rSCV could be enhanced in correspondence to the 
expressed p8 amounts. This clearly demonstrated that the absence of  p8 was responsible for the 
impaired replication efficiency of  delO8-rSCV. 
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Figure 3.30: Trans-complementation of  p8full and p8a in delO8-rSCV infected cells. 
VeroFM, MA104, and RhiLu-hACE2 cells were transfected with O8full and O8a by lentiviral transduction 
48h prior to infection with delO8-rSCV for 24h. Expression of  the proteins p8full and p8a was 
confirmed by Western blot analysis (A) using rabbit-anti-FLAG primary antibody (1:5000). As a loading 
control β-actin was detected with a mouse-anti-β-actin primary antibody (1:2000). In addition, expression 
and localization of  p8full and p8a were visualized by immunofluorescence assay (C). Cells were fixed in 
4% PFA and p8full and p8a were stained with mouse-anti-FLAG (1:100) and goat-anti-mouse-Cy3 
(1:200). Infection of  the cells was confirmed using a human-anti-SARS-CoV serum (1:100) and goat-anti-
human-Cy2 (1:200) for secondary detection. Nuclei were stained with DAPI (1:1000). Virus replication 
was determined by plaque titration of  cell culture supernatants (B). Virus growth of  delO8-rSCV was 
enhanced in correspondence to the amount of  expressed p8. 
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4  Discussion 
4.1  Reverse genetics 
Reverse genetic systems are highly valuable tools to study viral gene functions in the context of  
viral replication. Designing and successfully handling a full-length cDNA clone of  one of  the 
largest viral RNA genomes has proven to be immensely challenging. In this study the reverse 
genetic system established by our group was used to generate the investigated SARS-CoV 
mutants [49]. In this system the full-length SARS-CoV cDNA genome is cloned into a BAC 
vector. Large DNA fragments cloned into BAC vectors and then maintained in bacteria are 
subjected to various mutations, like deletions and insertions [99]. Nevertheless, in the course of  
generating subclones and full-length clones described here, the disintegration of  an insert 
occurred only once. When expanding the bacteria carrying the full-length genome of  delO6-
rSCV for a plasmid midipreparation, which was used for RNA in vitro transcription and 
subsequently an attempt to rescue recombinant virus, the complete degradation of  the full-length 
plasmid occurred. Unfortunately, degradation was not observed by agarose gel electrophoresis of  
the plasmid, but degradation could be rapidly detected by screening the plasmid using the PCRs 
which are routinely generated for sequencing. Moreover, resolution of  plasmids of  20-30 kb on 
agarose gels would not expose other modifications like deletions or insertions of  a few hundred 
base pairs. However, this could be achieved by performing a range of  PCRs spanning the entire 
genomic insert. In order to prevent the use of  disintegrated plasmids it is therefore suggested to 
screen and fully sequence the midipreparations (not minipreparations), which are either used for 
further assembly or in vitro RNA transcription. In addition, the use of  One Shot® Stbl3TM 
competent cells should be discontinued in favor One Shot® TOP10 competent cells. In contrast 
to TOP10 Stbl3TM still express E. coli cells primary endonuclease (endA) which degrades plasmid 
DNA [117].  
One demand on reverse genetics is the rapid generation of  recombinant viruses. Here the system 
described by Baric’s group probably provides the quickest solution [98]. The SARS-CoV genome 
is segmented into six fragments, which are maintained in conventional vectors. In order to 
generate the full-length cDNA genome, the fragments are released from the vector and ligated in 
a single step. These inserts of  about 5 kb can be easily mutated and the assembly of  the whole 
cDNA genome into one vector backbone is not required. Assembly of  the full-length genome in 
Discussion 
123 
a BAC vector is absolutely necessary in the system used in this work. The use of  Phusion® High-
Fidelity DNA Polymerase greatly reduced the time needed to generate a full-length clone. 
According to the manufacturer (Fermentas) Phusion® polymerase possess and error rate of  
4.4x 10-7, which is 50-fold less than Taq polymerase and a processivity 10-fold higher than Pfu 
polymerase. In addition, site-directed mutagenesis is possible on plasmids of  up to 23.4 kb in 
length (deletion of  ORF8 in subclone pDEF, described in chapter 3.1.7). The yield of  colonies 
after PCR-based mutation is rather low, e.g. only one of  three plasmids had the correct size in 
case of  delO8-2-pDEF. Nevertheless, the polymerase’s extremely low error rate almost 
guarantees for correct sequences. Furthermore, overlap extension-PCR is possible, thereby fusing 
long DNA fragments without introducing undesired mutations. Especially when performing a 
three-step overlap extension-PCR the single fragments undergo unusually many amplification 
cycles, raising the probability of  PCR based mutations. If  a PCR-based mutation would be 
introduced into the amplicon during the first cycles of  amplification, all subsequent extended 
PCR products would carry this mutation. Without the low error rate of  Phusion® polymerase 
overlap extension-PCR of  large fragments would very likely be less successful. A new timesaving 
approach to mutate large DNA fragments maintained in BAC vectors is the two-step Red 
recombination system [118]. This method allows for recombination based mutagenesis of  
plasmids within an engineered E.coli strain. Plasmid preparations and standard cloning 
procedures, like restriction digestions and ligations, are unnecessary. This system was already 
successfully used for the generation and mutagenesis of  a recombinant cow pox virus [119]. The 
adaptation of  this mutagenesis method to the BAC vector based SARS-CoV reverse genetic 
system of  our group will greatly improve the generation of  mutated recombinant viruses.   
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4.2  Transgenic bat cells 
All in vitro studies conducted on the importance of  SARS-CoVs accessory proteins to date were 
done on primate cells. Most of  these studies conclude that the actual relevance of  accessory 
proteins can only be seen in the reservoir host of  the virus [53, 120, 121]. Only two bat cell lines 
have been available before this study, but neither resembles the reservoir host of  SARS-related 
CoVs [104]. With the establishment of  the SARS-CoV-susceptible immortalized Rhinolophus cell 
line RhiLu-hACE2 a major step has been taken for SARS-CoV studies. 
In the present study it was shown that SARS-CoV replicated efficiently in the new bat cell line. 
As SARS-CoV is highly sensitive to IFN [107] it was important to clarify if  the IFN response was 
functional in RhiLu-hACE2. In particular, as the RhiLu cell culture was first immortalized and 
then provided with hACE2 both by lentiviral transduction (3.1.2). The stable integration of  
transgenes into the cellular genome can heavily influence signal transduction pathways [122-124]. 
The IFN response can be triggered by different methods mostly involving double-stranded RNA 
intermediates that are sensed by cellular RIG-like helicases or Toll-like receptors [125-127]. It has 
already been shown that bat cell cultures respond to polyinosinic polycytidylic acid (poly I:C) 
stimulation or virus infection by the upregulation of  genes involved in the IFN response pathway 
and the secretion of  biologically active IFN [105, 128-130]. Poly I:C is structurally similar to 
double-stranded RNA, which is present during virus replication (e.g. of  SARS-CoV) and 
routinely used to induce type I IFN response [131]. A functional IFN response of  RhiLu-hACE2 
was proven on different levels as described in detail in the Bachelor thesis of  Hanna Roth [103]. 
IFN induction was verified by upregulated ISGs upon transfection of  poly I:C. In addition, 
secretion of  biologically active IFN was confirmed with the RVFV-Ren bioassay. Determination 
of  the pan-species IFN concentration that reduces viral replication of  RVFV-Ren up to 50% 
gave additional indication of  an intact IFN response. RhiLu-hACE2 cells could be put into an 
antiviral state upon IFN treatment and virus replication was reduced in an IFN concentration-
dependent manner (3.1.2). Successful replication of  SARS-CoV was determined by measuring 
the increase of  viral RNA in real-time RT-PCR and production of  infectious particles by plaque 
titration in the course of  characterizing the newly established cell line. Notably, the overall 
replication efficiency on RhiLu-hACE2 was clearly reduced as compared to primate cells like 
VeroFM or MA104. This was most likely due to differences between bat and primate cellular 
processing machinery. As described above, many viral proteins are involved in establishing a virus 
replication-friendly environment in the infected cells. This is done, for example, by induction of  
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membrane rearrangements to induce the formation of  replication complexes [23, 56, 132]. It 
could also be possible that human-adapted SARS-CoV proteins interact less efficiently with bat 
cellular proteins. In addition, maturation of  the virions takes place in the ERGIC [23, 27]. 
Differences in protein processing between bat and primate cells might lead to the assembly of  
defective, non-infectious virus particles. Reduced production of  infectious virus particles might 
also be a mechanism used to establish a persistent infection. Another noticeable characteristic of  
RhiLu-hACE2 cells was that the transfection/transduction of  ORF8 was not possible. Firstly, the 
precursor cell line RhiLu was already successfully transduced with hACE2. Secondly, lentiviral 
vectors are pseudotyped with the G protein of  VSV. The G protein mediates viral entry by 
endocytosis and therefore makes a broad range of  cell lines accessible to the lentiviral vector 
[133]. Possibly, RhiLu cells immediately degrade expressed p8, which could be why the SARS-
related bat-CoV found in European Rhinolophus has lost ORF8. But the fact that SARS-related 
bat-CoVs found in Asian Rhinolophus bats carry the full-length ORF8 objects to this explanation 
[10, 77, 134]. It might also be possible that transcription of  ORF8 is inhibited. The undirected 
integration of  hACE2 into the RhiLu cells genome could also have destroyed some essential 
cellular functions for transcription or translation of  certain genes. To rule out the production of  
artifacts on RhiLu-hACE2 cells, resulting from the disruption of  important cellular genes, cells 
were not cloned. This measure created a heterologous cell population in which heavily 
degenerated cells would not considerably influence experimental outcomes. 
It is commonly known that cell culture models are only a substitute for animal models. In most 
parts of  the world bats are protected species and the breeding of  bat colonies for experimental 
studies is limited to very few laboratories. Therefore, the bat cell line described here is a unique 
tool for simulating reservoir host conditions for a variety of  viruses found in bats of  the genus 
Rhinolophus, especially SARS-CoV.  
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4.3  The potential of accessory proteins to serve 
as risk markers 
Bats carry a large diversity of  SARS-related CoVs, which demands predictions of  epidemic and 
pathogenic potential of  these viruses [72-76]. Features that discriminate high- and low-risk 
variants have to be identified to achieve this goal. Two accessory proteins of  SARS-CoV were 
chosen as potential risk markers. The ORF6 encoded p6 is a very well characterized IFN 
antagonist [59]. With the sequence information obtained from the first full-length genome 
sequence of  a European SARS-related bat-CoV a comparative study on SARS-CoV p6 and a 
reservoir-borne SARS-related CoV p6 was possible [88]. ORF8 displayed a striking genetic 
variation in geographically distant reservoir hosts. SARS-related CoVs detected in Asian 
Rhinolophus bats carry an intact full-length ORF8 [10, 72], while Rhinolophus bats sampled in 
Southern and Western Europe exclusively carry SARS-related CoVs without an ORF8 gene [88]. 
The human pandemic strain of  SARS-CoV is characterized by a 29nt-deletion within ORF8 that 
splits it in two separate ORFs, 8a and 8b [61]. 
Generally, protein functions are first characterized in overexpression systems. These settings are 
rather error-prone and might produce artifacts, because proteins are expressed at very high levels 
that are most likely not achieved during virus infection. With increasing advances in reverse 
genetics systems, proteins should additionally be studied in full virus context, which are usually 
conducted in primate cells. However, especially in the case of  SARS-CoV and related viruses, 
which were found to have their reservoir in bats of  the genus Rhinolophus [10, 72], additional cell 
culture models are needed. The establishment of  an immortalized SARS-CoV susceptible 
Rhinolophus cell line specifically fulfills this need. This allowed for comparative studies on the 
above-mentioned proteins in their respective hosts. 
 
4.3.1  Protein 6 
Proteins SA-p6 and BG-p6 were expressed in human and bat cells to investigate their distribution 
patterns. While both proteins were evenly distributed in the cytoplasm of  human cells, they 
localize in punctuate structures within close proximity of  the nucleus in bat cells. No protein-
specific differences in cellular localizations were observed. Therefore, the punctuated localization 
of  p6 in RhiLu-hACE2 might be specific for bat cells. As described by Frieman et al. SA-p6 is 
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able to retain the transport protein KPNA2 at the ER/Golgi and thus inhibits IFN signaling [59]. 
An inhibition of  KPNA2 nuclear translocation by SA-p6 could be reproduced. Interestingly, the 
bat-CoV derived BG-p6 also inhibited KPNA2 translocation into the nucleus but allowed 
KPNA1 to translocate. Furthermore, translocation of  STAT1 into the nucleus of  primate cells 
was blocked efficiently by both p6 upon IFN treatment. These findings strongly suggest that 
both proteins, sharing an amino acid similarity of  78.1%, interfere with the IFN signaling by the 
same mechanism. The C-terminal 10 amino acids of  SA-p6 (amino acids 54-63) are responsible 
for efficient binding to KPNA2 and thereby the blocking of  STAT1 nuclear translocation [59]. 
SA-p6 and BG-p6 differ in only 3 of  the last 10 amino acids. In two of  these three changes the 
amino acid maintains its properties. At amino acid position 54 the asparagine of  SA-p6 is 
changed into a glutamine in BG-p6, both amino acids are acidic. Leucine was changed into an 
Isoleucine at position 60, with both amino acids being non-polar and hydrophobic. These 
“silent” amino acid changes are most likely the reason why BG-p6 exhibits functions similar to 
SA-p6. The highly conserved C-terminus is the first implication that p6 has a similar IFN 
antagonistic function in bats. Mutagenesis studies on BG-p6 and studies on p6 of  other 
European SARS-related bat-CoVs will follow.  In addition, detailed functional studies in bat cells 
are needed including for example protein-protein interactions with bat-derived homologous 
proteins. These studies were not done during the course of  this work due to the lack of  bat 
genome sequence information. Sequencing of  bat homolog genes coding for bat-karyopherins 
and bat-STAT1 is in progress and will greatly increase understanding of  SARS-CoV protein 
interaction with the bat specific IFN response pathway.  
The greatest challenge when comparing homologous viral proteins in the context of  viral 
replication is to know when to define a replication difference as relevant and significant. There is 
obviously no general agreement and the literature is contradictory [54, 60]. BGO6-rSCV grew to 
titers 20-fold lower than that of  rSCV on VeroFM cells, while delO6-rSCV showed an 8.3-fold 
reduction in virus growth as compared to the wild type rSCV. Yount et al. described an ORF6 
deleted rSCV to “grow as efficiently as (the) wild type virus”, when they observed a 3-fold 
reduction in virus titers [60]. In contrast, Zhao et al. found that their ORF6 deleted rSCV after 
infection of  Vero E6 cells at an MOI of  0.01 grew to titers 3 to4-fold lower than wild type virus 
and described it as “to grow more slowly and to lower titers” compared to the wild type virus 
[54]. For example in the case of  influenza A, differences of  virus growth between mutant and 
wild type viruses of  5-10-fold were found to be significant [135]. The replication differences 
found by Yount et al. and Zhou et al. could be confirmed by our experimental setup. Moreover, 
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this replication pattern was reproduced in another primate and one bat cell line. The fact that 
replication differences, even though small, were found for rSCV and delO6-rSCV independently 
by three different groups, strongly suggests that even small differences are reproducible and 
therefore valid. Nevertheless, the focus of  this study was not the deletion of  p6 but the 
comparison of  SA-p6 and BG-p6 their influence on virus replication in their respective hosts. In 
all three tested cell lines BGO6-rSCV grew to lower titers as compared to rSCV. This suggested 
an attenuating effect of  the bat-CoV p6 when introduced into the genome of  the pathogenic 
SARS-CoV. Interestingly, the attenuating effect of  BG-p6 was also seen in bat cells. This rejects 
the initial assumption that BGO6-rSCV would be able to replicate more efficiently than rSCV in 
RhiLu-hACE2 because it possess the IFN antagonist matching the cell line. Correspondingly, 
rSCV was expected to exhibit replication advantages on primate cells as compared to BGO6-
rSCV. However, the results obtained here rather suggest a general attenuating effect of  BG-p6. 
This is consistent with previous findings, where p6 was described as a virulence factor that was 
able to fundamentally influence the pathogenicity of  a murine CoV [53]. Zhao et al. postulate 
that the presence of  ORF6 has no influence on the IFN sensitivity of  rSCV [54]. The results 
shown here indicate that IFN-pretreatment of  primate cells reduces the growth of  BGO6-rSCV 
less efficiently than rSCV, while the growth of  BGO6-rSCV is inhibited more than the growth of  
rSCV on IFN pretreated bat cells. This indicates that primate cells might have better tools to 
counteract the IFN antagonist from the human pathogenic virus. Accordingly, bat cells appear 
rather capable of  dealing with the IFN antagonist of  the bat derived virus. This implies that the 
IFN antagonists are host-adapted and virus growth can be reduced in order to save the new host. 
On the contrary, the dead-end host is inferior to the unknown IFN antagonist and the virus 
could replicate without hindrance. Nevertheless, the general virus replication is attenuated in the 
presence of  BG-p6. This might suggest that attenuation is not based on the IFN antagonistic 
feature of  p6, but rather on its second function, the N-terminal linked ability to induce 
membrane rearrangement [56]. The N-terminal region of  p6 is not as conserved as the C-
terminus. SA-p6 might therefore be more efficiently and universally able to create a replication-
friendly environment, e.g. by the induction of  replication complex formation, than BG-p6. This 
is admittedly speculative and further experiments are required to determine the speed of  RNA 
synthesis in the presence of  the different p6. As previously shown, viral RNA synthesis is 
significantly reduced in the absence of  p6 [54]. Moreover, it is necessary to clarify cellular 
architecture and organelle morphology in SARS-CoV infected bat cells. However, it is not yet 
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known whether membrane rearrangements and the formation of  double membrane vesicles as 
sites of  virus replication are also induced in bat cells.  
 
4.3.2  Open reading frame 8 
An overrepresentation of  mutations within ORF8 in the SARS-CoV genome was already noticed 
shortly after the epidemic, but these mutations had no apparent effect on the pathogenesis in 
humans and the encoded protein was said to be functionally irrelevant [61]. Nevertheless, in the 
following time many studies on the protein’s functionality were done [62-65, 68]. In the course of  
investigating the importance of  SARS-CoVs accessory proteins a variety of  recombinant viruses 
lacking different accessory genes were generated [60, 136]. Inexplicably, a virus deleted in ORF8 
was never among them. Studies on ORF8 were only conducted in the context of  the 29nt-
deletion, which distinguishes between early and late phase SARS pandemic isolates. The 
description of  the first SARS-related CoV found in European bats that lacks ORF8 entirely again 
raised the question of  the relevance of  ORF8 [88].  
Overexpression of  p8full and p8a by lentiviral transduction revealed profoundly different cellular 
distributions of  both proteins. P8full is diffused in the cytoplasm while p8a can be found in 
punctuate vesicle-like structures. This was also found by Keng et al. and emphasizes the proposed 
difference of  both proteins in structure and function, which were also implicated by the very 
distinct binding profiles of  p8full and p8a to other viral proteins [64] 
To resolve the detailed functionality of  this protein was not an aim of  the present study. It was 
rather to be clarified if  ORF8, based on its high susceptibility to mutations, might act as a 
virulence factor and might therefore be useful as a risk marker assessing newly discovered SARS-
related CoVs. 
In two primate cell lines and one bat cell line the same replication for the three ORF8 variants 
could be observed. The replication efficiency decreased with decreasing integrity of  the ORF8 
gene. Replication differences were similar in primate and bat cells which implied a host-
independent mechanism of  replication inhibition. IFN pretreatment of  infected cells resulted in 
an overall reduction in virus growth. No ORF8-specific differences were detected, suggesting 
that the encoded protein does not interfere with the cells’ IFN pathway. In addition, 
overexpression of  p8full or p8a resulted in enhanced replication of  the ORF8 deleted virus. This 
proves that decreased virus replication is due to the absence of  the ORF8 gene product. 
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Yount et al. characterized their recombinant SARS-CoV carrying the full-length ORF8 to 
replicate as efficiently as the wild type virus [60]. In fact, their O8full-rSCV grew to titers 3-fold 
higher as compared to wild type rSCV. This, admittedly small, growth difference was 
independently reproducible in all the three cell lines used in this study, and can therefore be 
regarded as credible. The most pronounced replication differences were those between viruses 
with an intact full-length ORF8 and the deleted ORF8. The lack or ORF8 led to a 25-270-fold 
reduction of  virus titers depending on the cell line used. This previously undetected genotype is 
likely to be the reason that the relevance of  ORF8 as a virulence factor was overlooked until now. 
The closest relatives of  SARS-CoV have been found in Rhinolophus bats in Asia and Europe [10, 
72, 80, 88]. The closest relative of  SARS-CoV in Africa was found in a Chaerephon bat [86], 
though both virus and host are only distantly related to SARS-CoV and Rhinolophus. Nevertheless, 
it would be useful to determine the presence of  ORF8 in the African SARS-CoV relative. In 
addition, phylogenetic analyses of  the European and Asian SARS-related bat-CoVs might 
provide valuable information on their common ancestor and their spread through Eurasia.  
 
Taken together the proteins encoded by ORF6 and ORF8 of  the SARS-CoV genome can be 
used to assess the zoonotic potential of  newly discovered SARS-CoV-related viruses. The 
experiments performed on both proteins in this work give profound evidence that SARS-related 
bat-CoV BtCoV/BM48-31 found in Europe is attenuated. Generally, due to the lack of  ORF8 in 
all European SARS-related bat-CoVs these viruses exhibit a greatly reduced risk potential to 
initiate another SARS epidemic as compared to the Asian viruses.   
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5  Summary 
The pandemic of  the „Severe acute respiratory syndrome“ (SARS) at the end of  2002 caused 
more than 8000 infections and led to more than 800 deaths. The disease was soon associated 
with a new zoonotic coronavirus, the SARS-CoV. At first, civet cats were thought to be the 
natural reservoir of  SARS-CoV, but further studies revealed that SARS-related CoVs are present 
at high diversities in Asian bats of  the genus Rhinolophus. Emerging viruses are a constant threat 
to public health and it is of  utmost importance to evaluate risk factors that facilitate host 
transitions.  
SARS-CoV encodes several accessory proteins with partially known functions in immune 
evasion. Minor relevance was assigned to those proteins in cell culture models, but it is generally 
assumed that they might have important functions in the natural reservoir.  
Using the full-length genome sequence of  a Bulgarian SARS-related bat-CoV (BG-CoV) 
identified by us in Rhinolophus blasii functionalities of  two selected accessory proteins were 
investigated. 
To this end, a Rhinolophus bat embryonic lung cell line carrying the human SARS-CoV receptor 
angiotensin converting enzyme 2 (hACE2) was established (RhiLu-hACE2) to resemble the 
SARS-CoV reservoir. Type I interferon assays were established for cells from different hosts and 
extensive reverse genetic studies on SARS-CoV were conducted to project the zoonotic risk of  
the bat-borne SARS-related CoV. 
(i) Protein 6, encoded by open reading frame 6 (ORF6), interacts directly with Karyopherin 
(KPN) α2 thereby inhibiting interferon (IFN) signaling. BG-CoV protein 6 (BG-p6) shares 78.1% 
amino acid similarity with human SARS-CoV protein 6 (SA-p6). Overexpressed BG-p6 was able 
to inhibit nuclear translocation of  co-transfected KPN α2 like SA-p6. Moreover, the IFN 
antagonistic ability of  both proteins was determined by the inhibition of  nuclear translocation of  
overexpressed STAT1 due to the effect described above. It was shown that overexpressed BG-p6 
inhibited STAT1 translocation as efficiently as SA-p6. 
With the help of  the SARS-CoV reverse genetics system a chimeric recombinant SARS-CoV 
carrying the BG-CoV ORF6 (BGO6-rSCV) was generated for studies in a in the context of  viral 
replication in primate and RhiLu-hACE2 cells.  
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In primate as well as in RhiLu-hACE2 cells BGO6-rSCV replicated less efficiently than wild type 
rSCV. Interestingly, when cells were preincubated with universal type I IFN BGO6-rSCV 
exhibited an increased IFN sensitivity on RhiLu-hACE2 cells only. This suggests a host-
independent attenuating effect of  BG-p6. 
(ii) The genomic region around ORF8 was subject to an unusual high mutation rate throughout 
the SARS pandemic. SARS-related CoVs found in Asian Rhinolophus bats, civet cats and early 
human isolates of  SARS-CoV carried a single full-length ORF8. The human pandemic SARS-
CoV acquired a 29 nucleotide deletion leading to the disruption of  ORF8 into two ORFs, 
ORF8a and 8b. In the Bulgarian SARS-related bat-CoV we found that ORF8 was entirely 
missing. Analysis of  more Rhinolophid bats from Spain, Italy and Slovenia revealed that most likely 
all European SARS-related bat-CoVs lack ORF8. 
The influence of  ORF8 integrity on virus replication was investigated with the help of  rSCVs 
carrying these three ORF8 variants. On primate and bat cell culture rSCV carrying the full-length 
ORF8 grew to the highest titers, while the ORF8 deletion variant grew the worst. IFN 
pretreatment of  the tested cell lines resulted in an overall decrease in virus replication of  all 
ORF8 variants suggesting an IFN-independent mechanism for ORF8 influenced virus 
replication. 
In summary, the present study showed that BG-p6 was able to antagonize type I IFN signaling in 
primate cells with wild type efficiency. In the full virus context a SARS-CoV expressing BG-p6 
was attenuated in primate and bat cell culture. Furthermore, the absence of  ORF8 greatly 
reduced virus replication efficiency. Taken together both findings suggest potentially reduced 
virulence of  the European SARS-related bat-CoVs. For the first time these data indicate a 
feasible approach to assessing zoonotic risks emanating from bat-borne SARS-related CoVs.  
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Summary in German/Zusammenfassung 
Die Pandemie des „Schweren akuten respiratorischen Syndroms“ (SARS), die Ende 2002 begann, 
führte weltweit zu über 8000 Infizierten von denen über 800 starben. Die Krankheit wurde 
schnell mit einem neuartigen, zoonotischen Coronavirus, dem SARS-CoV, assoziiert. Zunächst 
standen Schleichkatzen unter Verdacht das natürliche Reservoir des SARS-CoV zu sein. In 
weiteren Studien konnte jedoch gezeigt werden, dass SARS-ähnliche Coronaviren in hoher 
Diversität in asiatischen Fledermäusen der Gattung Rhinolophus zu finden waren. Neu auftretende 
zoonotische Viren stellen eine konstante Gefährdung für die öffentliche Gesundheit dar. Die 
Beurteilung von Risikofaktoren, die einen Wirtswechsel ermöglichen, ist von größter Bedeutung.  
Das SARS-CoV kodiert für eine für Coronaviren ungewöhnlich hohe Anzahl an akzessorischen 
Genen. Diesen Genen wird meist eine geringe funktionelle Relevanz in Zellkulturmodellen 
zugesprochen, aber es wird allgemein angenommen, dass sie wichtige Funktionen im natürlichen 
Reservoir besitzen.  
Mit Hilfe der Vollgenomsequenz eines bulgarischen SARS-ähnlichen Fledermaus-CoV (BG-
CoV), welches durch unsere Arbeitsgruppe in Rhinolophus blasii gefunden wurde, wurde die 
Funktionalität zweier ausgewählter akzessorischer Proteine untersucht. 
Zu diesem Zweck wurde eine embryonale Lungenzelllinie aus Rhinolophus hergestellt, die den 
humanen SARS-CoV-Rezeptor Angiotensin-konvertierendes Enzym 2 (hACE2) dauerhaft 
exprimiert, RhiLu-hACE2. Diese Zelllinie sollte dazu dienen, das Reservoir von SARS-CoV im 
Zellkulturmodell darzustellen. Es wurden Typ-I-Interferonassays für Zellen verschiedener 
Herkunft etabliert und umfangreiche revers-genetische Studien am SARS-CoV durchgeführt, um 
das zoonotische Risiko des SARS-ähnlichen Fledermaus-CoV zu beurteilen. 
(i) Protein 6, kodiert durch den offenen Leserahmen 6 (ORF6), interagiert direkt mit 
Karyopherin (KPN) α2 und inhibiert so den Interferon(IFN)-Signalweg. Das BG-CoV Protein 6 
(BG-p6) besitzt eine Aminosäureähnlichkeit von 78.1% im Vergleich zum humanen SARS-CoV 
Protein 6 (SA-p6). Überexprimiertes BG-p6 war wie SA-p6 in der Lage, die nukleäre 
Translokation von kotransfiziertem KPN α2 zu inhibieren. Die IFN-antagonistische Fähigkeit 
beider Proteine wurde mit Hilfe der Inhibition der nukleären Translokation von 
überexprimiertem STAT1, basierend auf  den beschriebenen Wechselwirkungen, bestimmt. 
Überexprimiertes BG-p6 inhibierte die Translokation so effektiv wie SA-p6. 
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Mit Hilfe des SARS-CoV reversen Genetiksystems wurde rekombinantes SARS-CoV hergestellt, 
dass das BG-CoV ORF6 trägt (BGO6-rSCV), um Studien im Vollviruskontext in Primaten- und 
RhiLu-hACE2-Zellen durchzuführen.  
Sowohl in Primaten- als auch in RhiLu-hACE2-Zellen replizierte das BGO6-rSCV weniger 
effizient als das Wildtyp-rSCV. Wurden die Zellen mit universellem Typ-I-IFN präinkubiert, 
zeigte BGO6-rSCV nur auf  RhiLu-hACE2-Zellen einer erhöhte IFN-Sensitivität. Das weißt auf  
einen wirtsunabhängigen attenuierenden Effekt durch BG-p6 hin. 
(ii) Die Genomregion um ORF8 unterlag während der SARS-Pandemie einer ungewöhnlich 
hohen Mutationsrate. SARS-ähnliche CoVs aus asiatischen Rhinolophiden, sowie SARS-CoV-Isolate 
aus Larvenrollern und Patienten in der frühen Phase der Pandemie trugen ein einzelnes, 
vollständiges ORF8. Das humane, pandemische SARS-CoV erwarb eine Deletion von 29 
Nukleotiden, die das ORF8 in ORF8a und 8b zweiteilte. Im Genom des bulgarischen SARS-
ähnlichen Fledermaus-CoVs fehlte ORF8 vollständig. Untersuchungen von weiteren Rhinolophiden 
aus Spanien, Italien und Slowenien ergab, dass ORF8 sehr wahrscheinlich in alle europäischen 
SARS-ähnlichen Fledermaus-CoVs fehlt.   
Zur Untersuchung des Einflusses der Vollständigkeit von ORF8 auf  die Virusreplikation wurden 
rSCVs konstruiert, die die jeweiligen ORF8-Varianten tragen. In Primaten- und RhiLu-hACE2-
Zellen wuchs das rSCV mit dem vollständigen ORF8 am besten. Die ORF8-Deletionsvariante 
replizierte hingegen am schlechtesten. Eine Behandlung der Zellen mit IFN führte zu einer 
allgemein verringerten Replikationsrate der Viren, was auf  einen IFN-unabhängigen 
Mechanismus der ORF8-beeinflussten Virusreplikation hindeutet.  
Die vorliegende Studie legt nahe, dass das BG-p6 mit Wildtyp-Effizienz den Typ-I-IFN-
Signalweg in Primatenzellen antagonisiert. Im Vollviruskontext war das SARS-CoV, was BG-p6 
exprimiert, in Primaten- und RhiLu-hACE2-Zellen attenuiert. Zusätzlich trug das Fehlen von 
ORF8 zu verminderter Virusreplikation bei. Zusammenfassend deuten diese Erkenntnisse darauf  
hin, dass europäische SARS-ähnliche Fledermaus-CoV vermutlich eine verminderte Virulenz 
besitzen. Außerdem präsentieren die Daten einen zulässigen Ansatz zur Beurteilung des 
zoonotischen Risikos durch Fledermaus übertragene SARS-ähnliche CoVs. 
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7  Abbreviations 
BSA Bovine Serum Albumin 
CoV Coronavirus 
cDNA Complementary DNA 
DNA Deoxyribonucleic acid 
dNTPs Deoxynucleoside triphosphate 
EC50 Half  maximal effective concentration 
EDTA Ethylenediaminetetraacetic acid 
GFP Green Fluorescent protein 
h Hour 
HA Hemagglutinin 
hACE2 Human angiotensin converting enzyme 2 
IFN Interferon 
ISG IFN-stimulated gene 
kDa Kilodalton 
KPNA Karyopherin α 
min Minutes 
µL Microliter 
mL Milliliter 
mM Millimolar 
MOI Multiplicity of  infection 
ng Nanogram 
nt nucleotide 
ORF Open reading frame 
PBS Phosphate buffered saline 
p.i. Post infection 
PCR Polymerase chain reaction 
PFU Plaque forming units 
Ren Renilla luciferase 
RhiLu Rhinolophus lung 
RNA Ribonucleic acid 
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rSCV Recombinant SARS-CoV 
RT-PCR Reverse transcription polymerase chain reaction 
RVFV Rift valley fever virus 
SARS Severe acute respiratory syndrome 
sec Second 
TAE Tris-acetate-EDTA buffer 
TRS Transcription regulatory sequence 
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